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Abstract 
(-)-Cycleanine is a bisbenzyltetrahydroisoquinoline (BBIQ) member of the 
large family of tetrahydroisoquinoline (IQ) alkaloids. The aim of the present work 
is the total synthesis of (-)-cycleanine via a strategy of using differential and 
selectively protected of gallic acid as the starting material. Subsequent 
homologation of the carboxyl group of the protected gallic acid intermediate to 
produce the secondary amine, followed by a Schotten-Baumann reaction and the 
Bischler-Napieralski cyclization to produce the desired intermediate. The 
presence of the chosen chiral auxiliary assisted the formation of the desired 
distereoisomers. Crystals of the key intermediates to the diaryl ether coupling 
step were collected and the absolute configurations were confirmed based on the 
X-ray data. Strategies involving the use of a SNAr reaction and Ullmann 
reactions on this intermediate were used to form the diaryl ether linkage to 
produce cycleanine. 
Anthrax is an acute transferable disease caused by Bacillus anthracis, and 
the disease is highly lethal in some forms. The design of appropriate anti-toxins 
to assist in the treatment of the infection in the advanced stages is desirable. A 
recent study that showed 5-hydroxydopamine derivatives were noncompetitive 
inhibitors of anthrax lethal factor (LF) encouraged our interest in discovering 
more potent LF inhibitors that posse a similar polyphenolic design. These studies 
led us to consider the use of some of the intermediates obtained in the course of 
the attempts towards the enantioselective synthesis of (-)-cycleanine and of other 
iii 
BBIQs of interest, for the enantioselective synthesis of some analogues of those 
LF inhibitors. Precursors for the final targets were prepared and these endeavors 
are reported in this thesis. 
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Chapter 1 
Introduction 
1.1 Definition and classification of alkaloids. 
1.1.1 Alkaloids. 
Meissner1 was the first to propose the term 'alkaloids' in 1819. He wrote: 
"To me it seems wholly appropriate to refer to those plant substances 
currently known not by the name alkalis, but alkaloids, since in some of 
their properties they differ from alkalis considerably, and would thus find 
their place before the plant acids in the field of plant chemistry." 
The word alkaloid is made up of two words 'alkali', from the Arabic word 
for 'plant ashes', namely, "al-qualja" and 'su5od , the Greek word meaning 
'similarity'. Thus, alkaloids are naturally-occurring substances with alkali-like 
characteristics. There are, of course, many other definitions for alkaloids. For 
example, in 1896, Guareschi2 wrote the following definition: 
"The term 'alkaloids' is applicable to all basic, organic compounds whether 
obtained either from animal or plant material, or prepared artificially; that 
is, the expression 'alkaloids' is synonymous with 'organic base' or 'organic 
alkali'. 
Stoll ,3 in 1953, proposed the following shorter definition: 
"Nitrogen-containing bases of vegetable origin were grouped together 
under the label 'alkaloidsn. 
1 
Finally, in his book "Alkaloids: Nature's Curse or Blessing" Hesse4 has 
collected many of the definitions of alkaloids and summarized them in the 
following single definition: 
"Alkaloids are nitrogen-containing organic substances of natural origin with 
a greater or lesser degree of basic character. " 
1.1.2 Classification of alkaloids. 
In Hesse's excellent recent book4 on alkaloids, a useful approach to 
classifying these compounds is outlined and will , in essence, be employed 
herein. Since a very large number of alkaloids exists, roughly estimated to be in 
the order of 10,000 compounds isolated and characterized so far, it is difficult to 
categorize them into specific groups. This difficulty comes about from the broad 
structural variation which is present in the alkaloids. In order to manage so many 
different compounds, therefore, it is essential to perform some form of sub-
classification. 
The standards used for alkaloid classification are: biogenesis, structural 
relationship, biological origin, and spectroscopic/spectrometric properties. 
According to those standards, alkaloids are classified into five main classes (see 
sections 1.1.2.1 to 1.1.2.5). These five classes are further classified into other 
sub-groups. There are examples for each of the major five classes shown in 
Figure 1.1. 
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1.1.2.1 Heterocyclic alkaloids. 
The class of heterocyclic alkaloids includes the following examples: 
a. Pyrrolidine alkaloids e.g. (+)-(R)-Hygrine (1) 
b. Indole alkaloids e.g. Carbazole (2) 
c. Piperidine alkaloids e.g. (+)-Coniine (3) 
d. Tropanes and related bases e.g. (+)-Tropinone (4) 
e. Histamine, imidazole, and guanidine alkaloids e.g. Alchornine (5) 
f. lsoquinoline alkaloids e.g. (+)-Salsoline (6) 
g. Quinoline alkaloids e.g. Dictamnine (7) 
h. Quinazoline alkaloids e.g. Glycosmicine (8) 
i. Benzoxazines and Benzoxazoles e.g. 3-Hydroxyoxindole (9) 
j . Pyrrolizidine alkaloids e.g. (-)-Retronecanol (10) 
k. lndolizidine alkaloids e.g. (+)-Eiaeocarpine (11) 
I. Quinolizidine alkaloids e.g. (-)-Lupinine (12) 
m. Pyrazine alkaloids e.g. 3-Ethyl-2,5-dimethylpyrazine (13) 
n. Purine Bases e.g. Adenine (14) 
4 
o. Pteridines e.g. Pteridine (15) 
1.1.2.2 Alkaloids having exocyclic nitrogen atoms. 
This class of alkaloids includes the following examples: 
a. Phenylalkylamine derivatives e.g. (-)-Ephedrine (16) 
b. Benzylamine- type alkaloids e.g. Capsaicine (17) 
c. Khat e.g. (-)-(S)-Cathinone (18) 
d. Muscarines e.g. (+)-Muscarine (19) 
1.1.2.3 Putrescine, Spermidine, and Spermine alkaloids. 
An example of this class is Paucine (20). 
1.1.2.4 Peptide alkaloids. 
An example of this class is the ergot peptide alkaloid 21 . 
1.1.2.5 Terpene and Steroid alkaloids. 
This class of alkaloids includes: 
a. Diterpenes e.g. (-)-Veatchine (22). 
b. Daphniphyllum alkaloids e.g. (+)-Daphniphylline (23) 
c. Taxus alkaloids e.g. (-)-Paclitaxel (24) . 
d. Steroid alkaloids e.g. (-)-Paravallarine (25). 
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1.1.2.6 Dimeric alkaloids. 
An example of this class is (+)-Salutadimerine (26) . 
1.2 Definition and classification of BBIQ alkaloids. 
4 4 4 5 4 (X)' CO' w CO' 6 3 ~2 N2 N2 7 N 1 1 2 
Bn 
Quinoline lsoquinoline Tetrahydroisoquinoline Benzyltetrahydroisoquinoline 
(Q) (IQ) (THIQ) (BIQ) 
Figure 1.2. Derivation of the term "benzyltetrahydroisoquinoline". 
As shown in Figure 1.2, the term benzyltetrahydroisoquinoline ("BIQ") is 
derived from the term quinoline ("Q") which has the nitrogen atom in position 1. 
lsoquinoline ("IQ") has the nitrogen atom at position 2. Reduction of the two 
double bonds of isoquinoline produces tetrahydroisoquinoline ("THIQ"), and 
finally introduction of a benzyl group to position 1 of ("THIQ") leads to an 
example of BIQ. 
The bisbenzyltetrahydroisoquinoline (BBIQ) family of alkaloids consists of 
almost 200 members. Two BIQ units are linked together by ether bridges, 
methylenoxy bridging and/or direct carbon-carbon bonds to form BBIQ alkaloids. 
Guha5 and Shamma6 have classified them into five groups (A-E) and twenty-
eight types (I-XXVII) based on four main features: 
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1. The nature of the bridges: when two benzyl groups link together, this is called a 
"tail-to-taif' linkage. If the link is between one isoquinoline and one benzyl group, 
it is called a "head-to-taif' linkage. However if the link is between two isoquinoline 
units, it is called a "head-to-head' linkage. 
2. The number of the oxygen substituents on the aromatic rings. 
3. The number of linkages between the two (BIQ) units. 
4. The sites at which the bonds exist between the two BIQ units. 
OMe 
(+)-Temuconine 
(27) 
(+)-Tiliacorine 
(29) 
H 
Figure 1.3. Examples of BBIQ alkaloids. 
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MeO 
Me 
OMe 
(+)-Oxyacanthine 
(28) 
OH 
(+)-Tubocurarine 
(30) 
Within the same group, members differ simply in: (1) the nature of the 
oxygenated substituents (e.g. OH, OMe, OCH20); (2) the nature of the 
substituents on the two nitrogen atoms (e.g. NH, NMe, Me2N+, NO); (3) the 
degree of unsaturation of the hetero-rings; and/or (4) the stereochemistry of the 
two asymmetric centers.5 The simplest representative for BBIQ alkaloids which 
have a "tail-to-tail" linkage, is (+)-temuconine (27, Figure 1.3) which is an 
example of a "Type I of Group A" according to Guha and Shamma's classification 
system. (+)-Oxyacanthine (28) has both a "head-to-head" and a "tail-to-tail" 
linkage. 
In addition to the two linkages between the two isoquinoline units, (+)-
tiliacorine (29) has an additional carbon-carbon bond between the two benzyl 
groups (biphenyl linkage). A "head-to-tail" and "tail-to-head" group is represented 
by (+)-tubocurarine (30). These examples are shown in Figure 1.3. 
(+)-Neothalibrine (31) and the degradation product 32 of (+)-antioquine 
(33) shown in Figure 1.4 are two representative examples for BBIQ alkaloids 
which respectively have one diaryl ether linkage and one biphenyl linkage. (+)-
Antioquine (33), and (-)-limacine (34) are examples of BBIQ alkaloids which have 
two diaryl ether linkages, and one diaryl ether and one biphenyl linkage, 
respectively. 
As shown in Figure 1.4, (+)-Norcocsuline (35) and (+)-N-
methylpachygonamine (36) are examples of BBIQ alkaloids respectively having 
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three diaryl ether linkages, and two diaryl ether linkages, together with one 
biphenyl.7 
~OMe MeO~ 
/~OH HO~~ 
~~ 
( + )-Neothalibrine 
(31) 
OMe HO 
(+)-Antioquine 
(33) 
( + )-Norcocsuline 
(35) 
Figure 1.4. Examples of BBIQ alkaloids. 
1.3 Biological significance of alkaloids. 
1.3.1 Biological activities of alkaloids. 
OMe HO 
(32) 
OMe MeO~ 
_ _ oH_~~ 
OM•~ 
(-)-Limacine 
(34) 
( + )-N-Methylpachygonamine 
(36) 
Various specialist literature reviews8-10 showed that alkaloids exhibit some 
biological activities such as antifungal activity, protection against UV- irradiation, 
insecticides, herbicides, and also as feeding deterrents. 
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Liriodenine (37) Lysicamine (38) Oxonantenine (39) 
HO 
~0 
DIBOA-Gic (R=H) (40) 
DIMBOA-Gic (R=OMe) (41 ) 
(-)-Senecionine (42) 
Figure 1.5. Examples of alkaloids which have biological activities. 
Some alkaloids work as plant protectors against insect attacks. (-)-
Senecionine (42), for example, is a highly effective defense for the plants that 
produce it (Figure 1.5) . 
1.3.2 Pharmacological activities of BBIQ alkaloids. 
Anti-tumor, anti-inflammatory, antibiotic, anti-hypertensive, and anti-
plasmodial are some of the most important known biological activities of BBIQ 
alkaloids.11 These are summarized in Table 1.1. Humans have always used 
drugs containing alkaloids in potions, medicines, poultices and poisons.12 Table 
1.1 shows some selected pharmacological activities of several BBIQ alkaloids.13 
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Table 1.1. Pharmacological activities of some BBIQ alkaloids. 
BBIQ alkaloid Pharmacological Activities 
(+)-Oxyacanthine (28) Antioxidant , anti-inflammatory, antiproliferative 
(-)-Limacine (33) Antiplasmodial, anti-inflammatory, antioxidant 
(+)-Tetrandrine (43) Antiplasmodial , anti-inflammatory 
(+)-Fangchinoline (44) Antiplasmodial , anti-inflammatory 
(+)-Cepharanthine (45) Anti-inflammatory 
(+)-Aromoline ( 46) Antiplasmodial , anti-inflammatory 
(-)-Repandine (47) Antiplasmodial, anti-inflammatory 
It can be seen that anti-inflammatory activity is common for those 
compounds and that individual BBIQ alkaloids have several additional 
pharmacological activities. A large number of studies have been undertaken by 
researchers to relate the structural features of such BBIQ alkaloids with their 
pharmacological activities.14•15 Chirality and substitution patterns have been 
found to be the most important factors that determine their pharmacological 
activities.16•17 Even though the pharmacological activities of the BBIQ alkaloids 
are assumed to be related to the chirality and the substitution patterns, no firm 
conclusions have been made about exactly how these features affect these 
biological activities, given the chemical complexity of living systems. 
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(33) (-)-(1R,1'R)-Limacine R1=CH3, R2=H, R3=CH3 
(43) (+)-(1 S, 1 'S)-Tetrandrine R1=CH3, R2=CH3, R3=CH3 
(44) (+)-(1R,1'S)- Fangchinoline R1=CH3, R2=CH3, R3=H 
(45) (+)-(1R,1'S)-Cepharanthine R1=CH3, R2=CH3, R3=CH3 
(46) (+)-(1R,1'S)-Aromoline R1=H, R2=CH3, R3=H 
(28) (+)-(1$,1' R)-Oxyacanthine R1=CH3, R2=CH3, R3=H 
(47) (-)-(1$,1'$)-Repandine R1=CH3, R2=CH3, R3=H 
Figure 1.6. Examples of alkaloids having pharmacological activities. 
1.3.3 Pharmacological activities of cycleanine. 
(-)-Cycleanine (48) has been found to have diverse pharmacological 
activities such as antibacterial, antifungal, antiplasmodial, anti-inflammatory, 
cytotoxic, analgesic, and muscle relaxant properties.18-22 The pharmacological 
activities of cycleanine can be traced back to early times in Southern Nigeria and 
other coastal regions of West Africa, where the natives used the root bark 
powder of the plant Synclisia Scarbrida which contains cycleanine, for medicinal 
purposes. A recent studl3 revealed that cycleanine has an effect on the central 
nervous system. However, cycleanine has various other pharmacological 
activities, and further investigations are required to relate its biological activities 
with its structural features. 
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OMe 
(-)-Cycleanine 
(48) 
Figure 1.7. The structure of (-)-cycleanine. 
1.4. Sources of BBIQ alkaloids. 
1.4.1. Botanical sources of BBIQ alkaloids. 
The nature and the quantity of the BBIQ alkaloids in plants are affected by 
geographical and climatic factors. For instance, Cissampelos pareira Linn, from 
Kashmir produces hayatine (49) and hayatinine (50) (Figure 1.8), both of the 
isoquinoline type, whereas the same plant grown in Pilibhit, produces only 
hayatine. Different groups of BBIQs are normally found in different genera. 
Hayatine 
(49) Hayatinine (50) 
Figure 1.8. The structure of hayatine (49) and hayatinine (50). 
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Furthermore, the BBIQs vary in their nature and in their relative proportions 
in the different parts of plants. For example, leaves of menispermum canadense 
Linn contain no alkaloids, whereas the stem, the roots, and the rhizome contain 
"Type (1)"5 alkaloids in which two BIQ units are linked together by a single ether 
bridge linking the two benzyl groups. Table 1.2 outlines some of the botanical 
sources of some BBIQ alkaloids.24 
Table 1.2. An outline of the botanical sources of some BBIQ alkaloids. 
Name of the plant Alkaloids 
T. patens oliv (+)-aromoline (46) 
C. pareira linn (-)-Cycleanine (48) 
C. /eaeba DC (+)-Oxyacanthine (28) 
S. tetrandra S. moore (+)-Tetrandrine (43) 
Abuta candicans ( + )-neothalibrine (31) 
Anisocyclea gradidieri H. Bn (+)-Norcocsuline (35) 
1.4.2 Synthetic approaches toward BBIQ alkaloids. 
1.4.2.1 Asymmetric synthesis of isoquinoline alkaloids. 
Plant parts 
leaf 
root and leaf 
root 
tuber 
stem 
stem 
There are two major strategies for the asymmetric synthesis of isoquinoline 
alkaloids: (1) stereochemical modification of the usual, typical methods (i.e. 
sequential Bischler-Napieralski (BN) cyclization/reduction, Pictet-Spengler 
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cyclization (PSC) and Pomeranz-Fritsch cyclization); and (2) Introduction of 
nucleophilic or electrophilic carbon units into the C-1 position for C-1 substituted 
isoquinoline derivatives (the "C-1, C-a connective approach").25 
In the Bischler-Napieralski reaction26 a 13-arylethylamide is cyclized to a 1-
substituted 3,4-dihydroisoquinoline, or, to a corresponding isoquinolinium salt 
which is reduced in the next step to its 1 ,2,3,4-tetrahydro-derivative. In this 
reduction step, a diasteroselective or enantioselective synthesis can be effected. 
In 1980, Nagubandi and Fodor 27 proposed a mechanism for the Bischler-
Napieralski reaction (Scheme1 .1 ). 
RoW" ~R1~~r-
OR 0 Cl 
(51) CJ-~~ 
II 
RO~~H ~ROW-H 
OR 1 OPOCJ2 OR H) R OPOCI2 
0 
RO 
(52) - 1 
Cl 
(53) j 
- rtf)_H RO~ 
OR OR R~ OPOCI2 
(55) (54) 
Scheme 1.1. The mechanism of the Bischler -Napieralski reaction . 
The Lewis acid initially coordinates with the carbonyl oxygen of the amide 
51 and forms the intermediate 52. Electrophilic attack by the aromatic ring and 
subsequent re-aromatization results in the formation of the tetrahydroisoquinoline 
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intermediate 53 and 54. The resultant iminium ion 55 is reduced by a reducing 
agent to the corresponding tetrahydroisoquinoline.Satisfactory-to-excellent 
results have been found when hydride reduction, or catalytic hydrogenation of 
chiral 1-substituted-3,4-dihydroisoquinolines, or of the corresponding 3,4-
dihydroisoquinolinium salts have been used. In some cases a chiral auxiliary can 
be attached to the imine nitrogen, resulting in subsequent enantioselective 
reduction as for example in the syntheses described below (Scheme 1.2). 
Rodrigues et af8 used the iminium salt 56 as the key intermediate In the 
synthesis of (+)-cularine (57) (Scheme 1.2). The chiral auxiliary was removed by 
reduction with NaBH4 leading directly to theN-methyl derivative. 
Me 
OMe 
(56) 
n 
')<rl hu~ 
NaBH4 
MeOH, rt 
Scheme 1.2. Reduction of 56 to (+)-cularine (57). 
OMe 
( + )-cularine 
(57) 
Kibayashi et af9 used the dihydroisoquinolinium salt 58, incorporating a 
chiral hydrazonium functionality, to prepare (+)-salsolidine (59) as shown in 
Scheme 1.3. 
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MeO:cy ,......osn ~ -I G> ! NaBH4 N . 
MeO ~ ~ 'NO MeOH, rt 
(58) 
Scheme 1.3. Synthesis of (+)-salsolidine from compound 58. 
MeO~ 
~NH 
MeO ~ 
( + )-salsolidine 
(59) 
The steric shielding effect presented by the chiral auxiliary group in both of 
these two examples, is assumed to account for the asymmetric reduction step by 
directing the hydride to the imine double bond from the sterically less-shielded 
face. 
MexrCHO Mex:n~ ~ 1 13 Steps 1 ~ .0 
::,... ~ ::,... HN 
H Me l 
(60) OBn (61 ) ! 
OH 0~1Pr ~ ~ ~ COOH D~ ('(~ ~ 
OHC ~ 
OTBDMS (62) 
Me 
Me 
~ /, _Hoh ---~~ 
(-)-Tejedlne 
(65) 
C02Me 
YJJ 
(64) 
Scheme 1.4. The total synthesis of (-)-tejedine_ 
The Georghiou group found (S)-a-methylbenzylamine to be a very 
effective chiral auxiliary in the total synthesis of (-)-tejedine30 (65) , shown in 
Scheme 1.4. 
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The chiral amine 61 was obtained from vanillin (60) in 13 synthetic steps, 
and the acid 62 was synthesized from 4-hydroxybenzaldehyde in 11 steps. The 
key intermediate 63 was prepared from the reaction of 61 and 62. Cyclization of 
63 using POCb in benzene, followed by reduction , gave the desired 
tetrahydroisoquinoline regioisomer 64 in 40% yield with 99% de. 
Chiral hydride reducing agents or chiral catalysis can also be used to 
accomplish the enantioselective synthesis of isoquinolines via a Bischler-
Napieralski cyclization/reduction approach. For example, Hajipour and 
Hantehzadeh,31 used sodium triacyloxy borohydride (67), prepared from Na8H4 
and N,N-phthaloyl-protected amino acid (Scheme 1.5) in the synthesis of (S)-(-)-
salsolidine (66) .The enantioselectivity (65-75% ee) increased when the reduction 
was achieved in the presence of ZnCI2 (72-80% ee) , or when carried out under 
solid-state conditions (83-1 00% ee). 
OMe 
Scheme 1.5. 
(67) 
OMe 
( S)-(-)-salsolidine 
(66) 
o I 
C~CHMe2 N~ 
co(). BH 
0 
(67) 
Use of chiral triacyloxy borohydrides for reduction of imine 
intermediate in the synthesis of (S)-(-)-salsolidine (66). 
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The Pictet-Spengler cyclization reaction32 is often the most effective 
method for constructing tetrahydroisoquinolines. The condensation of {3-
arylethylamine e.g. 68 with an aldehyde or its synthetic equivalent leads to the 
formation of the stereogenic C-1 center during the ring closure in a one-pot 
process as shown in Scheme 1.6. The mild reaction conditions and the lack of 
requirement for subsequent reduction give the Pictet-Spengler method some 
advantages over the Bischler-Napieralski reaction for the construction of 
isoquinolines. 
RO 
OR 
(68) 
oq) R~H N 
RO r 
OR R 
RO 
Scheme 1.6. Mechanism of the Pictet-Spengler cyclization reaction. 
Chiral cyclohexyl-based auxiliaries on compounds 6933 and 7034 are two 
examples which were used for the synthesis of 71 and 72 respectively. The two 
chiral auxiliaries were appended to the amine nitrogen (Figure 1.9). To control 
the formation of the chiral center at C-1 and to achieve the total synthesis of the 
alkaloid 76, a chiral aldehyde was used by Czarnock et a/. 35 The reaction 
between 73 and the chiral aldehyde 74 gave 75 in 80% yield (Scheme 1.7). 
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1.POCI3 C~~ 
0 2./Y') 
~OMe 
I 
/OXJO /OX() 0'-.. o........_ ~ I H~1.RCHO : I ~ & 2.~~u I H I ~ H 
R 
(70) (72) 
Figure 1.9. Preparing alkaloids 71, 72 using cyclohexyl-based chiral 
auxiliaries. 
The application of the Pictet-Spengler cyclization methodology in the 
synthesis of cycleanine was attempted in earlier investigations by Mark Ralph in 
the Georghiou laboratory. 36 
HOX)i ~ I NH3CI 
HO 
(73) HO 
+ 
HO 
(74) 
OH 
(75) 
OH 
MeO 
-
- MeO 
Scheme 1. 7. Use of chiral aldehyde to form the desired stereocenter at C-1. 
OMe 
OMe 
The Pomeranz-Fritsch reaction37·38 forms the completely aromatic 
isoqunolines by acid-catalyzed cyclization of benzalaminoacetals prepared from 
aromatic aldehydes and aminoacetal (Scheme 1.8). 
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Scheme 1.8. Pomeranz-Fritsch reaction. 
In the Schlittler-MOIIer modification39 the starting materials are benzyl 
amines and glyoxal semiacetal. (Scheme 1.9). 
OyNH, 
R 
Scheme 1.9 Schlittler-MOIIer reaction. 
~OEt 
~R OEt~ 
u -~N 
R 
0-Methylroemecarine (79) and (-)-0-methylthalisopavine (80) (Scheme 
1.1 0) were constructed in good yields with high enantiomeric purity by N-
alkylation of benzylamines 77 with bromoacetaldehyde acetal, followed by acid-
catalyzed cyclization of the secondary amines 78.40 
The three basic methods, described above involve the closure of the six-
membered nitrogen-containing rings by the formation of the new bonds between 
C-8a and C-1 (Bischler-Napieralski, Scheme 1.1 ), C-Sa-C-1 and N-2 (Pictet-
Spengler, Scheme 1.6), and C-4 and C-4a (Pomeranz-Fritsch, Scheme 1.8). 
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OEt 
RO RO ~OEt 
RO 
NH 
RO 
OMe BrCH2CH(OEt}z OMe 
OMe OMe 
(77) (78) 
~cOH 1.CH, O, Na87 2so4 
2.HCI 
OMe 
H 
MeO OMe 
MeO Me 
OMe 
(80) 
OMe 
Scheme 1.1 0. The total synthesis of compounds 79 and 80. 
However, there are other methods which have different strategies for 
formation of isoquinoline compounds, including hetrocyclic ring closure between 
the C1-N2 or C3-N2 atoms as well. Introduction of a carbon unit to the C-1 
position of the isoquinoline heterocycle has recently been discovered as an 
alternative to the traditional synthetic methods. To prepare isoquinolines by this 
methodology, there are two strategies which can be followed, as shown in 
Scheme 1 . 11 . 
The two approaches are: (1) Add ition of carbon nucleophiles to 
isoquinolines, 3,4-dihydroisoquinolines, or to the corresponding isoquinolinium 
ions,41 (2) C-alkylation of tetrahydroisoquinoline derivatives with electrophilic 
carbon reagents,42 the stereogenic center being created at this stage of the 
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synthesis. Munchhof and Meyers,43 have prepared several alkaloids from a 
common intermediate by the C-1-N-2 connectivity approach,. 
4 MeO~ _..-OR MeOXX? _..-OR 
~~~ 1.MeMgBr,THF,-50°C 0 ~ I ~ MeO 1 2 l_/ Me L_/ 
4 
Me Om I 3 
~ N 
MeO 1 211 H 1. t-Buli, -70°C- -1 00°C MeO 
• 8 , 02.HF i-· OMe 
UOTBDMS 
MeO 
N\-< 
I OMe 
OH 
Scheme 1.11. Tetrahydroisoquinoline synthesis Top: via nucleophilic 
carbon addition to iminum intermediate; and Bottom: via addition 
to an electrophilic carbon atom. 
1.4.2.2 Diaryl ether formation. 
The importance of the diaryl ether class of organic compounds comes 
from their use throughout the polymer and pharmaceutical industries.44 Some of 
these compounds have been described as having significant biological activity, 
such as the natural products of the isodityrosine family and its derivatives (e.g. 
the antibiotic vancomycin and the antitumoral bouvardin).45 The most 
straightforward way to synthesize diaryl ethers involves the direct formation of an 
aryl-oxygen bond from an aryl halide.46 The copper-mediated arylation of phenols 
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with aryl halides, discovered by Ullmann in 1904,47 seems to be the method of 
choice. This method is often limited due to the need to employ harsh reaction 
conditions and stoichiometric amounts of copper. Palladium catalysts have been 
used recently for arylation of phenols or their sodium salts.48 However, the high 
cost of palladium and non-commercial specialized phosphine ligands make this 
method potentially unattractive for large-scale and industrial applications. 
Therefore, less costly alternatives are needed. Considerable effort has been 
applied in the past few years toward the discovery of more cost-effective Ullmann 
0-arylation methodologies. For example, Buchwald's group49 has used copper 
(II) triflate salts as catalysts to carry out these reactions under milder conditions 
with a wider variety of substrates in good yields (e.g. the formation of 82 Scheme 
1.2). Cesium carbonate was shown to be the best base in this system and allows 
the use of a non-polar solvent (toluene) at reduced reaction temperatures. 
Addition of a carboxylic acid and molecular sieves was effective in promoting 
couplings of specific phenols devoid of electron-donating groups to unactivated 
aryl halides (e.g., the formation of 82). 
The limitation of these strategies comes from the relatively high cost of 
copper triflate and its air sensitivity. Pyridine-type ligands, or phosphine-type 
ligands in catalytic amounts, however have been used recently by a number of 
groups to accelerate or enhance the Ullmann reaction and to allow it to occur 
under more moderate conditions. 50 Several investigations have demonstrated 
that certain additives such as ethylene glycol diacetate,51 a 8-
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hydroxyquinoline,51 b,c 1-naphthoic acid 51d I triphenylphosphine51e and 
neocuproine51 f have been used successfully as promoters. These additives 
probably act as copper ligands which enhance reaction rates and allow the 
couplings to be carried out in the presence of reduced amounts of copper, at 
milder temperatures, or with a larger substrate range. 51 Smith53 prepared diaryl 
ethers (e.g. the formation of 82) by using catalytic copper (I) iodide and 
ultrasound. These reactions were conducted in the absence of solvent and in 
conjunction with sonication to break up particles of the base and catalyst. By 
using 2 mol equiv. of phenol, (Scheme 1.12) these reactions afforded diaryl 
ethers in yields generally greater than under the corresponding classical Ullmann 
conditions. 
aOHBru ao~ + I K2C03, Cui (0.05 eq) 
(81) "' I ::::::-... 140 °C, ultrasound 
97% 
&OHY Cs2C03,cat.(CuOTf)2.PhH &0~ + I I 
::::::-... 5 mol %, EtOAc, toluene ::::::-... 
87% (82) 
()
OH Brn Cs2C03,cat.(CuOTf)2.PhH ~OY'il 
+ ::::::-... I 1-naphthoic acid, SA 0 mol sevies V ~ 
t B t-Bu 
- u Smol %, EtOAc, toluene (83) 
81% 
Scheme 1.12. Diaryl ether coupling by using different reagents. 
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In 1999 Snieckus54 reported the use of catalytic CuPF6(MeCN)4 to assist 
the coupling of phenols to o-halo tertiary- and secondary benzamides and 
sulfonamides. The resulting diaryl ethers may then be submitted to direct ortho-
metalation, halogenation, and an additional Ullmann ether operation to produce 
bis- and triarylethers, as shown in Scheme1 .13. 
CONEt2 CONEt2 
~OH ~ Cs2C03,cat.CuPF6(MeCN)4 ~O~ "'1)....,s_-B_u_Li_, T_M_E_D_A_, T,.HF V + U toluene 87% 0 U 2) l2 
Cs2C03,cat.CuPFs(MeCN)4 
4-(Me0)C6H40H, toluene 
38% 
Scheme 1.13. Use of CuPF6(MeCN)4 for diaryl ether coupling. 
Chan55 and Evans56 have tried the coupling of aryl boronic acids and 
phenols in copper-mediated synthesis of diaryl ethers. These reactions employ 
stoichiometric quantities of copper (II) acetate. 
OH B(OH)2 
+ 
0~ ~ 1 ~0Me CH2CI2 , 4A mol sieves 81 % AcHN 
AcH OMe 
COOEt EtOOC 
Scheme 1.14. Diaryl ether coupling by using boronic acids. 
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However, the reaction is conducted at room temperature, tolerates a wide 
variety of substituents on both fragments, and proceeds in generally high yields 
(Scheme 1.14). The Ullmann condensation can be enhanced (10 to 15 fold) by 
using 25 mol% of 2,2,6,6-tetramethylheptane-3,5-dione (TMHD) as an additive 
along with CuCI as catalyst and Cs2C03 as the base. TMHD, which exists as the 
diketo tautomer under the reaction conditions, forms a co-complex with the 
copper (I)-phenolate species which kinetically enhances the rate-determining 
step.57 He and Wu58 used a microwave protocol which was developed by 
Buchwald49 to enhance the reaction of aryl bromides and iodides with a range of 
phenols. The same reaction conditions did not work with aryl chlorides since, 
even after 14 hat 195 °C, mostly unchanged starting materials were recovered. 
Phosphazene (P4-t-Bu, also known as Schwesinger base) has been used by 
Palomo et af9 to develop an efficient method for the coupling of aryl halides with 
phenols. They tried Cui , CuCI, CuBr and (Cu0Tf)2 C6H6 as Cu(l) sources and 
found that the use of CuBr in a 20 mol % catalytic amount was the best. No 
reaction was observed when Cu(ll) salts were used. 
Syntheses of diaryl ethers via nucleophilic substitution on the aromatic ring 
( SNAr) reactions were proposed in 1998 as an efficient and alternative method 
to the Ullmann ether synthesis. These reactions involve the base-mediated 
addition of a phenol to an appropriate aryl halide. Sawyer et af0 used KF/alumina 
and 18-crown-6 in acetonitrile or DMSO (Scheme 1.15). 
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SNAr reactions can be accelerated by using halo-substituted benzonitriles or 
nitrobenzenes in refluxing acetonitrile. Even the sterically-crowded nucleophile, 
2-tert-butylphenol, which is usually unreactive under normal Ullmann conditions, 
added smoothly to 4-fluorobenzonitrile to give the diaryl ether. 
t-Bu 
OOH+ F~ KF. Al20 3 , 18-crown-6 ~CN MeCN, reflux 
MeOOOH I + 
~ 
83% 
~ KF. Al20 3, 18-crown-6Meo~OY'jr'CN 
UcN oMso, 140 °c V V 
83% 
Scheme 1.15. SNAr-based addition reactions. 
SNAr-based addition reactions have been used by many researchers 
employing different reaction conditions, for instance KF/AI20 3, 18-crown-6, 
MeCN, reflux;61 K2C03, dimethylacetamide (DMAC), reflux;62 NaH, 4 mM in 
THF63; CsF, DMF;64 and KHC03, THF.65 
All of these examples suggest that the use of either improved Ullmann 
coupling or SNAr-based reactions are potential approaches to construct the biaryl 
ether bonds in the target cycleanine molecule. The use of both of these 
approaches will be presented and described in this thesis. 
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1.4.2.4 Previous synthetic approaches towards cycleanine. 
Cycleanine (48) (0, 0-dimethylisochondodendrine) is a C2-symmetrical 
compound having two benzyltetrahydroisoquinoline units connected by two biaryl 
ether linkages. According to the classification of BBIQ alkaloids by Guha5 and 
Shamma,6 cycleanine is a Type XX, Group B "head-to tail" dimer. Even though 
cycleanine was first isolated from plants in 1937 by Kondo eta/, 66 to date no 
successful enantionselective total synthesis has been reported. 
Me OX(/ 
::::,.., I NHCbz 
MeO Q 9 COOCH, Q COOCH, Me)Q/0 ::::,.., I NHCbz Me Q 
CH2COOH 
(83) 
• NH, ~OMe __ _. 
~OMe 
(84) 
MeO 
MeO 
( d~-cycleanine Methylation I 
(87) 
CH2Cw \ OMe 
NH '-':: 
(8s) I o 
1 
OMe 
Me OX(/ 
I NH 
MeO ::::,.., \ Q OQ 
OMe 
OMe 
CH2C~O O 
' W OMe NH '-':: I 
0 OMe 
(86) 
Scheme 1.15. First synthetic route of Tomita to prepare cycleanine. 
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Up to now there have been only two synthetic efforts toward cycleanine 
which have been reported.67-70 Both attempts however, were not synthetically 
useful because of the very low yield and the lack of regioselectivity and 
stereoselectivity. Tomita et af?-68 completed the first synthesis of (d,/)-cycleanine 
in 1966. As shown in Scheme1.16 in the presence of dicyclohexylcarbodiimide 
(DCC}, carboxylic acid 83 reacted with amine 84 to give the amide 85. 
Deprotection of the amino group and ester hydrolysis, followed by a second 
condensation reaction using DCC afforded the cyclic diamide 86. Cyclization via 
the Bischler-Napieralski reaction followed by reduction with sodium borohydride, 
gave a mixture of tetrahydroisoquinolines 87. Methylation of the secondary 
amines in 87 produced a mixture of (d,/)-cycleanine. This synthetic approach 
gave only <10% yield in the ring-closure step as a mixture of diastereoisomers 
which were not purified. 
The second attempt was conducted by the same group.69-70 As outlined in 
Scheme 1.16, this attempt depended on a dual Ullmann coupling reaction for 
compound 88 to form the macrocyclic compound 87. However, this attempt was 
unsuccessful since the Ullmann reaction gave only the diamine 89 instead. 
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HO 
(88) 
NH Attempted Dual 
H Ullmann Coupling 
MeO MeO 
MeO MeO 
OH 
OMe 
Scheme 1.16. The second attempt at the total synthesis of cycleanine 
OMe 
OMe 
Although this second attempt of the total synthesis of cycleanine was 
unsuccessful and the first attempt only produced a mixture which included 
racemic cycleanine, the information gained from the attempted syntheses by 
Tomita et a/ was significant. Our attempts toward the total synthesis of (-)-
cycleanine (48) include an extensive study to achieve a regioselective and 
stereoselective syntheses of several key benzyltetrahydroisoquinoline 
intermediates. These compounds have been investigated in order to complete 
the diary! ether coupling step that leads to our target. In Chapter 2 of this thesis 
the approach toward the synthesis of (-)-cycleanine (48) using two different 
strategies will be described. 
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Chapter 2 
Synthetic Attempts Towards (-)-Cycleanine 
2.1 Introduction 
The attempted synthesis of (-)-cycleanine (1) by the use of two different 
strategies will be described in this Chapter. The synthesis of 1 has been a long-
standing project of the Georghiou group. At this juncture, the previous 
approaches toward the total synthesis of (-)-cycleanine (1) undertaken by Ralph,1 
Cui2 and Zhou3 during their M.Sc. studies needs to be reviewed. This is 
necessary in order to identify the methodologies employed, and the problems 
encountered by these authors and to place the work described below in context. 
2.1.1 Review of synthetic studies previously conducted. 
2.1.1, 1 Ralph's synthetic studies. 
Cu(ll) mediated boronic 
acid coupling 
Br 
(-)-Cycleanine (1) (2a) 
Plctect-Spengler 
cycllzation P;>(o'('n~ 
0~ r CA 
~ OV PH OBn 
I i"Ph (3) ~ 0 = ¢" 
Br 
Br 
(2) (4) 
Scheme 2.1. Ralph's first retrosynthetic approach toward (-)-cycleanine. 
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The first of these studies conducted in the Georghiou lab 1 in 2001 by M. 
Ralph.1 The retrosynthetic analysis of the target 1, ( Scheme 2.1) suggested that 
the Pictet-Spengler cyclization methodology is one route that may be successful!. 
It was therefore first used to synthesize compound 2, an important precursor 
compound in this approach towards the synthesis of (-)-cycleanine. 
Ralph was unable to obtain the free hydroxyl compound 2a derived from 
the key intermediate, 8-benzyloxy-1-(4-bromo-benzyloxy)-6, 7 -dimethoxy-2-
methyl-1 ,2,3,4-tetrahydroisoquinoline (2), via the Pictet-Spengler cyclization of 3 
and 4. Attention, therefore, was next given to the application of a Bischler-
Napieralski cyclization methodology. 
Pd catalyzed coupling 
W OCH3 (8) OH N CQ" OCH3 
(·)·Cycleanlne (1) 
1 ==> Br 
"<:: 
I csl 
..-:; 
CA 
\ j N" OTBDMS 
' : 
~ischler-Napieralski 
cyclizatlon 
(6) 
==> ¢0H 
OTBDMS 
(7) 
Scheme 2.2. Ralph's second retrosynthetic approach toward (-)-cycleanine. 
The retrosynthetic analysis shown in Scheme 2.2, provided a second 
approach toward 1 using a Bischler-Napieralski cyclization (BNC) methodology. 
This approach targeted the preparation of the key intermediate 5 by using the 
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secondary amine, N-[(R)-methylbenzyl]-(5-bromo-3,4-dimethoxy)phenylethan-
amine (6) and carboxylic acid 7. Application of BNC conditions to the 
intermediate 5 successfully gave the benzyltetrahydroisoquinoline 8. However, 
because this cyclization step gave a very low yield in his preliminary 
experiments, and due to his M.Sc. program time constraints, no further 
investigations were conducted by Ralph using this BNC approach. 
2.1.1.2 Cui's synthetic studies. 
In the second study which was undertaken in 2003 by Jianwen Cui2 , 
vanillin (9) was chosen as the starting material. The synthetic analysis presented 
in Scheme 2.3, shows that bromination, methylation and reduction of vanillin 
could lead to 3-bromo-4,5-dimethoxy-phenylmethanol (10). The hydroxy group in 
10 was first protected as the tert-butyldimethylsilyl (TBDMS) ether to form (3-
benzyloxy-4,5-dimethoxy-benzyloxy)-t-butyldimethylsilane (11 ). t-Buli in the 
presence of B(OMe)3 and H20 2 was used to convert the bromide to a phenolic 
hydroxyl group, which was then subsequently protected as its benzyl ether. The 
aryl acetic acid 12 was then obtained by removal of the TBDMS protecting group, 
followed by chlorination with SOCb in benzene, cyanation with NaCN in DMSO-
benzene, and subsequent hydrolysis. Because (R)-(a)-methylbenzylamine was 
demonstrated to be a convenient reagent in the enantioselective total synthesis 
of (-)-tejedine,4 it was chosen to be the chiral auxiliary in Cui's attempt toward the 
total synthesis of (-)-cycleanine. The Introduction of the chiral auxiliary to 12, via 
a Schotten-Baumann reaction , was followed by reduction of the carbonyl group 
39 
to furnish the secondary amino compound 13. A Schotten-Baumann reaction was 
used again with 14a or 14b followed by a BNC reaction to provide the respective 
benzyltetrahydroisoquinolines 15a, or 15b, and 16a, or 16a. 
0 
CH Od 1-Brz, AcOH cH3o 1-TBSCI,imidazole, OMF 3 7 H 2-Mezso •• NaOH, HzO, CHzCiz V OH 2-t-Buli, B(OMe)J. H20 2 I 3-NaBH4, MeOH, THF ""- I 3-BnBr, K2C03, acetone 
HO ""- CH30 
Vanillin r 
(9) (10) 
CH,O 
VYI("'OTBS 
CH3cY"Y 
(11) BnO 
j 1-TBAF, THF 2-SOCI2 benzene 3-NacN; DMSO, benzene 
4-NaOH, ethanol, 
1-(COCI)2, benzene DMF 
2-(14a,b), NaOH, CH2CI2 
3·POCI3, benzene, refluxe j 4- NaBH4 , MeOH 
CH30p 1-(COCI)l, benzene DMF CH30~COOH 
""- I N'-../"' 2-(R)-(+)-methylbenzylamlne ,NaOH I 
CH30 w· i 3· BH3 JHF, BF3 EtzO, THF cH3 "'-
Bn o' BnO 
CH30 
CH30 
X 
(15a) X= B(OH)2 
(15b) X= I 
(13> I : (12l 
X 
(16a) X= B(OH)2 
(16b) X= I 
Qoo' 
X 
(14a) X= B(OH)2 
(14b) X= I 
Scheme 2.3. Cui's attempt toward the synthesis of (-)-cycleanine. 
After re-evaluation of this work, three drawbacks were noted: (1) The 
neccessity of creating a new hydroxy group demanded two additional steps. A 
starting material therefore, with three hydroxy groups already present could have 
some advantages; (2) Using an expensive protecting group (TBDMSCI) could be 
disadvantageous in a larger-scale synthesis; (3) Separation of the two isomers 
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which were generated in the BNC step is not an easy task, in addition to the low 
yields obtained of the desired compound. 
Despite these experimental difficulties, the methodology employed was seen to 
be a useful route towards the total synthesis of cycleanine. However, the 
problems encountered described above, coupled to the very small amounts of 
the precursors obtained for the biaryl ether formation step and his time 
constraints, a systematic investigation by Cui for the last steps required to 
produce the target compound was precluded. 
2.1.1.3 Zhou's synthetic studies. 
In the third study,3 vanillin was again chosen as a starting material. Zhou 
followed almost the same strategy as Cui but with some variations, as shown in 
Scheme 2.4. Vanillin was mono-brominated followed by conversion of the 
bromide to a hydroxyl group with Cu/NaOH, instead of via the t-Buli/B(0Me)3 
sequence used in Scheme 2.3. Mono methylation of the C-4 hydroxyl followed by 
sequential benzylation and reduction of the aldehyde group afforded 18. The 
carboxylic acid 12 was then prepared in three steps. Conversion of 12 to the 
chiral auxiliary-protected secondary amine 13 was achieved via a Schotten-
Baumann reaction and subsequent reduction of the precursor amide using 
BH3/BF3·Eh0. In order to prepare the key benzyltetrahydroisoquinoline 
intermediates 15b-d and 16b-d, the corresponding carboxylic acids 14b-d 
respectively were introduced to compound 13 each via a Schotten-Baumann 
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reaction, followed by a BNC reaction. The lack of regioselectivity in the BNC step 
however was a major impediment that prevented successful completion of the 
synthesis of (-)-cycleanine by Zhou. 
0 
1-Br2, AcOH CH3:v 
2-NaOH, Cu, H20 "" I H 
3-Me2so.,NaC03, acetone ,.,_ 
CH, 
(17) H 
0 
CH3X( ,;-- H 
I 
H :,... 
(9) 
Vanillin 
1-BnBr, K2C03 , acetone 
2-NaBH•, MeOH, THF 
CH,O:x;J <? OH 
I 
CH, :,... 
(1&) BnO 
j 1-SOCI2 benzene 2-NaCN, DMSO, benzene 
3-NaOH, ethanol, 
1-(COCI)2, benzene DMF CH30:q) 1-(COCI)2, benzene DMF CH,O:x;JCOOH 
2- (14b,c or d), NaOH, CH2Cil ,.,_ I _...N-.....,../2-(R)-(+)-methylbenzylamlne,NaOH ,.,_ I j '·"""'" b"Moo, ~''" CH, BoO H oj 3-BH31HF, BF,.Et20, THF CH3 BnO 
0~ I : 0~ 
X 
(15b) X=l Y=H 
(15c) X=F Y=N02 
(15d) X=BrY=H 
OBn 
X 
(16b) X=l Y=H 
(16c) X=F Y=N02 
(16d) X=Br Y=H 
(14b) X=l Y=H 
(14c) X=F Y=N02 
(14d) X=Br Y=H 
Scheme 2.4. Zhou's approach toward the synthesis of (-)-cycleanine. 
2.2 Results and Discussion. 
Cycleanine has been shown to be biologically-active with potential 
pharmacological applications. For further studies, a relatively inexpensive and 
concise process for producing the required starting materials and intermediates 
which could also allow for structural modifications as well would represent a 
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major contribution. Two different enantioselective synthetic strategies were 
examined in this work and are described in the following sections. 
2.2.1 Attempts toward the total synthesis of (-)-cycleanine. 
2.2.1.1 Preparation of the intermediates 15b-d, 19a-c and 20a-c. 
The benzyltetrahydroisoquinolines 15b-d, 19a-c and 20a-c (Figure 2.1) 
were targeted as potential precursors to achieve the synthesis of (-)-cycleanine 
(1). 
X 
(15b) X= I, Y=H 
(15c) X= F, Y=N02 
(15d) X= Br, Y=H 
X 
(19a) X= I, Y=H 
(19b) X= F, Y=N02 
(19c) X= Br, Y=H 
X 
(20a) X= I, Y=H 
(20b) X= F, Y=N02 
(20c) X= Br, Y=H 
Figure 2.1. Benzyltetrahydroisoquinolines 15b-d, 19a-c and 20a-c. 
As described in Chapter 1, (-)-cycleanine (1) has a C2-symmetric structure 
and is connected in a "head-to-tail" fashion by two diaryl ether linkages. The 
retrosynthetic approaches which were employed in the present study to achieve 
its total synthesis are outlined in Scheme 2.5. 
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y 
Ullmann coupling 
or 
SNAr coupling 
Ullmann coupling 
or 
SNArcoupling 
( -)-Cycleanine (1) 
+ 
X 
(14b) X=l, Y=H (13) PG1= Bn, PG2= CH3 
(14C) X=F , Y=N02 (24) PG1= Bn, PG2= PMB 
(14d) X=Br, Y=H (25) PG1= Bn, PG2= Bn 
==> 
<== 
Bischler-Napieralski cyclization 
y 
benzyltetrahydroisoquinoliens 
(15b-d), (19a-c) and (20a-c) 
u 
X 
y 
(21 a-c), (22a-c) and (23a-c) 
Scheme 2.5. Retrosynthetic analysis for the preparation of (-)-cycleanine via 
precursors 15b-d, 19a-c and 20a-c. 
Scheme 2.5 shows that there are at least four synthetic challenges 
needed to be overcome in order to complete the total synthesis of (-)-cycleanine 
(1). These include: 
1. What is the appropriate starting material which is suitable for preparation 
of the precursors 13, 24 and 25? 
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2. How can the regioselective cyclization steps be accomplished with 
acceptable yields? 
3 How can the desired stereocenter on 15b-d, 19a-c and 20a-c be created 
with high enantioselectivity? 
4. What is the best methodology to accomplish the diary! ether coupling step? 
The answers to questions 1, 2 and 3 are presented below with the 
assistance of Scheme 2.6. However, the last problem, namely, the diary! 
coupling will be addressed in a later section. 
2.2.1.2 The retrosynthetic analysis for the synthesis of benzyltetra-
hydroisoquinolines 15b-d, 19a-c and 20a-c. 
Even though the previous attempts did not reach the final target, they 
provided very valuable guidance. From those attempts it was evident that there 
were some drawbacks to the approaches which have been tried, and thus 
needed to be avoided as much as possible. At the same time, attention has been 
paid in order to benefit from those steps which were useful and constructive. 
As outlined in Scheme 2.6, gallic acid provides an answer to the first 
question noted above for three reasons: (i) It is a reasonably cheap starting 
material; (ii) It has three hydroxyl groups which can be selectively protected in 
order to build the key intermediates 13, 24 and 25; and (iii) It has a carboxylic 
acid group which can be utilized to assemble ring Bon 15b-d, 19a-c and 20a-c. 
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The plan for the synthesis of compounds 15b-d, 19a-c and 20a-c was 
then to first employ a Schotten-Baumann reaction using secondary amines 13, 
24 and 25 with 14b-d, respectively, followed by Bischler-Napieralski cyclizations. 
Selective protection of each of the three hydroxyl groups on the gallic acid, and 
elaboration of the carboxylic acid functional group to a chain- extended 
secondary amine lead to compounds 13, 24 and 25. The synthesis of the 
carboxylic acids 14b, 14c and 14d are discussed in later paragraphs. 
Bischler-Napieralski cyclization Schotten-Baumann reaction 
==> 
y X y X 
Benzyltetrahydroisoquinolines 
(15b-d), (19a-c) and (20a-c) 
(21a-c), (22a-c) and (23a-c) 
AH<= 
HO~OH 
OH 
Gallic acid (13) PG1= Bn, PG2= CH3 (24) PG1= Bn, PG2= PMB 
(25) PG1= Bn, PG2= Bn 
u 
X 
(14b) X=l , Y=H 
(14C) X=F, Y=N02 
(14d) X=Br, Y=H 
Scheme 2.6 The retrosynthetic analysis of 15b-d, 19a-c and 20a-c. 
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In the previous attempts toward the synthesis of cycleanine, the 
introduction of the hydroxyl group into the aromatic ring was one of the 
drawbacks. Gallic acid however possesses three hydroxyl groups and thus two 
steps could be eliminated from the synthesis. Benzyl bromide and para-methoxy 
benzyl bromide (PMBBr) were utilized to protect two of the hydroxyl groups on 
-gallic acid, thus producing the intermediates needed for 13, 24 or 25. To 
investigate the Bischler-Napieralski cyclization step and improve the yields 
obtained in this step, three strategies were decided upon: (i) To protect one of 
meta-hydroxyl groups as its benzyl ether and convert the others to methoxys; or 
(ii) To protect one meta-hydroxyl as its benzyl ether and the other meta hydroxyl 
as its PMB ether and convert the remaining one to a methoxy group; or (iii) To 
protect both of the two meta-hydroxyl groups as the benzyl ether and the 
remaining one as its methoxy ether. Subsequent to forming the BNC steps 
comparison was made to establish which approach gave a higher yield of the 
desired intermediates benzyltetrahydroisoquinoline 15b-d, 19a-c and 20a-c. 
2.2.1.3 Synthesis of the benzyltetrahydroisoquinolines 15b-d, 19a-c and 
20a-c. 
As shown in Scheme 2.7, the first step using the strategy presented in 
Scheme 2.6 is the esterfication of gallic acid by MeOH and SOCI2 to form methyl 
gallate (26) (95% yield). Methyl-3,5-dihydroxy-4-methoxygallate (27 R=H) and 
methyl-3-hydroxy-4,5-dimethoxygallate (28) are formed in yields of 61% and 69 
% respectively by treating compound 26 respectively with 1 or 2 (mol equiv) of 
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dimethyl sulfate5 and potassium carbonate in acetone. Selective mono-
methylation of the C-4 hydroxyl in greater than 61% yield was not achievable. 
After several conditions were tried , it was found that the yield could be increased 
to 61% by decreasing the dimethyl sulfate addition time and cooling the reaction 
temperature to 0 °C during the addition. Treatment of compound 27 ( R=H ) with 
1 (mol equiv) benzyl bromide, to form 27 ( R=CH3 ) and then with 1 (mol equiv) 
PMBBr in the presence of K2C03 and acetone5 afforded methyl-3-benzyloxy-4-
methoxy-5-(4-methoxy-benzyloxy)gallate (29) in 70.3% yield. Treating 27 with 2 
(mol equiv) BnBr in the presence of K2C03 and acetone furnished methyl-3,5-
dibenzyloxy-4-methoxy-gallate (30) in 95% yield . 
(29) 
C~H:JO O 
CH:JO (28) 
OCH3 
HO 
K2co3, (2 mol eq) BnBr, acetone K2C0 3, (1 mol eq) BnBr, acetone 
95% 95% 
BnO 
CH:JO h / ~OCH3 
BnO 
(30) (31) 
Scheme 2.7. Synthesis of intermediates 29, 30 and 31 . 
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Treatment of 28 with stoichiometric amounts of BnBr and K2C03 in 
acetone provided the dimethoxylated 31 in 95% yield . As summarized in 
Scheme 2.8, preparation of the three intermediates, 2-(3-benzyloxy-4-methoxy-5-
(4-methoxy-benzyloxy)phenyl acetonitrile (37), 2-(3,5-dibenzyloxy)-4-methoxy-
phenyl acetonitrile (38) and 2-(3-benzyloxy-4,5-dimethoxyphenyl) acetonitrile (39) 
from compounds 29-31 , respectively was each achieved in three steps. 
P~MBO O ~BnO O C~H30 O 
CH3 (29) CH3 (30) CH3 (31 ) 
OCH3 OCH3 OCH3 
BnO JLIAIH4, THF BnO JLIAIH4, THF BnO JLIAIH•, THF 
94% 94% 94% 
CH~ OH (32) CH,~OH (33) CH,~OH (18) 
BnO JsOCJ2, Py, benzene BnO jsocJ2, Py, benzene BnO j SOCI2, Py, benzene 
85% 85% 85% 
CH~  CH,~ CH,~ 
BnO JN•Cc~. :::o. benzen.""0 \- j j••c:. ~=~0. benzen."no \- A j••c:. :::0. benzene 
89% 89% 89% 
PMBO BnO CH30 
CH,n h CH, n h (38) CH,n - h (39) ~CN (37) ~CN ~CN 
BnO BnO BnO 
Scheme 2.8. Synthesis of intermediates 37, 38 and 39. 
First, reduction of the ester groups of compounds 29, 30 and 31 by lithium 
aluminum hydride provided the corresponding compounds 3-benzyloxy-4-
methoxy-5-(4-methoxybenzyloxy)benzyl alcohol (32), 3, 5-d ibenzyloxy-4-
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methoxybenzyl alcohol (33), and 3-benzyloxy-4,5-dimethoxybenzyl alcohol (18), 
each in almost the same yields (94%). Next, using SOCI2 in the presence of 
pyridine and benzene converted compounds 32, 33 and 18 to the corresponding 
chlorides namely 3-benzyloxy-4-methoxy-5-(4-methoxy-benzyloxy)benzyl 
chloride (34), 3,5-dibenzyloxy-4-methoxybenzyl chloride (35) and 3-benzyloxy-
4,5-dimethoxy- benzyl chloride (36). Finally, the cyanation of 34-36 to form 
compounds 37-39 respectively each in 89% yields was achieved using NaCN in 
dimethyl sulfoxide and benzene. It was found that the benzyl chlorides 
compounds 34-36 needed to be very dry, and that the addition of the NaCN must 
added in small portions, otherwise, oily products with difficulty to purify were 
formed. Scheme 2.9 shows the conversion of compounds 37-39 to the 
corresponding secondary amines on compounds 24, 25 and 13. 
The third question posed previously will now be addressed. There are 
many different strategies or methods available to produce the desired 
stereogenic centers on organic compounds. One of the most common methods 
is by using a chiral auxiliary. For the total synthesis of (-)-tejedine,4 several chiral 
auxiliaries were investigated to achieve this task. (R)-a-methylbenzylamine was 
found to be the best chiral auxiliary to use in order to realize the required target 
compounds. The same chiral auxiliary was therefore used in the syntheses of 
tetrahydroisoquinolines 15b-d, 19a-c and 20a-c. 
so 
CH~:Bh (37) 
~CN 
BnO l NaOH, ethanol, 
88% 
PMBO 
CH31'\ ~ (40) 
COOH 
BnO j 1. (COCI),. benzene, rt 
2. (R)-«-methylbenzylamine 
NaOH, CH2CI2, H20 
79% 
PMBO n CH,~~ 
BnO 0 H 
(42) 
1. BF,.Et20, THF 
2. BH3•THF, 10% 
PMBO f ' CH,~N 
' H BnO (24) 
CH30Bn~ (38) 
)-peN 
BnO NaOH, ethanol, 
88% 
BnO f ' CH,~N, 
BnO 0 H 
(43) 
CH30 f ' CH,O~N, 
BnO 0 H 
(44) 
1. BF3oEt20, THF 
2. BH3 ·THF, 85% 
1. BF,.Et20 , THF 
2. BH3•THF, 85% 
BnO f ' CH,~N 
' H BnO (2S) 
Scheme 2.9. Syntheses of intermediates 24, 25 and 13. 
This chiral auxiliary afforded excellent results in the present study. 
Scheme 2.9 shows the hydrolysis of the cyano groups on compounds 37-39 in 
basic media using NaOH and ethanol, to produce, after acidification, the 
corresponding carboxylic acids 3-benzyloxy-4-methoxy-5-( 4-methoxybenzyloxy)-
benzoic acid (40), 3,5-dibenzyloxy-4-methoxy benzoic acid (41) and 3-benzyl-
oxy-4,5-dimethoxybenzoic acid (12) each in 88% yields. Before introducing the 
chiral auxiliary to compounds 40, 41 and 12, model reactions as outlined in 
Scheme 2.10 were first evaluated in order to determine which method afforded 
the best results for amide formation . 
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1.(COCI)2, CH2CI2 
2.NaOH, CH2CI2, 79% 
Scheme 2.10. Model reactions for introducing the chiral auxiliary group. 
As outlined in Scheme 2.1 0, the model reactions were used on p-
bromophenylacetic acid and the chiral auxiliary by using three different methods: 
(i) Oxalyl chloride conversion of the carboxylic acid to the acid chloride, followed 
by a Schotten Baumann reaction; (ii) Use of dicyclohexylcarbodiimide (DCC), in 
the presence of 1-hydroxybenzotriazole (H0Bt);6 and (iii) use of 
dichlorotriphenylphosphorane (Ph3PCI2) reagenf in CH2Cb to form the acid 
chloride in situ. The three methods provided almost the same yields of chiral-
auxiliary-functionalized amide. Even though dealing with oxalyl chloride makes 
the Schotten-Baumann procedure the most demanding technique of these three 
methods, it was chosen as the method for introducing the chiral auxiliary to 
compounds 40, 41, and 12 because the subsequent purification step proved to 
be the simplest of the three. The amides N-((R)-a-methylbenzyl)-(3-benzyloxy-4-
methoxy-5-( 4-methoxy-benzyloxy) phenylacetam ide (42), N-((R)-a-
methylbenzyl)-(3,5-dibenzyloxy-4-methoxy) phenylacetamide (43) and N-((R)-a-
methylbenzyl)-(3-benzyloxy-4,5-dimethoxy) phenylacetamide (44) were 
synthesized in approximately 10% and 85% yields, respectively. 
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Conditions for the optimal reductions of the secondary amides to the 
corresponding secondary amines were evaluated using two different methods 
summarized in Scheme 2.11. Even though use of LiAIH4 in THF has been 
reported as being a successful reagent for reduction of an amide group,8 
attempts in our hands did not meet with great success. Using borane 
tetrahydrofuran complex (BH3THF) and catalytic amounts of boron trifluoride 
etherate (BF3· Et20) however, produced the desired product in 85% yield. 
BnO 
(44) 
q_ 
N 
\ 
0 H 
LiAIH4 , THF 10% 
1.8F3.et20 
2.BH3 ·THF 85% 
Scheme 2.11. Reduction of the amide group using two different methods. 
Interestingly, reduction of the three different amides with BH3 ·THF did not 
provide the same yields. While the reduction yield of compounds 43 and 44 were 
both approximately 85%, the reduction yield of compound 42 was only 10%. As 
outlined in Scheme 2.12 the major product was compound 45 instead of the 
desired product 24. The proposed mechanism of this deprotection of PMB ether 
is illustrated in Scheme 2.12.9·10 Boron trifluoride can co-ordinate with the PMB 
ether oxygen atom, after that, an electronic delocalization takes place to release 
the parent phenol. The boron trifluoride can also be attacked by the benzyl ether 
oxygen. Nevertheless, the lack of a p-methoxy group on the benzyl protecting 
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group makes this kind of electronic delocalization ineffective in the case of a 
simple benzyl group. Therefore, some Lewis acids can be utilized for selectively 
removing of the PMB protecting group in the presence of a benzyl protecting 
group. 
Scheme 2.12. Proposed mechanism of cleavage of PMB-protecting group by 
BF3·Et20. 
Since the yield of the transformation from the secondary amide 42 to the 
secondary amine 24 was very low, no further investigations were conducted on 
24. Instead, amide 45 was re-protected with a benzyl group to produce the di-
benzylated secondary amide 43. Attention was concentrated on the remaining 
secondary amines 25 and 13. Since compounds 25 and 13 were on hand, 
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Schotten-Baumann conditions were again applied to obtain the tertiary amides 
22a-c and 23a-c respectively, in 72-75% yields (Scheme 2.13). 
Before proceeding to the next steps, the strategies for preparing the 
carboxylic acids 14b-d have to be revealed first. As mentioned in Chapter 1, 
there are two major methodologies to achieve the diaryl ether coupling reactions: 
(i) Ullmann reactions, and (ii) SrvAr reactions. 
BnO f ' CH,~N, 
BnO (25) H 
CH30 f ' 
CH,« N, 
BnO (13) H 
j (COCI)2, benzene, rt, (14b, c and d) NaOH, CH2CI2, 70-75% j (COCI)2, benzene, rt, (14b, c and d) NaOH, CH2CI2, 70-75% 
BnOWJ ~ ;) 
Bn 
CH30 ~ O~N 
(22a) X= I, Y=H 
(22b) X= F, Y=N02 
(22c) X=Br, Y= H 
,;7 
I 
~ X 
y (23a) X=l, Y=H 
(23b) X=F, Y=N02 
(23c) X=Br, Y= H 
Scheme 2.13. Preparation of the tertiary am ides 22a-c and 23a-c. 
One of the requirements of the Ullmann reaction is the presence of a good 
leaving group on the aromatic ring such as Br, I, or B(OH)2. However, part of the 
requirements of the SNAr reactions is the presence of a good electron-
withdrawing group on the aromatic ring. In attempts to investigate which strategy 
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would give better results in the diaryl ether coupling step, three different 
carboxylic acids were prepared: 14c which was utilized for the StAr reaction , and 
14b and 14d which were utilized in the Ullmann reactions. As illustrated in 
Scheme 2.14, 4-fluoro-3-nitrophenylacetic acid was prepared in five steps. A 
previous study11 has shown that the presence of a nitro group ortho to a fluoride 
group facilities the nucleophilic substitution of the fluoride on the aromatic ring 
(StAr). 
Scheme 2.14 commences with the nitration of the commercially-available 
starting material 4-fluorobenzaldehyde (46) using a mixture of HN03 and H2S04 
to produce 4-fluoro-3-nitrobenzaldehyde (47) in 85% yield . Reduction of the 
aldehyde group to the corresponding primary alcohol was accomplished using 
sodium borohydride to furnish 4-fluoro-3-nitrobenzyl alcohol (48) in 95% yields. 
F 
(46) 
NaBH
4 
~OH 
NOTHF,CH3oi'f NO 
2 95% 2 
F F 
(47) (48) 
rOCI2, benzene, 95% 
coo:onc HCI(aq) ~~N NaCN ~~~ 
reflux :::::-.... benzene :::::-.... 
N02 920, N02 N02 /0 75% 
F F F 
(14c) (50) (49) 
Scheme 2.14. Preparation of the carboxylic acid 14c. 
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Conversion of the primary hydroxyl group using SOCb in benzene 
furnished 4-fluoro-3-nitrobenzyl chloride (49) in 95% yields. Cyanation of 49 
using sodium cyanide gave 4-fluoro-3-nitrophenyl acetonitrile (50) in 75% yields. 
Finally, hydrolysis of the cyano group in acidic media using aqueous 
concentrated HCI under reflux conditions gave the desired carboxylic acid 14c in 
92% yields. 
p-Bromophenylacetic acid (14d) is commercially available, but p-
iodophenyl acetic acid (14b) was synthesized in three steps as shown in Scheme 
2.15. Treatment of the starting material, p-iodotoluene (51) with N-
bromosuccinimide (NBS) lead to the formation of p-iodobenzylbromide (52) in 
quantitative yields. Cyanation followed by hydrolysis of compound 52 gave P-
iodophenyl acetonitrile (53) and p-iodophenylacetic acid (14b) respectively. 
Q COOH 
Br 
(14d) 
¢ NBS benzene a 
100% 
I 
(51) 
B CN Q r NaCN, DMSO <-' benzene ~ 
75% 
I I 
(52) (53) 
NaOH a 
EtOH 
95% 
Scheme 2.15. Preparation of the carboxylic acid 14b. 
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I 
(14b) 
Extensive investigations were conducted in order to explore whether 
compounds 22a, 22b and 22c, which each have two protecting groups or 
compounds 23a, 23b, and 23c, which each have a single protecting group gave 
better results in the BNC step. 
Application of BNC conditions therefore on compounds 23c, and 23d each 
formed two regioisomers 15c and 16c; and 15d and 16d, respectively (Scheme 
2.16). Since there are two promising ringclosure sites, ortho and para to the 
benzyloxy group, on each of the amides 23c, and 23d, the BNC step would be 
predicted to produce two ring closure products 
(541) 
(15c) X• F, Y• NO: 
(15d) X• Br, Y• H 
OCH3 
d~ 11 I 0 f OCH, OBn U s 23c X• F, Y• N02 u 23dX• Br, Y• H 
OCH3 
T OCH, 
OBn 
X 
11-P: I3,benzene,reflux 
~ j_ ~ 
OBn -
~ - ~ I d . ~ QCH3 (54b) OCH3 ~ 
~ !. 
NaBH4,MeOH, -78 •cl X ' 
' OBn 
I OCH, 
OCH3 (16c) X• F, Y• NO, (16d) X• Br, Y• H 
X 
Scheme 2.16. Preparation of the benzyltetrahydroisoquinolines 15c, d 
and 16c, d. 
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After heating the amides 23a, and 23c with phosphorus oxychloride in 
anhydrous benzene for 6 h at reflux, the resulting mixture of iminium salts 54a, 
and 54b were reduced by sodium borohydride to produce two regioisomers 15b 
and 15d; and 16bc and 16d for each pair in 23%, 91de% and 30%, 91de% 
yields, respectively. The desired regioisomers 15c-d were produced in > 91 % de, 
as calculated approximately from their 1 HNMR spectra. 
The presence of the chiral auxiliary most probably causes the reduction to 
occur from the less-hindered face (Re-face) to produce the desired stereogenic 
center.12 This would be as a result of the steric hindrance offered by the phenyl 
and benzyl groups of the chiral auxiliary moiety (Scheme 2.17). 
13 -face addition of hydrogen to imine CH30 
the less hindered face 
a-face addition of hydrogen to imine 
the more hindered face 
/ 
OBn 
X 
Scheme 2.17. Effect of the chiral auxiliary on the direction of the reduction . 
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The cyclization to the site para to the benzyloxy group was preferred to 
that of the ortho site due to the steric hinderance offered by the benzyloxy group, 
the yields of compound 16b and d were higher than those of compound 15b and 
15d. The chromatographic purification of each of the regioisomers was not easily 
achieved, since their properties are very similar to each other. Three successive 
columns chromatographic separation were needed. 
l S d A J -·~--· 
16d B 
5 .5 5 .4 5 . ) 5 .;2 5. 1 5.0 4 .9 .... 4 .7 4.6 4 .5 ..... " · ' 
fl (ppm) 
Figure 2.2. (A) : Ha and Hb 1H NMR shifts of compound 15d; (B): Ha and Hb 1H 
NMR shifts of compound 16d. 
Distinguishing between each of two regioisomers was achieved using two 
different techniques. First; the NMR spectra of the 
benzyltetrahydroisoquinoline 15d shows two doublet signals at 5=5.1 2 and 4.20 
ppm (JAx = 9.7Hz) (Figure 2.2 A) which is a first-order splitting pattern. These two 
signals belong to protons Ha, and Hb, on the benzyl group. The two protons have 
different chemical shifts, because they are influenced unequally by the adjacent 
60 
p-bromobenzyl group. Since there is no direct influence of the p-bromobenzyl 
group on protons Ha and Hb for compound 16d the two protons appear at o= 5.19 
and 5.15 ppm (JAB =5 Hz), which is a second-order splitting pattern (Figure 2.1 B). 
Second, X-ray crystallography13 (Figure 2.3) confirms the ring closure site and 
the desired stereogenic center of compound 15d. 
Figure 2.3. The X-ray crystallographic structure of compound 15d. 
Applying the BNC conditions to compounds 22a-c resulted in the 
formation of benzyltetrahydroisoquinolines 19a-c in 55-65% yields and in > 91% 
de, as calculated approximately from their 1HNMR spectra. 
dwB~= ::~l OBn ,_ 
~ /, 
X y 
(22a) X= I, Y= H 
(22b) X= F, Y=N02 
(22c) X= Br, Y= H 
1.POCI3, benzene, refluxd 
2.NaBH4, MeOH, ·78°C fj ~ 
55~5% -
91de'lo 
y 
(1 9a) X= I, Y= H 
(1 9b) X= F, Y=N02 
(1 9c) X= Br, Y= H 
Scheme 2.18. Preparation of the intermediates 19a-c. 
61 
.---------------------- -------
As shown in Figure 2.4, the X-ray crystal structure of compound14 19c 
shows the desired stereogenic center. Unfortunately, attempts to crystallize 
compounds 19a and 19b did not meet with similar success. 
Figure 2.4. The crystallographic structure of compound 19c. 
Moreover, two side-products 55 which was obtained in 5% yield and 56 
which was obtained 10% yield were separated after the application of BNC step 
on compound 22b (Figure 2.5). 
BnO BnO 
Cl 
OBn 
(55) (56) 
Figure 2.5. The two-side products 55 and 56. 
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X-ray crystallography15 for compound 56 established the structure of this 
compound (Figure 2.6). 
Figure 2.6 The crystallographic structure of compound 56. 
Before continuing the description on the synthetic endeavors, two 
observations will be elaborated upon. First, the proposed mechanisms of 
formation of compounds 55 and 56 from compound 22b, will be presented with 
the assistance of Schemes 2.19 and 2.20. 
As shown in Scheme 2.19, intermediates I-IV are formed via the standard 
BNC process. However, it is presumed that intermediate IV undergoes a 
hydrolysis reaction instead of the usual NaBH4 reduction that forms the 
corresponding benzyltetrahydroisoquinoline 19b. This hydrolysis can be 
envisioned to form isoquinoline 55 via intermediates V-VI. Presumably, the more 
stable aromatic form, IX, is formed via tautomerization of VIII. The lone pair 
electrons on the nitrogen atom of compound V delocalized to form the 
intermediates VIII and VI. Compound 55 can be formed by de-protonation from 
the intermediate VI. 
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0~ F 
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0~ Ill F 
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~ 
0~ F 
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F 
IX (55) 
Scheme 2.19. Proposed mechanism of formation of compound 55. 
The proposed mechanism of formation of compound 56 is illustrated in 
Scheme 2.20. A chloride ion presumably displaced the amide group which could 
have been assisted by the POCb as shown, to form 56.16 
Scheme 2.20. Proposed mechanism of formation of compound 56. 
Secondly, the 1H- and 13C-NMR spectra in CDCI3 of compounds 22a-c and 
23a-c showed a doubling of the majority of the signals. Several studies 17"20 
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reported that the presence of the amide bond in some tetrahydroisoquinolines 
results in the formation of rotamers. As shown in Scheme 2.21, rotation about 
the amide bond of compound 23b leads to interconversion of the two rotamers 
23b and 23b' which is sufficiently slow on the NMR time scale, and as a result, 
the 1H- and 13C-NMR signals are duplicated. 
Scheme 2.21. The structure of the two rotamers 23b and 23b'. 
Using the 1H-NMR spectrum of 23b in CDCb (Figure 2.7) as an example, 
the H-W signals appeared as two doublets at o 1.62-1.49 ppm, while the two 
methoxy groups appear as four singlets at o 3.91-3.78 ppm. Furthermore, the 
integration of the signals obtained from the 1H-NMR spectra under ambient NMR 
conditions reveals that the two rotational conformers are present in a ratio :::::: 1:1.8 
(in CDCb). 
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Figure 2.7. The 1H-NMR spectrum of 23b. 
2.2.1.4 Attempts at the diaryl ether coupling. 
2.2.1.4.1 The formation of compounds 58a-c. 
In order to effect the diaryl ether coupling steps, the benzyl groups need 
first to be removed from compounds 15a-c and 19a-c. The most common 
method to cleave benzyl groups in general, is via Pd/C-catalyzed 
hydrogenolysis.21 -23 In order to test the hydrogenolysis conditions required for our 
compounds, compound 19c was first utilized. A mixture of 19c, 10% Pd/C, 
ethanol, EtOAc and HCI(aq), was stirred for 24h under H2. However, these 
conditions did not give the desired de-benzylated product. 1-Benzyl-6,8-
dihydroxy-7-methoxy-1 ,2,3,4-tetrahydroisoquinoline (57) was formed instead, in 
which the bromine, the chiral auxiliary, and both benzyl groups were removed 
(Scheme 2.22). 
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OBn OH 
OCH H2, Pd/C, 3 EtOH, EtOAc, HCI 
(57) 
Br 
Scheme 2.22. Hydrogenation of Compound 19c. 
A study in 200624 showed that selective de-benzylation in the presence of 
a halogen group can be achieved using Raney nickel in MeOH. However, when 
similar conditions were employed on compound 19c, compound 57 was again 
produced, this time in 19% yield, along with compounds 58 in 33 %, and 59 in 30 
%yields, respectively (Scheme 2.23). 
From the results of the previous two hydrogenation conditions it was 
presumed that, since the benzyl group on C-5 is sterically hindered, the bromide 
aryl is more susceptible for hydrogenolysis. Consequently, attention was paid to 
milder hydrogenation conditions or a different debenzylation method. 
Br 
H2• Raney Ni, 
MeOH 
Scheme 2.23. Hydrogenation of Compound 19c. 
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Even though compound 57 is not the desired product it is nevertheless of 
interest. Many recent reports25-27 have identified that, 1-benzyl-1 ,2,3,4-
tetrahydroisoquinoline and some of its derivatives, for example, papaverine (60), 
1-benzyl-6, 7 -dimethoxy-3,4-dihydroisoquinoline (61 ), 1-(3' ,4' -dihydroxybenzyl)-
6, 7 -dihydroxy-1 ,2,3,4-tetrahydroisoquinoline (62), and 1-(3' ,4' -dimethoxybenzyl)-
6,7-dimethoxy-1 ,2,3,4-tetrahydroisoquinoline (63), are endogenous neurotoxins 
that have been proposed as etiological factors for Parkinson's disease28 (Figure 
2.8). Further investigation needs to be done on compound 57 to establish 
whether it too, could be a potential endogenous or exogenous neurotoxin. 
CH30 
HO 
HO 
Figure 2.8. The structures of 60 - 63. 
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Using milder hydrogenation conditions (H2, Pd/C in CH2Cb) on 16d led to 
the formation of only 64, in which the bromine was removed, together with 
unreacted starting material (Scheme 2.24). 
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OBn OBn 
0 OCH3 H2. Pd/C OCH3 CH2CI2 
(16d) Br (64) 
Scheme 2.24. Reduction of 16d via Pd/C catalyzed hydrogenolysis conditions. 
Attention was then directed torwards an alternative mild-condition method 
to achieve the debenzylation. Many studies 19-34 have reported that Lewis acids 
[e.g. titanium tetrachloride (TiCI4) or tin tetrachloride (SnCI4)] can be utilized at 
room temperature to cleave a benzyl group. 
Br 
15% 
TiCI4, CH2CI2, rt 
35% 
Scheme 2.25. Debenzylation of 15d via SnCI4 and TiCI4. 
Br 
When compound 15d was stirred with SnCI4 for 48 h however, only a 15 % 
yield of the desired phenolic compound 65c was obtained (Scheme 2.25). Even 
though the reaction was conducted under relatively mild conditions, only 20% of 
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unreacted starting material was recovered . Reaction of compound 15d with TiCI4 
under the same conditions that were used with SnCI4, increased the yield of 65 to 
35%. 
(15b) X= I, Y= H 
(15c) X= F, Y= N02 
OCH3 
X 
TiCI4 , CH2CI2 
35% 
(65b) X= I, Y= H 
(65c) X= F, Y= N02 
Scheme 2.26. Reduction of 15b and 15c. 
X 
As with SnCI4, only a small amount of the starting material was recovered 
and the rest was a brown intractable residue (Scheme 2.25). Since the TiCI4 
conditions afforded the desired phenolic compound the same conditions were 
employed with compounds 15b and 15c to give compounds 65b and 65c, 
respectively (Scheme 2.26). 
It was expected that since in the case of compounds 19a-c each contains 
two benzyl groups that the debenzylation steps would result in more complex 
results. As shown in Scheme 2.27, the desired selective mono-debenzylation for 
compounds 19c by using 1 mol eq of TiCI4 in CH2CI2 was unachievable. 
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However, the steric hinderance around the C-8 benzyloxy group 
presumably could again (Scheme 2.23) account for the reduced the yield of 66c 
to less than 5%. 
less than 5% 
OBn 
r J 1 
)-N \{I ' ' OCH3 0 (66c) ~ 
~ I 
r 
25% 16% 
Scheme 2.27. Reduction of 19c via TiCI4-mediated debenzylation. 
On the other hand, because the benzyloxy group on C-6 was more 
accessible, compound 58c was formed in 25% yields. Compound 67c in which 
the two benzyl groups on 19c were removed, was formed in 16% yield. The 
desired intermediate 65c was nevertheless prepared from compound 58c by 
methylation of the C-6 hydroxy group with dimethyl sulfate to produce compound 
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15c in 95% yields, followed by debenzylation. However, the C-6 hydroxy group of 
compound 67c was methylated to form 65c in 65% yields. 
Increasing the number of molar equivalents of TiCI4 in the reacton 
elevated the yields of 67a-c to -52%. When methylated, 67a-c formed 65a-c in 
-34 % yields from 19a-c (Scheme 2.28). 
y 
(19a) X= I, Y= H 
(19b) X= F, Y= N02 
(19c) X= Br, Y= H 
y 
(67a) X= I, Y= H 
(67b) X= F, Y= N02 
(67c) X= Br, Y= H 
OH 
OCH3 MeS04, CHzCiz 
65 % 
y 
(65a) X= I, Y= H 
(65b) X= F, Y= NOz 
(65c) X= Br, Y= H 
Scheme 2.28. Reduction of 19a-c via 4 mol equivalent of TiCI4. 
X 
In order to assign some 1H-NMR signals in the spectra of intermediates 
that were produced after the BNC step, 2-D correlation spectroscopy (COSY) 
experiments were conducted. For compound 58b, as shown in Figure 2.9, for 
example, there is a cross-peak correlation between the signals at o 1.31 and 
3.68 ppm. These two signals are attributed to the protons on C-~· and C-~ . 
respectively. Furthermore, there is a cross-peak correlation between the signals 
at o 2.58 and 3.43 ppm, which are attributed to the protons on C-a' and C-1, 
respectively. There is also a cross-peak correlation between signals at o 2.44, 
2.95, and 3.46 ppm. These signals are attributed to the protons on C-3 and C-4. 
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Figure 2.9. The structure and COSY spectrum of compound 58b. 
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The NOESY spectra showed a NOE between H5 and the two protons of 
the benzyl group for compound 66b. This effect was not shown in 58b in which 
there is a NOE between the two protons of the benzyl group and Ha' (Figure 2.3). 
NOE 
H 
Figure 2.1 0. NOED used to distinguish between regioisomers 58b and 66b. 
2.2.1.4.2 The first attempt toward the diaryl ether coupling via the improved 
Ullmann coupling approach. 
With enantiomerically-pure benzyltetrahydroisoquinolines 65a-c in hand, 
the corresponding diaryl ether couplings were attempted. As mentioned in a 
previous section, there are two major approaches to achieve diary ether 
coupling, namely Ullmann coupling and SrvAr reactions. 
-1-0-0H+ l-o-N02 _ _,.+-O-Q-o-N02 
Scheme 2.29. A model reaction for the Ullmann reaction . 
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Table 2.1. Yields of the diaryl ether products (Scheme 2.29) using different 
Ullmann coupling conditions. 
Conditions Yields% 
Cs2C03, 0.25 mol% ( Cu0Tf)2. PhH, toluene, 66% 
5 mol% EtOAc, 1-naphthoic acid, 96 °C 
Cs2C03, 0.25 mol% CuCI, toluene, 5 mol% EtOAc, 33% 
1-naphthoic acid, 96 °C 
CsF, 0.25 mol% ( Cu0Tf)2. PhH, toluene, 5 mol% 35% 
EtOAc, 1-naphthoic acid, 96 °C 
BaO, CuCI2, DMF, 115 °C 54% 
Cs2C03, CuCI, TMHD, 120 °C 70% 
Cs2C03, Cui , N,N-dimethyl glycine, dioxane, 90 °C 64% 
In order to experiment with different Ullmann reaction conditions and to 
test the reactivity of the reagents used in those experiments, and also to save the 
valuable intermediates 65a-c, model reactions were first conducted (Scheme 
2.29). Six different conditions were tried to determine which method afforded the 
best results.35-38 As shown in Table 2.1, the yields of 4-nitrophenyl-4-t-
butylphenyl ether varied under all the conditions examined. Since the procedure 
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in which CuCI was used with Cs2C03 in the presence of a catalytic amount of 
2,2,6,6-tetramethylheptane-3,5-dione (TMHD), as reported by Song and co-
workers,37 and which afforded the highest yield, it was tried first with 65a and 
65c. 
After stirring either of 65a and 65c with Cs2C03, CuCI and TMHD at 120°C 
for 96 h, no changes in the starting materials were observed (Scheme 2.30), and 
only unreacted starting materials were recovered. Attention was then directed to 
the use of other procedures. However, none of these approaches gave the 
desired product 68. 
(65a) X= I 
(62c) X= Br 
X 
Scheme 2.30. The first attempts via Cs2C03 I CuCI/ TMHD Ullmann reaction 
conditions. 
In order to try to ascertain factors which could be responsible for the 
unreactivity of the intermediates 65a and 65c a molecular mechanics modeling 
study was conducted. 
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Figur 2.11. The structure of compound 65c generated by Spartan' 08. 
As shown in Figure 2.11, the p-bromobenzyl and the chiral auxiliary 
moieties shield the top and bottom faces of the intermediate 65c and 
presumably, also, of 65a. These steric effects could consequently inhibit the 
hydroxyl group of a reacting partner in the homodiaryl ether coupling step from 
displacing the halide of the other partner. 
The optimal way to decrease these steric effects could conceivably be to 
first remove the chiral auxiliary group. Unfortunately, the chiral auxiliary is 
removed under the same hydrogenation conditions which remove the halide 
group as well , and selective removal conditions would be necessary to establish 
first. 
2.2.1.4.3 The second attempt toward the diaryl ether coupling via the SNAr. 
Attention was then directed to the StAr approach. As mentioned in 
previous sections, the presence of a nitro group ortho or para to the halide(s) 
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enhances the direct nucleophilic substitution coupling reactions. Such an 
approach has been successfully utilized recently by using different reagents; for 
instance: KF/Ab03, 18-crown-6, MeCN, reflux; 39 K2C03, dimethylacetamide 
(DMAC), reflux;40 NaH, 4 mM in THF;41 CsF, DMS0;42 and KHC03, THF.43 
Since positive results were obtained in the synthesis of (-)-tejedine with 
CsF in DMS0,42 these conditions were used first. During 144 h of stirring of 
compound 65b with CsF in DMSO at room temperature, the reaction was 
monitored by TLC and HPLC techniques. After 48 h, monitoring of the reaction 
showed the presence of some new small spots on the TLC. The reaction was 
stirred for 6 days in total, after which work-up afforded a brown residue. HPLC-
ms analysis of this residue suggested the presence of compound 69 and 70. 
(Scheme 2.31) as indicated by peaks corresponding to 893.01 and 913.01. 
Unfortunately, attempts towards the purification of either of these compounds did 
not meet with success, and no further characterizations could be made. 
Even though compounds 69 and 70 could not be completely characterized 
via the previous procedure, the S~r-based approach showed some promising 
results for forming the diaryl ether linkages needed for the target compound, (-)-
cycleanine. 
Other conditions were employed with compound 65b, such as K2C03, 
THF, 18-C-6,44 K2C03, CH3CN, 18-C-6,45 and 0.5 mol% Pd2dba3, 2.0% mol t-
Bu3P, K3P03 ( 3 eq) in dioxane,46 respectively. 
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F 
CsF. OMSQ 
114 h, rt 
Scheme 2.31. The diaryl ether coupling of compound 65b. 
However, none of these methods gave the desired product. Approximately 
80 % of the starting material was recovered in each experiment. Therefore, the 
subsequent steps (Scheme 2.32) such as removing the nitro and chiral auxiliary 
groups, and the introduction of the methyl group to the secondary amine were 
not completed. 
Scheme 2.32. 
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2.3 Summary and conclusions. 
After re-evaluation of the BNC steps using compounds 22a-c and 23a-c, 
and debenzylation of compounds 15a-c, 16a-c, and 19a-c, three significant 
observations were concluded: (i) the presence of two similar protecting groups 
along with a suitable chiral auxiliary on compounds 22a-c produced 
stereoselective isomers with acceptable yields in the BNC step; (ii) the presence 
of one protecting group on compounds 23a-c produced two hard-to-separate 
regioisomers. (iii) after the BNC, the debenzylation and the methylation steps, the 
final yields of the desired intermediates 65a-c via the use of two similar 
protecting groups in the starting materials 22a-c were :::::: 22% however, while the 
final yields for the same steps but different protecting groups as in 23a-c were :::::: 
5%, as well as having the disadvantage of having to separate regioisomers. 
As a conclusion, the use of intermediates 22a-c, having similar protecting 
groups, was a successful approach to improve the yields of the BNC step. 
Moreover, the drawback of forming two regioisomers that faced the previous 
students in Georghiou group during their attempts toward the total synthesis of 
(-)-cycleanine was avoided. 
The enantioselective homo-aryl ether coupling synthesis of (-)-cycleanine 
was attempted via two different approaches namely: (1) the improved Ullmann 
approach using 65a which has a free hydroxyl group and an iodide, with 65c 
which has a free hydroxyl group and a bromide; and (2) the StAr approach using 
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65b which has a free hydroxyl group, a fluoride and a nitro group ortho to the 
fluoride. However, neither of these two approaches gave a satisfactory result. 
This auther suggests that the total synthesis of (-)-cycleanine is still achievable if 
the intermediate benzyltetrahydroisoquinolines that are used as precursors can 
be prepared by shorter routes and in higher yields, and if the steric-hindering 
effect around the nucleophile and the electrophile can be decreased. 
2.4 Proposal for future endeavours toward the total synthesis of 
(-)-cycleanine. 
The procedure outlined below in Scheme 2.33 involves ten steps to 
achieve the total synthesis of (-)-cycleanine. As shown is Scheme 2.33, this 
proposal commences with di-bromination of the commercially-available p-
methoxybenzaldehyde to form compound A. Due to the meta-orientation of the 
aldehyde group on the starting material this step always gives very high yields. 
Substitution of the two bromines on A to form the corresponding 
benzyloxy groups provides compound 8 ,36 with the subsequent step being the 
well-known Henry reaction .47 Addition of nitro methane to the aldehyde in the 
presence of a base, followed by reduction leads to a primary amine. The 
Schotten-Baumann reaction , then BNC leads to the formation of D. The chiral 
auxiliary, which is proposed in this approach is one reported by Rodrigues et a/. 
in 1994.48 This chiral auxiliary is introduced by reaction of the imine with (+)-8-
phenylmenthyl chloroacetate, in methanol (Scheme 2.34). 
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1. Scholten-Baumann ! 
2. BNC i 
3. introducing of the i 
chiral auxiliry t 
4. NaBH4 , MeOH 
(-~cleanine 
CH O 1. TiCI,, CH2CI2 BnO ~-,._.,.,.,_~,,., __ CH:m.:--''-C~·' ·-~·C~·---~".m"' 
OH ·u OBn u· 7 
E I D I 
"'- X "'- X 
Scheme 2.33. A proposed procedure for the total synthesis of (-)-cycleanine. 
Introduction of the chiral auxiliary followed by addition of Na8H4 leads to 
the reduction from the desired side, removal of the chiral auxiliary group and 
methylation of the nitrogen atom in the same step form the required isomer 
enantioselectively. (+)-8-Phenylmenthyl group anticipated to shield one side of 
the dihydroisoquinoline much more efficiently than the other (Scheme 2.34). 
+ CICH,COY 
( +)-8-Phenylmenthyl 
X X 
Scheme 2.34. The structure of the proposed chiral auxiliary. 
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Debenzylation of compound D followed by methylation leads to the 
desired precursor E. Preparation of E in nine steps, and without the chiral 
auxiliary, should increase the yields of the intermediates and decrease the 
potential steric effect around the nucleophilic hydroxyl group which would 
potentially enhance the possibility of effecting the diaryl ether coupling. 
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Experimental 
General 
Flash column chromatography was performed using 240-400 mesh silica gel 
and preparative layer (1 mm) chromatography (PLC) was conducted using 60 A 
mesh silica gel. All solvents and reagents used were either of the highest 
commercial grade available or were redistilled (CH2CI2 , hexane, and benzene 
distilled over CaH2 ; MeOH was dried over Mg and 12). 1H and 13C NMR spectra 
were obtained on the Bruker Advance 500 MHz instrument with a TXI inverse-
detect gradient probe in CDCI3 unless otherwise specified, and shifts are relative 
to an internal tetramethylsilane signal. The following abbreviations are used in 
descriptions of the 1H NMR spectra: s (singlet), d (doublet), t (triplet), q (quartet), 
m (multiple) and b (broad). The 1H and 13C NMR spectra chemical shifts were 
measured relative to the solvent. Overlap may have prevented the reporting of all 
resonances. Low-resolution mass spectral data were obtained from the V.G. 
Micromass 7070HS instrument or obtained from Atmospheric Pressure Chemical 
Ionization-Mass Spectrometry (APCI-MS). Mass spectral data and intensity (%) 
are described as MS (m/z) unless mass data were obtained from Atmospheric 
Pressure Chemical Ionization-Mass Spectrometry (APCI-MS), which are 
described as (APCI-MS (m/z). Melting points (m.p.) were determined using a 
Fisher-Johns hot stage apparatus and are uncorrected. 
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Methyl gallate (26). 
0 
HO 
HO 
To a solution of gallic acid (12 g, 71 mmol) in methanol (200 ml) was 
added drop-wise SOCI2 (5 .6 ml, 78 mmol) at 0 °C. The solution was allowed to 
warm to rt before it was heated at reflux for 2 h. The reddish-brown solution was 
cooled to rt and quenched by addition of water (30 ml), and then the mixture was 
extracted with ethyl acetate (20 ml x 3). The combined organic phases were 
washed with water (20 ml x 3) , dried over MgS04, filtered , and the solvent was 
evaporated to give 26 (13 g, 97%) as a colourless solid ; m.p 204-205 °C. 1H 
NMR (MeOD): o 7.05 (s, 2H, H-2, H-6), 4.87 (s, 3H, OH), 3.81 (s, 3H, OCH3); 
13C NMR o 166.7, 148.87, 138.39, 126.21 , 110.00, 61 .08; MS (m/z, %): 185 
(M++1, 1}, 184 (M+, 5), 183 (M+ -1 , 100), 167 (4), 166 (30), 153 (4). 
Methyl-3,5-dihydroxy-4-methoxygallate (27). 
0 
A mixture of 26 (10 g, 54 mmol), potassium carbonate (6.7 g, 49 mmol), 
dimethyl sulfate (4.6 ml, 49 mmol) in water-free acetone (150 ml) stirred at rt for 2 
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h. The solution was diluted by addition of water (30 ml), and then the mixture was 
extracted with ethyl acetate (20 ml x 3). The combined organic phases were 
washed with water (20 ml x 3), dried over MgS04 , filtered , and the solvent was 
evaporated to give 27 (6.7 g, 61%) as a colourless solid ; m.p 149-150 °C. 
1H NMR: o 7.25 (s, 2H, H-6, H-2), 5.62 (s, 2H, OH), 3.98 (s, 3H, OCH3), 3.90 (s, 
3H, OCH3); 13C NMR: o 166.76, 148.87, 138.39, 126.21, 110.00, 61 .08, 52.62; 
MS(m/z): 198 (M+ +1, 1), 197 (M+, 5), 196 (M+-1 , 100), 182 (4), 181 (30), 166 (4). 
Methyl 3-hydroxy-4,5-dimethoxy gallate (28). 
0 
A mixture of 26 (9.1 g, 49 mmol), potassium carbonate (14 g, 98 mmol), 
dimethyl sulfate (9.2 ml, 98 mmol) in water-free acetone (150 ml) stirred at rt for 3 
h. The solution was diluted by addition of water (30 ml), and then the mixture was 
extracted with ethyl acetate (20 ml x 3). The combined organic phases were 
washed with water (20 ml x 3), dried over MgS04, filtered, and then the solvent 
was evaporated to give 28 (7.3 g, 69%) as a colourless solid ; m.p 76-77 °C. 1H 
NMR: o 7.30 (d, J= 5 Hz, 1 H, H-6), 7.20 (d , J= 5 Hz, 1 H, H-2), 3.95 (s, 3H, 
OCH3), 3.90 (s, 3H, OCH3), 3.89 (s, 3H, OCH3); 13C NMR: o 166.88, 152.13, 
149.18, 139.88, 125.83, 110.10, 105.88, 61 .18, 56.23, 52.52; MS(m/z): 213 
(M++1, 1), 212 (M+, 5), 211 (M+ -1, 100), 197 (4) , 196 (30), 181 (4). 
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Methyl 3-benzyloxy-4-methoxy-5-(4-methoxybenzyloxy) benzoate (29). 
-0 
1 0 
a 
_}) 
0 a 
Methyl-3-benzyloxy-5-hydroxy-4-methoxy benzoate (27a) was prepared in 
74% yield by the reaction of 27 (10 g, 51 mmol) with benzyl bromide (8.7 g, 51 
mmol) in the presence of potassium carbonate (7.1 g, 51 mmol) in acetone. A 
mixture of 27a (12 g, 42 mmol) potassium carbonate (5.8 g, 42 mmol), p-
methoxybenzyl bromide (PMBBr) (7.3 ml, 50 mmol) in anhydrous acetone (150 
ml) was stirred at rt for 48 h. The solution was diluted by addition of water (30 
ml), and then was extracted with ethyl acetate (20 ml x 3). The combined organic 
phases were washed with water (20 ml x 3), dried over MgS04, filtered, and the 
solvent was evaporated to give 29 (16 g, 93%) as colourless solid ; m.p. 116-117 
°C; 1H NMR: o 7.45 (m, 9H, Ar-H), 6.97 (s, 1 H, H-2), 6.95 (s, 1 H, H-6), 5.20 (s, 
2H, H-a), 5.12 (s, 2H, H- a'), 3.85 (s, 3H, OCH3), 3.84 (s, 3H, OCH3) 3.80 (s, 3H, 
OCH3); 13C NMR: o 166.79, 159.64, 152.37, 150.58, 143.89, 136.90, 128.74, 
128.61, 127.57, 125.10, 114.17, 109.63, 109.40, 71.39, 71 .21 , 61 .13, 55.42, 
52.39; MS(m/z): 407 (M+, 1 00), 375 (4), 361 (10), 302 (95), 241 (25), 211 (15), 
121 (65). 
91 
Methyl 3,5-dibenzyloxy-4-methoxybenzoate (30). 
q_ 
a 0 
y 
0 a 
A mixture of 27 (10 g, 51 mmol), potassium carbonate (149 g, 101 mmol), 
benzyl bromide (11 .8 ml, 101 mmol) in anhydrous acetone (150 ml) was stirred at 
rt for 8 h. The solution was diluted by addition of water (30 ml), and then was 
extracted with ethyl acetate (20 ml x 3). The combined organic phases were 
washed with water (20 ml x 3), dried over MgS04 , filtered , and the solvent was 
evaporated to give 30 (18 g, 95%) as a colourless solid; m.p. 119-120 °C; 1H 
NMR: o 7.47-7.31 (m, 12H, Ar-H), 5.16 (s, 4H, H-a), 3.93 (s, 3H, OCH3), 3.87 (s, 
3H, OCH3); 13C NMR: o 166.73, 152.54, 143.90, 136.94, 128.77, 128.21, 127.61 , 
125.04, 109.44, 71.19, 61 .05, 52.33. 
Methyl-3-benzyloxy-4, 5-dimethoxybenzoate (31 ). 
y 
0 a 
A mixture of 28 (1 0 g, 47 mmol), potassium carbonate (6.5 g, 47 mmol), 
benzyl bromide (5.5 ml, 47 mmol) in anhydrous acetone (150 ml) was stirred at rt 
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for 8 h. The solution was diluted by addition of water (30 ml), and then was 
extracted with ethyl acetate (20 ml x 3). The combined organic phases were 
washed with water (20 ml x 3), dried over MgS04, filtered, and the solvent was 
evaporated to give 31 (14 g, 95%) as colourless solid; m.p 74-75 °C. 1H NMR: o 
7.49-7.29 (m, 7H, Ar-H), 5.19 (s, 2H, H-a), 3.95 (s, 3H, OCH3) , 3.94 (s, 3H, 
OCH3), 3.92 (s, 3H, OCH3); 13C NMR: o 166.93, 153.35, 152.25, 143.16, 136.90, 
128.81 , 128.28, 127.72, 125.30, 109.23, 107.34, 71.44, 61 .21 , 56.48, 52.41 ; MS 
(m/z): 302 (M+, 62), 271 (18) , 243 (5), 211 (10), 155 (15), 91 (100). 
3-Benzyloxy-4-methoxy-5-(4-methoxybenzyloxy)-phenylmethanol (32). 
2 
rr8 7 a' 0 1 '-.....0 2 
11 
6 I 14 
4 0~15 
OCH3 18V 16 
17 
To a suspension of LiAIH4 (1 .1 g, 29 mmol) in THF (30 ml) was added a 
solution of compound 29 (1 0 g, 25 mmol) in THF (75 ml). The solution was stirred 
under an argon atmosphere for 4 h. The resulting grey solution was quenched 
with aqueous 10% HCI, filtered and dissolved in EtOAc (1 00 ml). The aqueous 
layer was separated and re-extracted with EtOAc (3 x 15 ml) . The combined 
organic extracts were washed with brine and dried over MgS04 filtered and the 
solvent was evaporated to afford 32 (8.8 g, 94 %) as colourless solid, m.p. 11 2-
113 °C.; 1H NMR: o 7.46-7.30 (m, 7H, Ar-H), 6.91 (d, J=10 Hz 2H, H-9, H-11 ), 
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6.66 (d, J=5 Hz 2H, H-2, H-6), 5.13 (s, 2H, H-a), 5.06 (s, 2H, H-a'), 4.56 (s, 2H, 
CH2), 3.87 (s, 3H, OCH3), 3.81 (s, 3H, OCH3), 2.05 (s, 1 H, OH); 13C NMR: o 
159.52, 152.96, 152.82, 139.11 , 137.28, 136.60, 129.20, 128.73, 128.03, 127.41 , 
114.13, 106.87, 106.65, 71.29, 71 .12, 65.54, 61 .09, 55.46; MS (m/z): 380 (M+, 
1 ), 379.1 (5), 364.3 (26), 363 (1 00). 
3,5-Dibenzyloxy-4-methoxyphenyl methanol (33). 
q_ 
a 0 
To a suspension of LiAIH4 (1.2g, 32 mmol) in THF (30 ml) was added a 
solution of compound 30 (1 0 g, 26 mmol) in THF (75 ml). The solution was stirred 
under an argon atmosphere for 4 h. The resulting grey solution was quenched 
with aqueous 10% HCI, filtered and dissolved in EtOAc (1 00 ml). The aqueous 
layer was separated and extracted with EtOAc (3 x 15 ml). The combined 
organic extracts were washed with brine and dried over MgS04 , filtered and the 
solvent was then evaporated to afford 33 (8.8 g, 94%) as a colourless solid ; m.p. 
104-105 °C; 1H NMR: o 7.45-7.31 (m, 10H, Ar-H), 6.65 (s, 2H, H-2, H-6), 5.13 (s, 
4H, H-a), 4.54 (d, J=5 Hz, 2H, CH2), 3.89 (s, 3H, OCH3); 13C NMR: o 152.94, 
137.37, 128.79, 128.15, 127.50, 106.77, 71 .57, 65.82, 61 .22; MS(m/z): 351.2 
(M+, 1 ), 334.2 (25), 333.3 (1 00) , 241 (5). 
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3-Benzyloxy-4,5-dimethoxyphenyl methanol (18). 
To a suspension of LiAIH4 (1.6 g, 43 mmol) in THF (30 ml) was added a 
solution of 31 (1 0 g, 33 mmol) in THF (75 ml). The solution was stirred under an 
argon atmosphere for 4 h. The resulting grey solution was quenched with 
aqueous 10% HCI, filtered and dissolved in EtOAc (100 ml). The aqueous layer 
was separated and extracted with EtOAc (3 x 15ml). The combined organic 
extracts were washed with brine, dried over MgS04 , filtered, and the solvent was 
then evaporated to afford 18 (8.7 g, 94%) as a yellow oil. 1H NMR: o 7.40-7.25 
(m, 5H, Ar-H), 6.58 (d, J=5 Hz, 1 H, H-6), 6.53 (d , J=5 Hz, 1 H, H-2), 5.03 (s, 2H, 
H-a), 4.49 (d, J=5 Hz, 2H, CH2), 3.82 (s, 3H, OCH3), 3.76 (s, 3H, OCH3); 13C 
NMR: o 153.45, 152.40, 137.75, 137.13, 136.39, 128.53, 127.90, 127.29, 105.88, 
104.14, 71 .02, 65.02, 60.99, 56.14; MS(m/z): 274 (M+, 1), 142 (100), 91 (56). 
3-Benzyloxy-4-methoxy-5-(4-methoxybenzyloxy)-benzyl chloride (34). 
-0 
95 
To a solution of 32 (10 g, 26 mmol), pyridine (1.3 ml, 26 mmol) in anhydrous 
benzene (75 ml) was added thionyl chloride dropwise (1.9 ml, 26 mmol). After 
stirring at rt for 2 h, the reaction was quenched by addition of water (25 ml), and 
the mixture was extracted with ethyl acetate (20 ml x 3).The combined extracts 
were washed with aqueous saturated NaHC03 (1 0 ml x 3), water (20 ml x 3), 
dried over anhydrous MgS04, filtered, and the solvent was evaporated to afford 
34 (8.9 g, 85 %) as a colourless solid m.p. 76-77 °C. 1H NMR: o 7.45-7.30 (m, 
7H, Ar-H), 6.91 (d, J=5 Hz 2H, H-9, H-11), 6.67 (d , J=5 Hz 2H, H-2, H-6), 5.13 
(s, 2H, H-a), 5.06 (s, 2H, H-a), 4.47 (s, 2H, CH2), 3.87 (s, 3H, OCH3), 3.82 (s, 3H, 
OCH3); 13C NMR: o 159.86 153.14, 153.1 , 140.17, 137.39, 133.07, 129.50, 
128.34, 127.73, 114.38, 109.01, 108.78, 71.65, 71.51, 61.26, 55.45, 47.08; 
MS(m/z): 398.88 (M+, 19), 379.1 (5), 364.3 (26), 363 (1 00). 
3,5-Dibenzyloxy-4-methoxybenzyl chloride (35). 
Q_ 
a 0 9 0 a 
To a solution of 33 (1 0 g, 29 mmol), pyridine (1.4 ml, 29 mmol) in 
anhydrous benzene (75 ml) was added thionyl chloride dropwise (2.1 ml, 29 
mmol). After stirring at rt for 2 h, the reaction was quenched by the addition of 
water (25 ml), and the mixture was extracted with ethyl acetate (20 ml x 3). The 
combined extracts were washed with aqueous saturated NaHC03 (1 0 ml x 3), 
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water (20 ml x 3) dried over anhydrous MgS04 and filtered . The solvent was 
evaporated to afford 35 (9.1 g, 85 %) as a colourless solid, m.p. 79-81 °C; 1H 
NMR: o 7.46-7.30 (m, 1 OH, Ar-H), 6.68 (s, 2H, H-2, H-6), 5.14 (s, 4H, H-a), 4.47 
(s, 2H, CH2), 3.90 (s, 3H, OCH3); 13C NMR: o 152.88, 139.85, 137.14, 132.87, 
128.72, 128.10, 127.43, 108.62, 71.44, 61 .15, 46.85; MS(m/z): 368.85 (M+,1), 
333.1 (100), 241 (10), 91(10). 
3-Benzyloxy-4,5-dimethoxybenzyl chloride (36). 
y 
0 a 
To a solution of 18 (16 g, 57 mmol), pyridine (2.9 ml, 57 mmol) in 
anhydrous benzene (75 ml) was added thionyl chloride dropwise (4.2 ml, 57 
mmol). After stirring at rt for 2 h, the reaction was quenched by addition of water 
(25 ml), and the mixture was extracted with ethyl acetate (20 ml x 3).The 
combined extracts were washed with aqueous saturated NaHC03 (10 ml x 3), 
water (20 ml x 3), dried over anhydrous MgS04, filtered, and the solvent was 
evaporated to afford 36 (14 g, 85 %) as a colourless solid, m.p 83-84 °C. 1H 
NMR: o 7.45-7.31 (m, 5H, Ar-H), 6.66 (d, J= 5 Hz, 1 H, H-6), 6.62 (d, J= 5 Hz, 1 H, 
H-2), 5.12 (s, 2H, H-a), 4.51 (s, 2H, CH2), 3.87 (s, 3H, OCH3), 3.85 (s, 3H, 
OCH3); MS (m/z): 292 (M+, 13), 91 (1 00). 
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3-Benzyloxy-4-methoxy-5-(4-methoxybenzyloxy)phenyl acetonitrile (37). 
To a solution of 34 (6.1 g, 15 mmol) in DMSO (20 ml) and benzene (15 ml) 
was added NaCN (0.74 g, 15 mmol) powder in 3 portions. After stirring for 2 hat 
rt, the reaction mixture was poured into water (40 ml) and extracted with benzene 
(40 ml x 3).The combined organic layers were washed with brine (30 ml x 3), 
dried over anhydrous MgS04, filtered , and the solvent was evaporated to afford 
37 (5.3 g, 89%) as a colourless solid, m.p 99-100 °C . 1H NMR: o 7.45-7.30 (m, 
7H, Ar-H), 6.95 (d, J=1 0 Hz, 2H, H-9, H-11 ), 6.61 (d, J=1 0 Hz, 2H, H-2, H-6), 
5.16 (s, 2H, H-a), 5.09 (s, 2H, H-a), 3.91 (s, 3H, OCH3), 3.86 (s, 3H, OCH3) ), 
3.66 (s, 2H, CH2); 13C NMR: o 159.69 153.16, 139.66, 136.98, 128.76, 128.17, 
127.45, 125.17, 117.94, 114.21, 108.15, 107.88, 71 .48, 71 .30, 61.09, 55.49, 
23.90; MS(m/z): 388.88 (M+, 35) , 361.1 (15), 331 .1 (6), 241 .1 (13}, 221 (25), 121 
(1 00). 
3,5-Dibenzyloxy-4-methoxyphenyl acetonitrile (38). 
Q_ 
a 0 
_9 
0 a 
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To a solution of 35 (9.1 g, 24 mmol) in DMSO (20 ml) and benzene (15 ml) 
was added NaCN (1.2 g, 24 mmol) powder in 3 portions. After stirring for 2 h at 
rt, the reaction mixture was poured into water (40 ml) and extracted with benzene 
(40 ml x 3). The combined organic layers were washed with brine (30 ml x 3), 
dried over anhydrous MgS04, filtered, and the solvent was evaporated to afford 
38 (8.7 g, 91%) as a colourless oil. 1H NMR: o 7.46-7.30 (m, 10H, Ar-H), 6.58 (s, 
2H, H-2, H-6), 5.13 (s, 4H, H-a), 3.89 (s, 3H, OCH3) , 3.61 (s, 2H, H-!3); 13C NMR: 
0 153.15, 139.23, 136.80, 128.80, 128.22, 127.49, 125.28, 117.54, 107.95, 
71 .71 , 61 .04, 23.68; MS(m/z): 358.1 (M+, 5), 333.1 (1 00), 282 (15}, 181 ,1 (5) , 
91 (18). 
3-Benzyloxy-4, 5-dimethoxyphenylacetonitrile (39). 
To a solution of 36 (8.2 g, 27 mmol) in DMSO (20 ml) and benzene (1 5 ml) 
was added NaCN (1.3 g, 27 mmol) powder in 3 portions. After stirring for 2 h at 
rt, the reaction mixture was poured into water (40 ml) and extracted with benzene 
(40 ml x 3). The combined organic layers were washed with brine (30 ml x 3}, 
dried over anhydrous MgS04 , filtered, and the solvent was evaporated to afford 
39 (6.9 g, 89% ) as a colourless solid , m.p 56-57 °C. 1H NMR: o 7.45-7.30 (m, 
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5H, Ar-H), 6.57(d, J=5 Hz, 1 H, H-6), 6.53(d, J=5 Hz 1 H, H-2), 5.13(s, 2H, H-a), 
3.87(s, 3H, OCH3), 3.86 (s, 3H, OCH3), 3.64(s, 2H, CH2); 13C NMR: o 154.09, 
153.00, 138.72, 136.93, 128.76, 128.18, 127.48, 125.36, 118.0, 107.56, 105.64, 
71.47, 61.07, 56.40, 24.0; MS(m/z): 283 (M+ +1, 24), 91 (1 00). 
3-Benzyloxy-4-methoxy-5-(4-methoxybenzyloxy)phenylacetic acid (40). 
a' 
0 
A solution of 37 (5.2 g, 12 mmol) in 95% ethanol (40 ml) and aqueous 4.0 
M NaOH (7.0 ml) was heated at reflux for 20 h. The reaction mixture was cooled 
to rt and then acidified with aqueous concentrated HCI to pH=1, to give a 
precipitate which was then filtered and washed with water to afford 40 as a 
yellow solid (4.8 g, 88 %), m.p. 139-141 °C; 1H NMR: o 7.49-7.32 (m, 7H, Ar-H), 
6.93 (d, J=5 Hz, 2H, H-9, H-11), 6.64 (d, J=5 Hz, 2H, H-2, H-6), 5.14 (s, 2H, H-
a), 5.07 (s, 2H, H-a'), 3.91 (s, 3H, OCH3), 3.82 (s, 3H, OCH3) ,3.56 (s, 2H, CH2); 
13C NMR: o 177.57, 159.39, 152.59, 138.83, 137.21 , 129.21, 128.58, 127.94, 
127.45, 113.98, 109.40, 109.25, 71 .26, 71 .10, 60.91 , 55.29, 41 .24; MS (m/z): 
408.1 (M++1 , 25), 407.1 (M+, 1 00), 395 (65), 380.1 (45), 363.1 (45), 257.0 (35). 
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A solution of 38 (5.1 g, 13 mmol) in 95% ethanol (40 ml) and aqueous 4.0 
M NaOH (7.0 ml) was heated at reflux for 20 h. The reaction mixture was then 
cooled to rt and acidified with aqueous concentrated HCI to pH=1 to give a 
precipitate which was filtered, and washed with water to give 41 as a yellow solid 
(4.7 g, 88%), m.p. 139-141 °C. 1H NMR: o 7.44-7.32 (m, 10H, Ar-H), 6.60 (s, 2H, 
H-2, H-6), 5.14 (s, 4H, H-a), 3.92 (s, 3H, OCH3), 3.51 (s, 2H, CH2); 13C NMR: o 
205.45, 153.11, 137.92, 128.75, 127.83, 109.40, 71.09, 60.23, 40.82; MS(m/z): 
379.1 (M++1, 5), 379.1 (M+, 25), 379.1 (M+-1, 100), 365 (20), 350 (25), 333.1 
(85), 318 (15). 
3-Benzyloxy-4, 5-dimethoxyphenylacetic acid (12). 
9 0 a 
A solution of 39 (5.9 g, 21 mmol) in 95% ethanol (40 ml) and aqueous 4.0 
M NaOH (7.0 ml) was heated at reflux for 20 h. The reaction mixture was then 
cooled to rt and then acidified to pH=1 to form a residue which was filtered and 
washed with water to give 12 (6.2 g, 88%) as a colourless solid , m.p. 104-105 °C. 
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1H NMR: o 7.44-7.30 (m, 5H, Ar-H), 6.57 (d, J= 1.5 Hz, 1 H, H-6), 6.52 (d, J= 1.5 
Hz, 1 H, H-2), 5.12 (s, 2H, H-a), 3.86 (s, 3H, OCH3) , 3.85 (s, 3H, OCH3), 3.56 (s, 
2H, CH2); 13C NMR: o 177.61 , 153.59, 152.53, 138.23, 137.18, 128.70, 128.08, 
127.52, 108.90, 107.08, 104.38, 71 .36, 61.07, 56.33, 41.42; MS(m/z): 301 (M+, 
6), 196 (16) , 151 (32), 91 (22), 84 (100), 47 (24). 
N-((R)-a-Methylbenzyl)-(3-benzyloxy-4-methoxy-5-(4-methoxybenzyloxy)-
phenylacetamide (42). 
a ' 
To a stirred solution of oxalyl chloride (1 .3 ml, 15 mmol) in anhydrous 
benzene (60 ml) were added 40 (4.1 g, 9.8 mmol) in one batch and DMF (1 0 
drops). The reaction mixture was stirred until the evolution of gas ceased. The 
benzene was evaporated using a rotary evaporator to give the crude acid 
chloride of 40, which was used directly in the next step. The crude acid chloride 
was re-dissolved in CH2CI2 (30 ml ) at 0 °C and the resulting solution was added 
dropwise to a stirred mixture of (R)-a-methylbenzylamine (1 .4 ml, 11 mmol) and 
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CH2CI2/aqueous 5% NaOH (1 :1.5, 14.7 ml). After stirring at rt for 1 h, the reaction 
mixture was extracted with chloroform (30 ml x 3), washed with water (20 ml x 
3), dried over anhydrous MgS04, filtered. The solvent was evaporated and the 
residue was purified by flash column chromatography (30% EtOAc/hexane) to 
afford amide 42 (4.1 g, 79%) as a colourless solid ; m.p 73-74 °C. 1H NMR: o 
7.42-7.15 (m, 12H, Ar-H), 6.90 (d , J= 5 Hz, 2H, H-9, H-1 1 ), 6.48 (d , J=5 Hz, 2H, 
H-6, H-2), 5.54 ( d, J=1 0 Hz, 1 H, N-H), 5.08 (q , J=1 0 Hz, 1 H, H- l3) , 5.08 (s, 2H, 
H-a), 5.01 (s, 2H, H- a'), 3.87 ( s, 3H, OCH3) , 3.79 (s, 3H, OCH3) , 3.43 (s, 2H, 
CH2) , 1.34 (d, J=1 0 Hz, 3H, H-13'); 13C NMR: o 170.00, 159.55, 153.96, 152.96, 
143.28, 137.11, 129.15, 127.48, 126.12, 114.14, 109.29, 109.07, 71 .22, 71 .15, 
61.06, 55.40, 48.80, 44.13, 21.86; APCI-MS; 512.2 (M+ + 1, 100). 
N-((R)-a-Methylbenzyl)-(3,5-dibenzyloxy-4-methoxy)phenylacetamide (43). 
ap 
0 I 2 0 
H3C N, 6 ! ~ 4 
To a stirred solution of oxalyl chloride (1 .1 ml, 12 mmol) in anhydrous 
benzene (60 ml) were added 41 (3.2 g, 7.9 mmol) in one batch and DMF (1 0 
drops). The reaction mixture was stirred until the evolution of gas ceased . The 
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benzene was evaporated using a rotary evaporator to give the acid chloride of 
41, which was used directly in the next step. The crude acid chloride was re-
dissolved in CH2CI2 (30 ml ) at 0 °C and the resulting solution was added 
dropwise to a stirred mixture of (R)-a-methylbenzylamine (1 .2 ml, 9.5 mmol) and 
CH2CI2/aqueous 5% NaOH (1: 1.5, 12.6 ml). After stirring at rt for 1 h, the reaction 
mixture was extracted with chloroform (30 ml x 3), washed with water (20 ml x 
3), dried over anhydrous MgS04, filtered and the solvent was then evaporated. 
The residue was purified by flash column chromatography (30% EtOAc/hexane) 
to afford amide 43 (3.2 g, 79%) as a yellow solid m.p. 89-90 °C; 1H NMR: i5 7.41-
7.16 (m, 15H, Ar-H), 6.50 (s, 2H, H-2, H-6), 5.54 (d, J= 5 Hz, N-H), 5.09 (q, J=5 
Hz, H-13). 5.08 (s, 4H, H-a), 3.87 ( s, 3H, OCH3), 1.32 (d, J= 5Hz, H-13'); 13C 
NMR: o 170.11, 153.09, 137.14, 129.02, 127.73, 127.60, 126.35, 109.29, 71.39, 
61.52, 49.10, 44.16, 21.85; APCI-MS; 482.1 (M+ + 1), 100). 
N-((R)-a-Methylbenzyl)-(3-benzyloxy-4,5-dimethoxy)phenylacetamide (44). 
To a stirred solution of oxalyl chloride (1.7 ml, 20 mmol) in anhydrous 
benzene (60 ml) were added 12 (3.9 g, 13 mmol) in one batch and DMF (10 
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drops). The reaction mixture was stirred until the evolution of gas ceased. The 
benzene was evaporated using a rotary evaporator to give the acid chloride, 
which was used directly in the next step. The crude acyl chloride was re-
dissolved in CH2CI2 (30 ml ) at 0 °C and the resulting solution was added 
dropwise to a stirred mixture of (R)-a-methylbenzylamine (2.1 ml, 16 mmol) and 
CH2CI2/aqueous 5% NaOH (1: 1.5, 21 .5 ml). After stirring at rt for 1 h, the reaction 
mixture was extracted with chloroform (30 ml x 3), washed with water (20 ml x 
3), dried over anhydrous MgS04, filtered , and the solvent evaporated to afford 
44 as a viscous oil (4.1 g, 79 %); 1H NMR: o 7.44-7.21 (m, 1 OH, Ar-H), 6.53 (d, 
J=5 Hz, 1H, H-6}, 6.48 (d, J=5 Hz, 1H, H-2), 6.12 (d , J=5 Hz, 1H, N-H), 5.13 (q, 
J=10Hz, 1 H, H-~). 5.07 (s, 2H, H-a) , 3.88 (s, 3H, OCH3), 3.80 (s, 3H, OCH3), 
3.46 (s, 2H, CH2) , 1.40 (d , J=10 Hz, 3H, H-W); 13C NMR: o 167.89, 153.68, 
152.60, 143.25, 136.96, 128.53, 127.94, 127.37, 126.03, 108.43, 106.68, 71 .04, 
60.91, 56.07, 48.70, 43.99, 21 .77; MS (m/z): 405 (M+, 46), 300 (7), 257 (8), 105 
(98), 91 (1 00). 
N-((R)-a-Methylbenzyl)-2-[(3-benzyloxy-4-methoxy-5-(4-methoxy benzyloxy)] 
phenylethanamine (24). 
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To a solution of chiral amide 42 (2 g, 4 mmol) in anhydrous THF (60 ml) 
under argon was added BF3-Eh0 (0.22 ml, 1.7 mmol). The mixture was heated to 
gentle reflux and BH3THF (9.7 ml, 9.7 mmol) was then added dropwise. The 
reaction mixture was heated at reflux for 2 h, and then cooled to 0 °C and 
aqueous 20% HCI (1 00 ml) was added to the mixture. The reaction mixture which 
was stirred at 0 °C for 1 h and then overnight at rt, was made basic to pH=13 with 
aqueous 50% KOH solution. The mixture was then extracted with CH2CI2 (30 ml 
x 3). The combined organic layers were washed with water (20 ml x 3), dried 
over anhydrous MgS04, filtered, and the solvent was evaporated to afford 24 
(0.29 g, 10 %) as a yellow oil. 1H NMR: o 7.42-7.15 (m, 12H, Ar-H), 6.90 (d, J= 5 
Hz, 2H, H-9, H-11), 6.48 (d, J=5 Hz, 2H, H-6, H-2), 5.08 (s, 2H, H-a), 5.01 (s, 2H, 
H-a'), 3.87 (s, 3H, OCH3) , 3.79 (s, 3H, OCH3) , 3.74 (q, J=5Hz, 1H, H-!3), 2.71-
2.62 (m, 4H, CH2CH2) , 1.32 (d, J= 5Hz, H-13'); 13C NMR: o 170.00, 159.55, 
153.96, 152.96, 143.28, 137.11 , 129.15, 127.48, 126.12, 114.14, 109.29, 109.07, 
71.22, 71 .15, 61.06, 55.40, 48.80, 44.13, 21 .86; APCI-MS; 497.6 (M+ + 1 ), 1 00). 
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N-((R)-a-Methylbenzyl)-2-{3,5-dibenzyloxy-4-methoxy)phenylethanamine 
{25). 
To a solution of chiral amide 43 (2.1 g, 4.2 mmol) in anhydrous THF (60 
ml) under argon was added BF3·Eh0 (0.23 ml, 1.8 mmol). The mixture was 
heated to gentle reflux and BH3THF (1 0 ml, 10 mmol) was then added dropwise. 
The reaction mixture was heated at reflux for 2 h, and then cooled to 0 °C and 
aqueous 20% HCI (1 00 ml) was added to the mixture. The reaction which was 
stirred at 0 °C for 1 h and then at rt overnight, was basified to pH=13 with 
aqueous 50% KOH solution. The mixture was then extracted with CH2CI2 (30 ml 
x 3). The combined organic layers were washed with water (20 ml x 3), dried 
over anhydrous MgS04, filtered , and the solvent evaporated to afford 25 (1.7 g, 
85 %) as a yellow oil, which was pure enough to be used directly in the next step. 
1H NMR: o 7.46-7.24 (m, 15H, Ar-H), 6.46 (s, 2H, H-2, H-6) , 5. 12 (s, 4H, H-a), 
3.91 (s, 3H, OCH3) , 3.74 (q, J=5Hz, 1 H, H-~) . 2.71-2.62 (m, 4H, CH2CH2, ), 1.58 
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(s, 1H, NH), 1.32 (d, J= 5Hz, H-13'); 13C NMR: o 152.66, 145.72, 137.50, 135.71 , 
128.71, 128.61, 128.01, 127.47, 127.10, 126.75, 71 .1 9, 61.06, 54.41 , 48.55, 
36.38, 24.22; APCI-MS; 467.2 (M+ + 1), 100). 
N-((R)-a-Methylbenzyl)-2-(5-benzyloxy-3,4-dimethoxy)phenylethanamine 
(13). 
To a solution of chiral amide 44 (2.1 g, 4.9 mmol) in anhydrous THF (60 
ml) under argon, was added BF3'Et20 (0.33 ml, 2.2 mmol). The mixture was 
heated to gentle reflux and BH3THF (12 ml, 12 mmol) was then added dropwise. 
The reaction mixture was heated at reflux for 2 h, and then cooled to 0°C and 
aqueous 20 % HCI (1 00 ml) was added to the mixture. The reaction mixture 
which was stirred at 0°C for 1 h and then at rt overnight, was basified to pH=13 
with aqueous 50% KOH solution. The mixture was then extracted with CH2CI2 
(30 ml x 3). The combined organic layers were washed with water (20 ml x 3), 
dried over anhydrous MgS04 , fi ltered , and the solvent was evaporated to afford 
13 (1.7 g, 85%) as a yellow oil , which was pure enough to be used directly in the 
next step. 1H NMR: o 7.47-7.25 (m, 10H, Ar-H), 6.45 (d , J=5 Hz, 1H, H-6), 6.41 
108 
(d, J=5 Hz, 1 H, H-2), 5.12 (s, 2H, H-a), 3.89 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 
3.78 (q, J=1 0 Hz, 1 H, H-13'), 2.80-2.66 (m, 4H, CH2CH2), 1.35 (d, J=1 0 Hz, 3H, H-
13'); 13C NMR: 153.48, 152.38, 144.88, 137.37, 135.68, 128.66, 127.39, 127.08, 
126.72, 108.01 , 106.21 , 71 .14, 61.00, 58.35, 56.07, 48.85, 36.68, 24.16; APCI-
MS 392.20 (M+ + 1, 1 00). 
N-((R)-a-Methylbenzyl)-5-benzyloxy-3-hydroxy-5-methoxy-benzylacetamide 
(45). 
6 
Compound 45 was prepared as outlined above as a by-product during the 
preparation of compound 24 to afford 45 as a by-product. 1H NMR: o 7.44-7.21 
(m, 10H, H-Ar), 6.50 (s, 1H, H-6), 6.42 (s, 1H, H-2), 5.92 (s , 1H, OH), 5.68 (d, 
J=5 Hz, 1 H, NH), 5.13-5.06 (q, 1 H, H-13'), 5.03 (s, 2H, H- a), 3.92 (s, 3H, OCH3), 
3.44 (s, 2H, CH2), 1.39 (d, J=1 0 Hz, H-~) ; 13C NMR: o 170.01 , 151 .90, 149.87, 
149.87, 143.22, 135.31 t 128.88, 128.21 t 127.48, 126.19, 109.61 t 106.86, 70.98, 
61 .23, 48.87, 44.06, 21.96. 
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N-((R)-a-Methylbenzyi)-N-((5-benzyloxy-3,4-dimethoxy)phenylethyl)-4-
iodophenylacetamide (23a). 
To a stirred solution of oxalyl chloride (2.1 ml, 24 mmol) in anhydrous 
benzene (60 ml) were added 14b (4.2 g, 16 mmol) in one batch and DMF (10 
drops). The reaction mixture was stirred until the evolution of gas ceased. The 
benzene was evaporated using a rotary evaporator to give the crude acid 
chloride of 14b, which was used directly in the next step. The crude acid chloride 
was re-dissolved in CH2CI2 (30 ml) at 0 °C and the resulting solution was added 
dropwise to a stirred mixture of 13 (6.8 g, 18 mmol) and CH2CI2:aqueous 5% 
NaOH (1 :1.5, 24 ml). After stirring at rt for 1 h, the reaction mixture was extracted 
with chloroform (30 ml x 3), washed with water (20 ml x 3), dried over anhydrous 
MgS04, filtered and the solvent was evaporated. The residue was purified by 
flash column chromatography (30% EtOAc:hexane) to afford amide 23a (7.8 g, 
71%) as a viscous oil : 1H NMR: o 7.41-6.02 (m,16H, Ar-H), 5.99 and 5.14 (q, 1H, 
H-~) . 5.05 and 5.00 ( two s, 2H, H-a), 3.88-3.76 ( four s, 6H, OCH3) , 3.62-3.57 
(two s, 2H, H-a'), 3.21 -2.04 (5m, 4H, CH2CH2), 1.49-1 .37 (two d, 3H, H-W) ; 13C 
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NMR: 170.71, 153.66, 153.40, 152.58, 152.36, 139.36, 132.05, 130.81, 128.68, 
128.04, 127.22, 121 .11 , 121.00, 108.05, 106.07, 99.73, 61.05, 60.99, 55.91 , 
52.01, 45.75, 41.03, 40.03, 37.47, 35.29, 18.17, 16.77. APCI-MS(m/z): 635.05 
(M++1 , 100). 
N-((R)-a-Methylbenzyi)-N-((3,5-dibenzyloxy-4-methoxy)phenylethyl)-4-fluoro 
-3-nitrophenylacetamide (22b). 
y 
0 a 
To a stirred solution of oxalyl chloride (2.5 ml, 30 mmol) in anhydrous 
benzene (60 ml) were added 14c (3.9 g, 20 mmol) in one batch and DMF (10 
drops).The reaction mixture was stirred until the evolution of gas ceased. The 
benzene was evaporated using a rotary evaporator to give the crude acid 
chloride of 14c, which was used directly in the next step. The crude acid chloride 
was re-dissolved in CH2CI2 (30 ml) at 0 °C and the resulting solution was added 
dropwise to a stirred mixture of 33 (10 g, 22 mmol) and CHzCiz/aqueous 5% 
NaOH (1:1.5, 29.5 ml). After stirring at rt for 1h, the reaction mixture was 
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extracted with chloroform (30 ml x 3), washed with water (20 ml x 3), dried over 
anhydrous MgS04 , filtered, and the solvent was evaporated. The residue was 
purified by flash column chromatography (30 % EtOAc:hexane) to afford amide 
22b (10 g, 70.0 %) as a viscous oil. 1H NMR: o 7.99-6.26 (m, 20H, Ar-H), 6.11 
and 5.29 (two q, 1H, H-~). 5.17 and 5.11 (twos, 4H, H-a), 3.79-3.65 (twos, 3H, 
OCH3), 3.59 (s, 2H, H-6), 3.34-2.22 ( m, 4H, CH2CH2), 1.63-1 .51 (two d, 3H, H-
W). APCI-MS(m/z): 648.05 (M+ +1, 1 00). 
N-((R)-a-Methylbenzyi)-N-((5-benzyloxy-3,4-dimethoxy)phenylethyl)-4-fluoro 
-3-nitrophenylacetamide (23b). 
a' 
F N02 
To a stirred solution of oxalyl chloride (2.5 ml, 30 mmol) in anhydrous 
benzene (60 ml) were added 14c (4.1 g, 20 mmol) in one batch and DMF (10 
drops). The reaction mixture was stirred until the evolution of gas ceased. The 
benzene was evaporated using a rotary evaporator to give the crude acid 
chloride of 14c, which was used directly in the next step. The crude acid chloride 
was re-dissolved in CH2CI2 (30 ml) at 0 °C and the resulting solution was added 
dropwise to a stirred mixture of 13 (8.6 g, 22 mmol) and CH2CI2:aqueous 5% 
NaOH (1:1.5, 29.5 ml). After stirring at rt for 1 h, the reaction mixture was 
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extracted with chloroform (30 ml x 3), washed with water (20 ml x 3), dried over 
anhydrous MgS04 , filtered and the solvent was evaporated. The residue was 
purified by flash column chromatography (30% EtOAc:hexane) to afford amide 
23b (9.1g, 70 %) as a viscous oil. 1H NMR: o 7.98-6.29 (m,15H, Ar-H), 6.11 and 
5.29 (two q, 1 H, H-~) . 5.17 and 5.11 (two s, 2H, H-a), 3.79-3.65 (four s, 6H, 
OCH3), 3.63 (s, 2H, H-a'), 3.34-2.22 ( m, 4H, CH2CH2), 1.63-1.51 (two d, 3H , H-
W); 13C NMR: o 169.98, 153.73, 137.60, 137.12, 135.18, 129.31 , 127.21, 118.75, 
108.36, 106.51 , 71.46, 61.31 , 61.24, 56.52, 56.38, 46.54, 39.60, 35.72, 29.68, 
19.00; APCI-MS(m/z): 572.04 (M+ +1, 1 00). 
N-((R)-a-Methylbenzyi)-N-((5-benzyloxy-3,4-dimethoxy)phenylethyl)-4-
bromophenylacetamide (23c). 
To a stirred solution of oxalyl chloride (1 .8 ml, 21 mmol) in anhydrous 
benzene (60 ml) were added 14d (3.1 g, 14 mmol) in one batch and DMF (1 0 
drops). The reaction mixture was stirred until the evolution of gas ceased. The 
benzene was evaporated using a rotary evaporator to give the crude acid 
chloride of 14d, which was used directly in the next step. The crude acid chloride 
was re-dissolved in CH2CI2 (30 ml) at 0 °C and the resulting solution was added 
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dropwise to a stirred mixture of 13 (6.1 g, 15 mmol) and CH2CI2:aqueous 5% 
NaOH (1 : 1.5, 20 ml). After stirring at rt for 1 h , the reaction mixture was 
extracted with chloroform (30 ml x 3), washed with water (20 ml x 3), dried over 
anhydrous MgS04 , filtered and the solvent was evaporated . The residue was 
purified by flash column chromatography (30% EtOAc:hexane) to afford amide 
23c (6.5 g, 71%) as a viscous oil: 1H NMR: o 7.57-6.18 (m,16H, Ar-H), 5.34 (q, 
1 H, H-p), 5.01 and 5.03 ( two s, 2H, H-a), 3. 79-3.65 ( four s, 6H, OCH3), 3.62-
3.61 (two s, 2H, H-a'), 3.29-2.19 ( m, 4H, CH2CH2), 1.49-1.37 (two d, 3H, H-W); 
13C NMR: o 169.15, 155.21 , 153.21 , 151 .96, 139.65, 136.43, 136.36, 134.48, 
128.61 , 128.18, 127.82, 127.75, 127.63, 127.50, 126.96, 126.84, 126.51 , 118.21 , 
118.04, 107.64, 105.82, 70.76, 60.61 , 60.54, 55.68, 51 .81 , 45.58, 39.20, 35.02, 
28.29, 18.29, APCI-MS(m/z): 587.03 (M++1 , 100), 585.02 (M+-1, 96). 
N-((R)-a-Methylbenzyi)-N-((3,5-dibenzyloxy-4-methoxy)phenylethyl)-4-
bromophenylacetamide (22c). 
a 
::o 
To a stirred solution of oxalyl chloride (1 .8 ml, 21 mmol) in anhydrous 
benzene (60 ml) were added 14d (2.9 g, 14 mmol) in one batch and DMF (10 
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drops). The reaction mixture was stirred until the evolution of gas ceased. The 
benzene was evaporated using a rotary evaporator to give the crude acid 
chloride of 14d, which was used directly in the next step. The crude acid chloride 
was re-dissolved in CH2CI2 (30 ml) at 0 °C and the resulting solution was added 
dropwise to a stirred mixture of 33 (7.6 g, 15 mmol) and CH2CI2:aqueous 5% 
NaOH (1: 1.5, 20 ml). After stirring at rt for 1 h , the reaction mixture was 
extracted with chloroform (30 ml x 3), washed with water (20 ml x 3), dried over 
anhydrous MgS04 , filtered , and the solvent was evaporated. The residue was 
purified by flash column chromatography (30% EtOAc:hexane) to afford amid 
22c (7.7 g, 71 %) as a viscous oil. 1H NMR: o 7.75-6.18 (m,21 H, Ar-H), 6.11 and 
5.34 (two q, 1 H, H-13). 5.01 and 5.03 ( two s, 4H, H-a), 3.79-3.65 ( four s, 3H, 
OCH3) , 3.60 (s, 2H, H-6), 3.29-2.19 ( m, 4H, CH2CH2). 1.49-1 .37 (two d, 3H, H-
13'). APCI-MS(m/z): 663.03 (M+ +1, 1 00), 661 .02 (M+-1, 96). 
N-((R)-a-Methylbenzyi)-N-((3,5-dibenzyloxy-4-methoxy)phenylethyl)-4-
iodophenylacetamide (22a). 
0~ 
OCH3 I /-
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To a stirred solution of oxalyl chloride (1.5 ml, 17 mmol) in anhydrous 
benzene (60 ml) were added 14b (2.9 g, 11 mmol) in one batch and DMF (10 
drops). The reaction mixture was stirred until the evolution of gas ceased. The 
benzene was evaporated using a rotary evaporator to give the crude acid 
chloride of 14b, which was used directly in the next step. The crude acid chloride 
was re-dissolved in CH2Cb (30 ml) at 0 °C and the resulting solution was added 
dropwise to a stirred mixture of 33 (6.0 g, 13 mmol) and CH2CI2:aqueous 5% 
NaOH (1 :1.5, 17.5 ml). After stirring at rt for 1 h, the reaction mixture was 
extracted with chloroform (30 ml x 3), washed with water (20 ml x 3), dried over 
anhydrous MgS04, filtered, and the solvent was evaporated. The residue was 
purified by flash column chromatography (30% EtOAc:hexane) to afford amide 
22a (6.7 g, 70%) as a viscous oil. 1H NMR: o 7.65-6.19 (m, 21H, Ar-H), 6.01 and 
5.32 (two q, 1 H, H-!3), 5.01 and 5.03 ( two s, 4H, H-a), 3.89-3.75 ( four s, 3H, 
OCH3), 3.59 (s, 2H, H-a'), 3.25-2.19 ( m, 4H, CH2CH2), 1.49-1 .37 (two d, 3H, H-
13'). APCI-MS(m/z): 711 .05 (M++1, 100). 
(R)-6,8-Dibenzyloxy-1-(4-iodobenzyl)-7 -methoxy-2-((R)-1-phenylethyl)-
1 ,2,3,4-tetrahydroisoquinoline (19a). 
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Compound 22a (1.1 g, 1.5 mmol), POCb (2.6 ml, 28 mmol) and benzene 
(50 ml) were combined under an atmosphere of argon and bought to a gentle 
reflux. After approximately 5 h, the solvent and excess POCb were evaporated 
on a rotary evaporator and finally on a vacuum pump for 1 h. The resultant 
residue was re-dissolved in MeOH (20 ml) and the solution was cooled to -78 °C 
in a dry ice bath. To this solution was added NaBH4 (0.34 g, 9.1 mmol) in five 
portions over 3 h. The reaction was quenched through the addition of aqueous 
10% HCI (30 ml), and the mixture was stirred at rt for 30 min. The MeOH was 
evaporated on a rotary evaporator. The residue was re-dissolved in CH2Cb (25 
ml) and transferred to a separatory funnel containing H20 (15 ml). The combined 
aqueous layers were re-extracted with CH2Cb (15 ml x 3). The combined organic 
layers were washed with brine (5 ml x 3), dried over MgS04, filtered, and the 
solvent was evaporated in vacuo. The residue was purified by PLC (30% 
EtOAc:hexane) to give compound 19a (0.56 g, 58%) as a yellow oil. 1H NMR: o 
7.54-6.50 (m, 20H, Ar-H), 5.25 (d, JAx=1 0 Hz, 1 H, Ha), 5.15 (d, JAa=1 0 Hz, 1 H, 
H-a'), 5.14 (d, JaA=1 0 Hz, 1 H, H-a'), 4.26 (d , JxA=1 0 Hz, 1 H, H-a), 3.96 (s, 3H, 
OCH3), 3.75 (t, 1H, H-1), 3.63 (q, 1H, H-!3), 3.51 (m, 1H, H-3), 3.43 (m, 1H, H-4), 
2.94 (m, 1 H, H-3), 2.68 (d , J=5 , 2H, H-1'), 2.43 (dd, J=5, 10, 1 H, H-4), 1.28 (d, 
J=5 Hz, H-13'); 13C NMR: o 154.96, 152.88, 151.61 , 150.55, 145.96, 141.16, 
138.00, 137.98, 137.32, 136.78, 136.72, 130.77, 129.31, 128.77, 128.31, 127.48, 
127.34, 126.96, 126.77, 123.72, 117.04, 116.88, 109.68, 75.78, 71.10, 61 .12, 
58.79, 56.73, 39.84, 38.54, 22.48, 22.27. APCI-MS(m/z): 696.04 (M++1, 100); 
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(RJ-6,8-Dibenzyloxy-1-(4-fluoro-3-nitrobenzyl)-7 -methoxy-2-((R)-1-N-
phenylethyl)-1 ,2,3,4-tetrahydroisoquinoline (19b). 
Compound 22b (1.1 g, 1.5 mmol), POCI3 (4.7 ml, 30 mmol) and benzene 
(50 ml) were combined under an atmosphere of argon and bought to a gentle 
reflux. After approximately 5 h, the solvent and excess POCI3 were evaporated 
on a rotary evaporator and finally on a vacuum pump for 1 h. The resultant 
residue was re-dissolved in MeOH (20 ml) and the solution was cooled to -78 °C 
in a dry ice bath. To this solution was added NaBH4 (0.33 g, 8.5 mmol) in five 
portions over 3 h. The reaction was quenched through the addition of aqueous 
10% HCI (30 ml), and the mixture was stirred at rt for 30 min. The MeOH was 
evaporated on a rotary evaporator. The residue was re-dissolved in CH2Cb (25 
ml) and transferred to a separatory funnel containing H20 (15 ml). The combined 
aqueous layers were re-extracted with CH2CI2 (15 ml x 3). The combined organic 
layers were washed with brine (5 ml x 3), dried over MgS04 , filtered , and the 
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solvent was evaporated in vacuo. The residue was purified by PLC (30 % 
EtOAc:hexane) to give compound 19b (0.58 g, 60%) as a yellow oil. 1H NMR: 1H 
NMR: o 7.51-6.69 (m, 18H, Ar-H), 6.59 (s, 1H, H-5), 5.25 (d, J.¢=10 Hz, 1H, 
Ha), 5.15 (d, JAa=1 0 Hz, 1 H, H-a), 5.11 (d, JaA=1 0 Hz, 1 H, H-a'), 4.31 (d, JxA=1 0 
Hz, 1 H, H-a), 3.94 (s, 3H, OCH3), 3.74 (m, 1 H, H-1 ), 3.60 (q, 1 H, H-~). 3.41 (m, 
2H, H-3), 2.94 (m, 1 H, H-4), 2.73 (m, 2H, H-1'), 2.43 (d, J=15, 1 H, H-4), 1.28 (d, 
J=5 Hz, H-W); 13C NMR: o 154.96, 152.88, 151.61, 150.55, 145.96, 141.16, 
138.00, 137.98, 137.32, 136.78, 136.72, 130.77, 129.31, 128.77, 128.31, 
128.12,127.48, 127.34, 126.96, 126.77, 123.72, 117.04, 116.88, 109.68, 75.78, 
71 .10, 61.12, 58.79, 56.73, 39.84, 38.54, 22.48, 22.27. APCI-MS(m/z): 634.2 
(M++1, 100). Small amounts of 55 and 56 were obtained 
6,8-Dibenzyloxy-7 -methoxy-2-( (R)-1-N-phenylethyl)-3,4-isoquinoline-1-one 
(55). 
H NMR: o 7.76-7.31 (m, 15H, H-Ar), 6.51 (s, 1 H, H-5), 6.25 (q, 1 H, H-~). 5.25 (d, 
JAs=5 Hz, 1 H, H-a), 5.22 (d, JsA=5 Hz, 1 H, H-a), 5.18 (s, 2H, H-a), 3.82 (s, 3H, 
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OCH3), 3.23 (m, 1 H, H-3), 2.92 (m, 1 H, H-3), 2.59 (m, 2H, H-4), 1.52 (d , 3H, H-
W). 
1 ,3-Dibenzyloxy-5-(2-chloroethyl)-2-methoxybenzene (56). 
Q 2 
a 16 Cl 0~-:/""1 
0 4~ 
I ~ 
1H NMR: o 7.45-7.32 (m, 1 OH, H-Ar) , 6.48 (s, 2H, H-6, H-2), 5.13 s, 2H, H- a), 
3.89 (s, 3H, OCH3), 3.61 (t, J= 10 Hz, 2H, H-1 '), 2.93 (t, J= 10 Hz, 2H, H-2'); 13C 
NMR: o 152.75, 138.64, 137.35, 133.71 , 128.72, 128.10, 127.47, 108.92, 71.48, 
61 .07, 44.51 ' 39.30. 
(RJ-1-(4-Bromobenzyl)-6,8-dibenzyloxy-7 -methoxy-2-((R)-1-phenylethyl)-
1 ,2,3,4-tetrahydroisoquinoline (19c). 
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Compound 22c (1.1 g, 1.5 mmol), POCb (4.7 ml, 30 mmol) and benzene 
(50 ml) were combined under an atmosphere of argon and bought to a gentle 
reflux. After approximately 5 h, the solvent and excess POCb were evaporated 
on a rotary evaporator and finally on a vacuum pump for 1 h. The resultant 
residue was re-dissolved in MeOH (20 ml) and the solution was cooled to -78 °C 
in a dry ice bath. To this solution was added NaBH4 (0.33 g, 8.5 mmol) in five 
portions over 3 h. The residue was re-dissolved in CH2Ch (25 ml) and transferred 
to a separatory funnel containing H20 (15 ml). The combined aqueous layers 
were re-extracted with CH2CI2 (15 ml x 3). The combined organic layers were 
washed with brine (5 ml x 3) , dried over MgS04, filtered , and the solvent was 
evaporated in vacuo. The residue was purified by PLC (30% EtOAc/hexane) to 
give compound 19a (0.58 g, 60 %) as a yellow oil. 1H NMR: o 7.54-6.49 (m, 20H, 
Ar-H), 5.20 (d, JAx=10 Hz, 1 H, Ha), 5.12 (d, JAa=1 0 Hz, 1 H, H-a'), 5.09 (d, 
JaA=1 0 Hz, 1 H, H-a'), 4.21 (d, JxA=1 0 Hz, 1 H, H-a), 3.91 (s, 3H, OCH3), 3.73 (t, 
1 H, H-1 ), 3.45 (q, 1 H, H-p), 3.37 (m, 1 H, H-3), 2.92 (m, 1 H, H-4), 2.65 (d , J=5, 
2H, H-a'), 2.37 (dd, J=5, 10, 1H, H-4) , 1.22 (d, J=5 Hz, H-pt); 13C NMR: o 150.85, 
145.97, 140.17, 137.49, 132.10, 128.38, 124.96, 119.53, 107.90, 71 .32, 61.44, 
59.10, 57.34, 40.69, 38.66, 23.17, 22.51 . APCI-MS(m/z): 648.2 (M++1 , 100), 
546.2 (M+-1, 96). 
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(R)-8-Benzyloxy-6, 7 -dimethoxy-1-(4-iodobenzyi)-2-((R)-1-phenylethyl)-
1 ,2,3,4-tetrahydroisoquinoline (15b) and (R)-6-benzyloxy-7 ,8-dimethoxy-1-
(4-iodobenzyi)-2-(R)-1-phenylethyl)-1 ,2,3,4-tetrahydroisoquinoline (1Gb). 
4 4 
y 
0 a 
(15b) (16b) 
Compound 22a (1 .1 g, 1.6 mmol), POCb (2.9 ml, 32 mmol) and benzene 
(50 ml) were combined under an atmosphere of argon and brought to a gentle 
reflux. After approximately 5 h, the solvent and excess POCb were evaporated 
on a rotary evaporator and finally on a vacuum pump for 1 h. The resultant 
residue was re-dissolved in MeOH (20 ml) and the solution was cooled to -78 °C 
in a dry ice bath. To this solution was added NaBH4 (0.29 g, 7.8 mmol) in five 
portions over 3 h. The reaction was quenched through the addition of aqueous 
10% HCI (30 ml), and the mixture was stirred at rt for 30 min. The MeOH was 
evaporated on a rotary evaporator. The residue was re-dissolved in CH2CI2 (25 
ml) and transferred to a separatory funnel containing H20 (15 ml). The combined 
aqueous layers were re-extracted with CH2CI2 (15 ml x 3). The combined organic 
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layers were washed with brine (5 ml x 3) , dried over MgS04, fi ltered, and the 
solvent was evaporated in vacuo. The residue was purified by PLC (30% 
EtOAc/hexane) to give two diastereoisomers 15b (0.22 g 23%) and 16b (0.31 g, 
31%) as yellow oils. 15b: 
1H NMR: 6 7.39-6.61 (m, 14H, Ar-H), 6.47 (s, 1 H, H-5), 5.20 (d, JAx=9.7 Hz, 1 H, 
Ha), 4.20 (d, JxA=9.7 Hz, 1 H, H-a), 3.91 (s, 3H, OCH3), 3.89 (s, 3H, OCH3), 3.73 
(t, 1 H, H-1 ), 3.60 (q, J=7.3 Hz, 1 H, H-p),_3.50 (m, 1 H, H-3), 3.39 (m, 1 H, H-4), 
2.96 (m, 1 H, H-3), 2.73 (d, J=4.5, 2H, H-a'), 2.49 (dd, J=5, 10, 1 H, H-4), 1.31 (d, 
J=7.3 Hz, H-P'); 13C NMR: o 152.05, 150.53, 146.31 , 143. 54, 140.54, 137.21 , 
133.21 , 132.98, 132.88, 130.01, 129.19, 127.34, 126.98, 124.95, 119.99, 107.77, 
75.87, 62.67, 58.77, 57.32, 56.33, 40.01, 38.21, 24.34, 22.89; 13C NMR: o 
152.12, 150.61, 146.42, 140.82, 137.31, 136.63, 132.41 , 130.82, 129.53, 128.65, 
128.51, 127.42, 126.63, 124.21 , 107.81 , 90.66, 75.72, 61 .22, 58.93, 57.22, 
56.22, 40.71 , 38.51 , 31 .11 , 23.01 , 22.43; APCI-MS(m/z): 620.05 (M++1, 100); 
(16b): 1H NMR: o 7.53-6.66 (m,14H, Ar-H), 6.52 (s, 1H, H-5), 5.09 (d, JAa=10 
Hz, 1 H, H-a), 5.06 (d, JaA=1 0 Hz, 1 H, H-a), 3.87 (s, 3H, OCH3), 3.68 (m, 1 H, H-
1 ), 3.65 (s, 3H, OCH3), 3.52 (q, J=6.4 Hz, 1 H, H-p), 3.45 (m, 1 H, H-3), 3.33 (m, 
1 H, H-4), 2.88 (m, 1 H, H-3), 2.69 (m, 2H, H-d), 2.36 (dd, J=5, 10, 1 H, H-4), 1.23 
(d, J=5 Hz, H-P'). APCI-MS(m/z) : 620.05 (M+ +1, 1 00); 
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(RJ-8-Benzyloxy-1-(4-bromobenzyl)-6,7 -dimethoxy-2-(R)-1-phenylethyl)-
1,2,3,4-tetrahydroisoquinoline (15d) and RJ-6-benzyloxy-1-(4-bromobenzyl)-
7,8-dimethoxy-2-(R)-1-phenylethyl)-1,2,3,4-tetrahydroisoquinoline (16d). 
4 4 
_y 
0 a. 
(15d) (16d) 
Compound 22b (1.2 g, 1.7 mmol}, POCI3 (3.3 ml, 33 mmol) and benzene 
(50 ml) were combined under an atmosphere of argon and bought to a gentle 
reflux. After approximately 5 h, the solvent and excess POCb were evaporated 
on a rotary evaporator and finally on a vacuum pump for 1 h. The resultant 
residue was re-dissolved in MeOH (20 ml) and the solution was cooled to -78 °C 
in a dry ice bath. To this solution was added NaBH4 (0.38 g, 10 mmol) in five 
portions over 3 h. The reaction was quenched through the addition of aqueous 
10% HCI (30 ml), and the mixture was stirred at rt for 30 min. The MeOH was 
evaporated on a rotary evaporator. The residue was re-dissolved in CH2CI2 (25 
ml) and transferred to a separatory funnel containing H20 (15 ml). The combined 
aqueous layers were re-extracted with CH2Cb (15 ml x 3). The combined organic 
layers were washed with brine (5 ml x 3), dried over MgS04, filtered , and the 
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solvent was evaporated in vacuo. The residue was purified by PLC (30 % 
EtOAc/hexane) to give compound 15d and 16d as a yellow oils in 23% and 30% 
respectively. 15d: 1H NMR: o 7.41 -6.57 (m,15H, Ar-H), 5.28 (d , JAx=10 Hz, 1 H, 
Ha), 4.29 (d, JxA=10 Hz, 1 H, H-a), 3.98 (s, 3H, OCH3), 3.94 (s, 3H, OCH3), 3.66 
(t, 1 H, H-1), 3.57 (q, 1 H, H-~) . 3.54 (m, 1 H, H-3), 3.43 (m, 1 H, H-4), 3.00 (m, 1 H, 
H-3), 2.73 (d, J=5, 2H, H-1 '), 2.49 (dd, J=5, 10, 1 H, H-4), 1.31 (d , J=5 Hz, H-W); 
13C NMR: o 152.05, 150.53, 146.31 , 143. 54, 140.54, 137.21 , 133.21 , 132.98, 
132.88, 130.01 , 129.19, 127.34, 126.98, 124.95, 119.99, 107.77, 75.87, 62.67, 
58.77, 57.32, 56.33, 40.01 , 38.21, 24.34, 22.89; APCI-MS(m/z): 574.2 (M+ +1, 
100), 572.2 (M+-1, 96). 
(16d): 1H NMR: o 7.46-6.51 (m, 15H, Ar-H), 5.09 (d, JAa=1 0 Hz, 1H, H-a), 5.06 
(d, JaA=1 0 Hz, 1 H, H-a), 3.86 (s, 3H, OCH3), 3.69 (m, 1 H, H-1 ), 3.65 (s, 3H, 
OCH3), 3.52 (q, 1 H, H-~) . 3.39 (m, 1 H, H-3), 3.32 (m, 1 H, H-4), 2.88 (m, 1 H, H-
3), 2.73 (m, 2H, H-1'), 2.34 (dd, J=5, 10, 1H, H-4), 1.23 (d, J=5 Hz, H-W). APCI-
MS(m/z): 574.2 (M++1, 100), 572.2 (M+-1, 96). 
4-Fiuoro-3-nitrobenzaldehyde (47). 
CHO 
To a solution of 4-fluorobenzaldehyde (5.1 g, 50 mmol ) in concentrated 
sulfuric acid (25 ml ) at 0 °C was added 70% nitric acid (3 ml) slowly. The 
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resulting reaction mixture was stirred under argon for 2 h and then was poured 
into ice water (1 00 ml) , and extracted with benzene (30 ml x 3). The combined 
benzene extracts were washed with water, dried over anhydrous MgS04, and 
concentrated in vacuo. The residue was purified by flash column chromatography 
(EtOAc/hexane= 5:95) to afford 47 (5.1 g, 85%) as a yellow solid m.p 44-45 °C. 
1H NMR: o 10.04 (s, 1 H, CHO), 8.61 (dd , J=2 , 5 Hz, 1 H, H-2), 8.21 (m, 1 H, H-6), 
7.51 (m, 1 H, H-5); 13C NMR: 188.35, 160.08, 157.90, 135.71 , 133.06, 128.01 , 
119.89; MS(m/z): 169 (M+. 97), 168 (100), 122 (55), 94 (56), 75 (97). 
4-Fiuoro-3-nitrobenzyl alcohol (48). 
To a solution of 47 (4.9 g, 29 mmol) in THF (25 ml) and methanol (25 ml) 
was added sodium borohydride (0.65 g, 17 mmol) in portions. The reaction 
mixture was stirred for 2 h, and then concentrated to give a residue which then 
was dissolved in CH2CI2 (25 ml) and water (25 ml) containing aqueous 1M HCI 
solution (15.6 ml). The organic phase was washed with water, and dried over 
anhydrous MgS04. The solvent was then removed to yield a yellowish oil which 
was purified by flash column chromatography (silica gel, 20% EtOAc in hexane) 
to afford 48 as a yellow oil (4.7 g, 95%). 1H NMR: o 8.07 (dd, J=2, 5Hz, 1H, H-
2), 7.63 (m, 1 H, H-6), 7.29 (m, 1 H, H-5), 4.77 (s, 2H, -CH2-), 2.18 (bs, 1 H, OH); 
126 
13C NMR: 156.08, 153.69, 137.83, 133.77, 124.17, 118.35, 63.36; MS (m/z): 171 
(M+. 78), 154 (30), 125 (99), 107 (86), 95 (100), 75 (73). 
4-Fiuoro-3-nitrobenzyl bromide (49). 
To a solution of 48 (10 g, 58 mmol) in CH2CI2 (300 ml), PBr3 (4.5 ml, 58 
mmol ) was added dropwise at 0 °C. After 3 h of stirring at 0 °C, the reaction 
mixture was quenched by addition of water, the organic phase was washed with 
aqueous NaHC03, water, dried over anhydrous MgS04, and concentrated in 
vacuo. The crude product was further purified by flash chromatography 
(Et0Ac:hexane=2:8) to afford 49 as a colourless solid (11 g, 80%). m.p 56-57 °C; 
1H NMR: o 8.10 (dd, J=2, 5Hz, 1H, H-2), 7.67 (m, 1H, H-6), 7.29 (m, 1H, H-5), 
4.48 (s, 2H, -CH2-); MS (m/z): 235 (M++2, 3), 233 (M+-1, 3), 154 (99), 108 (100), 
96 (23), 81 (28). 
4-Fiuoro-3-nitrophenylacetonitrile (50). 
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To a solution of 49 (6.1 g, 26 mmol) in DMSO (20 ml) and benzene (15 ml) was 
added NaCN (1.3 g, 26 mmol) powder in 3 portions. After stirring for 2 hat rt, the 
reaction mixture was poured into water (40 ml) and extracted with benzene (40 
ml x 3). The combined organic layers were washed with brine (30 ml x 3), dried 
over anhydrous MgS04, filtered, and the solvent was evaporated to afford 50 (3.4 
g, 75%) as a colourless oil. 1H NMR: o 8.06 (dd, J=2 , 5Hz, 1H, H-2), 7.78 (m, 
1 H, H-6), 7.36 (m, 1 H, H-5), 3.91 (s, 2H, -CH2-); 13C NMR: 156.32, 154.03, 
135.16, 127.06, 125.90, 119.56, 116.30; MS (m/z): 180 (M+, 100), 134 (80), 122 
(77), 107 (99), 95 (74), 81 (50). 
4-Fiuoro-3-nitrophenylacetic acid (14c). 
A solution of 59 (5.1 g, 27 mmol) in 95% ethanol (40 ml) and aqueous 4.0 
M NaOH (7 ml) was heated at reflux for 20 h. The reaction mixture was then 
cooled to rt and then acidified to pH=1 to form a residue which was filtered and 
washed with water to give crude 14c (5.1 g, 92% ) as a colourless solid. m.p 95-
96 °C. 1H NMR: o 8.01 (dd, J=2 , 5 Hz, 1 H, H-2), 7.56 (m, 1 H, H-6), 7.29 (m, 1 H, 
H-5), 3.74 (s, 2H, CH2); 13C NMR: o: 176.75, 156.32, 154.21 , 137.02, 130.51, 
127.37, 119.16, 39.94; MS (m/z): 199 (M+, 100), 154 (99), 122 (77), 108 (99), 97 
(48), 77 (50). 
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4-lodobenzyl bromide (52). 
To a solution of 51 (1 .1 g, 4.6 mmol) and a few crystal of dibenzoyl 
peroxide in CH2Cb was added NBS (0.9 g, 5 mmol). The mixture was stirred 
under the light of a 1 00-watt lamp at a gentle reflux. After 1 h, the reaction was 
stopped, brine (8 ml) with Kl (0.26 g) was added to the reaction mixture. Then 
aqueous Na2S203 solution (20 ml) was added to remove the produced l2. After 
this, the organic layer was separated and the aqueous layer was extracted by 
CH2CI2 (4 ml x 3). The combined organic layers was washed by brine(8 ml), 
dried by MgS04, filtered and the solvent was evaporated to give crude 52 which 
was further purified by crystallization by using EtOH to afford 52 as a colourless 
solid (1 .50 g, 100%); m.p. 77-78 °C; 1H NMR: o 7.68 (d, J=5 Hz, 2H, H-3, H-5), 
7.13, (d, J=1 0 Hz, 2H, H-2, H-6), 4.42 (s, 2H, CH2); 13C NMR: 137.92, 137.37, 
130.72, 94.07, 32.45; MS (m/z): 298 (M++1 , 10), 296 (M+-1, 9), 217 (100), 127 
(41), 90 (74), 63 (43) . 
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4-lodophenylacetonitrile (53). 
To a solution of 52 (9.9 g, 33 mmol) in DMSO (40 ml) and benzene (60 
ml) was added NaCN (4.25 g, 87.7 mmol) powder in 3 portions. After stirring for 2 
h at rt, the reaction mixture was poured into water (40 ml) and extracted with 
benzene (40 ml x 3).The combined organic layers were washed with brine (30 ml 
x 3), dried over anhydrous MgS04, filtered , and the solvent was evaporated to 
afford 53 (6.1 g, 75% ) as a colourless solid , m.p 52-53 °C. 1H NMR: o 7.65 (d, 
J=10 Hz, 2H, H-3, H-5), 7.08 ( d, J=10 Hz, 2H, H-2, H-6), 3.69 (s, 2H, H-a); 13C 
NMR: o 138.37, 130.26, 117.57, 93.77, 23.70; MS(m/z): 243 (M+ + 1, 100), 116 
(88), 89 (42). 
4-lodophenylacetic acid (14b). 
A solution of 53 (7.5 g, 31 mmol) in 95 % ethanol (150 ml) and aqueous 
4.0 M NaOH (30 ml) was heated at reflux for 20 h. The reaction mixture was then 
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cooled to rt and then acidified to pH=1 to form a residue which was filtered and 
washed with water to to give 14b (7.6 g, 95 %) as a yellow solid , m.p.126-127 °C. 
1H NMR: o 7.67 (d, J=5 Hz, 2H, H-3, H-5), 7.03 (d , J=5 Hz, 2H, H-2, H-6), 3.57 
(s, 2H, Ha); 13C NMR: o 177.19, 137.79, 132.85, 131.36, 93.19, 40.73; MS(m/z): 
261 (M+, 93), 217 (100), 91 (21) . 
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(R)-1-Benzyl-6-benzyloxy-7 ,8-dimethoxy-2-((R)-1-N-phenylethyl)-1 ,2,3,4-
tetrahydroisoquinoline (64). 
4 5 0~ 
a 
A solution of compound 16d (75 mg, 0.1 3 mmol) in CH2CI2 (5 ml) and 10% 
Pd/C was hydrogenated for 14 h. The solution was then Filtered through Celite 
followed by evaporation of solvent which afforded a residue, which was dissolved 
in water (5 ml) and CH2Cb and basified to pH 8 with saturated NaHC03. The 
organic layer was separated and the aqueous layer was extracted with CH2CI2 (3 
x 20 ml). The combined organic layers were washed with brine, dried over 
MgS04, and concentrated in vacuo to afforded a colourless oil which was purified 
by preparative TLC (silica gel, 10% EtOAc in hexane) to afford compound 64 as 
a yellow oil (45 mg, 70%). 1H NMR: o 7.48-6.66 (m, 15H, Ar-H), 6.51 (s, 1 H, H-5), 
5.10 (d, JAa=5 Hz, 1 H, H-a), (d , JaA=5 Hz, 1 H, H-a), 3.87 (s, 3H, OCH3), 3.56 (t, 
J=1 0 Hz, 1 H, H-~). 3.66 (s, 3H, OCH3), 3.56 (q, J=6.4 Hz, 1 H, H-~) , 3.48 (m, 1 H, 
H-3), 3.31 (m, 1 H, H-4), 2.90 (m, 1 H, H-3), 2.80 (m, 2H, H-a), 2.37 ( dd, J=5, 15 
Hz, 1H, H-4), 1.22 (d, J=6.4 Hz, 3H, H-W); 13C NMR: o 151.38, 151 .15, 145.77, 
140.77, 140.71' 137.24, 136.62, 131 .88, 130.49, 128.56, 127.89, 127.33, 127.23, 
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126.37, 124.42, 109.24, 90.51, 70.89, 60.89, 60.53, 58.67, 56.50, 40.76, 38.40, 
22.39, 22.09. APCI-MS: 494.2 (M++1 , 100). 
(RJ-8-Benzyloxy-6-hydroxy-7 -methoxy-1-(4-lodobenzyi)-2-(R)-1-phenyl 
ethyl)-1,2,3,4-tetrahydroisoquinoline (58a). 
4 5 
To a solution of 19b (63 mg, 0.090 mmol) in dry CH2CI2 was added 
dropwise TiCI4 (0.18 ml) at °C. The solution was warmed to rt and stirred for 5 h. 
The reaction solution was poured into cooled aqueous saturated NaHC03. The 
combined mixture was filtered through a Celite pad, and the organic layer was 
isolated. The aqueous layer was extracted with CH2CI2 (1 0 ml x 3). The 
combined organic layers were washed with brain (5 ml x 3), dried over anhydrous 
MgS04, filtered and the solvent was removed on a rotary evaporator. The 
residue obtained was further purified by using PLC (EtOAc/hexane= 30:7) to give 
58a as yellow oil (15 mg, 29% ); 1H NMR: o 7.46-6.69 (m, 14H, Ar-H), 6.59 (s, 
1 H, H-5), 5.11 (d , JAx=1 0 Hz, 1 H, H-a), 4.20 (d , JxA=1 0 Hz, 1 H, H-a), 3.95 (s, 3H, 
OCH3), 3.74 (dd, J=5, 5Hz, 1H, H-1), 3.62 (q, J=5 Hz, 1H, H-!3), 3.43 (m, 2H, H-
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3), 2.96-2.90 (m, 1H, H-4), 2.76-2.72 (m, 2H, H-a'), 2.44 (d, J=15 Hz, 1H, H- 4), 
1.28 (d, J=5 Hz, 3H, H-W); APCI-MS(m/z): 605.5 (M++1, 100). 
(RJ-8-Benzyloxy-7 -Hydroxy-6-methoxy-1-(4-fluoro-3-nitrobenzyi)-2-(R)-1-
phenylethyl)-1 ,2,3,4-tetrahydroisoquinoline (58b). 
4 5 OH 
02N F 
To a solution of 19b (51 mg, 0.080 mmol) in dry CH2CI2 was added 
dropwise TiCI4 (0.16 ml) at °C. The solution was warmed to rt and stirred for 5 h. 
The reaction solution was poured into cooled aqueous saturated NaHC03. The 
combined mixture was filtered through a Celite pad, and the organic layer was 
isolated. The aqueous layer was extracted with CH2CI2 (1 0 ml x 3). The 
combined organic layers were washed with brain (5 ml x 3) , dried over anhydrous 
MgS04, filtered and the solvent was removed on a rotary evaporator. The 
residue obtained was further purified by using PLC (EtOAc/hexane= 30:7) to give 
58b as yellow oil (13 mg, 29% ); 1H NMR: o 7.46-6.69 (m, 13H, Ar-H), 6.59 (s, 
1 H, H-5), 5.75 (s, 1 H, OH), 5.11 (d, JAx=1 0 Hz, 1 H, H-a), 4.22 (d, JxA=1 0 Hz, 1 H, 
H-a), 3.95 (s, 3H, OCH3) , 3.74 (dd, J=5, 5Hz, 1H, H-1), 3.61 (q, J=5 Hz, 1H, H-
~). 3.44 (m, 2H, H-3), 2.96-2.90 (m, 1 H, H-4), 2.76-2.72 (m, 2H, H-a'), 2.44 (d, 
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J=15 Hz, 1 H, H- 4), 1.28 (d , J=5 Hz, 3H, H-13'); 13C NMR: o 150.53, 146.42, 
140.65, 139.92, 137.19, 131.96, 130.47, 129.46, 128.27, 127.24, 126.55, 124.17, 
119.28, 107.78, 61.08, 58.85, 57.02, 56.05, 40.48, 38.44, 22.96, 22.29; APCI-
MS(m/z): 543.1 (M+ +1, 1 00). 
(RJ-8-Benzyloxy-6-hydroxy-7 -methoxy-1-(4-bromobenzyi)-2-(R)-1-phenyl 
ethyl)-1 ,2,3,4-tetrahydroisoquinoline (58c). 
4 5 
Br 
A solution of compound 19c (71 mg, 0.11mmol) in MeOH (5 ml) at 0 °C 
was treated with Raney Nickel and the reaction mixture was stirred under an 
atmosphere of H2 at 0 °C for 15 h. The mixture was then filtered over Celite 
followed by evaporation of solvent afforded a residue, which was dissolved in 
water (5 ml) and EtOAc and basified to pH 8 with saturated NaHC03. The 
organic layer was separated and the aqueous layer was extracted with EtOAc (3 
x 20 ml). The combined organic layers were washed with brine, dried over 
MgS04, and concentrated in vacuo to afforded a brown oil which was purified by 
preparative TLC (silica gel, 20% EtOAc in hexane) to afford compound 58 as a 
yellow oil (20 mg, 33%). 1H NMR: o 7.29-.6.0 (m, 15H, Ar-H), 5.65 (s, 1 H, OH), 
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5.11 (d, JAa=5 Hz, 1 H, H-a), 4.16 (d , JaA=5 Hz, 1 H, H-a), 3.98 (s, 3H, OCH3), 
3.56 (dd, J=5, 10Hz, 1H, H-1), 3.60 (q, J=5 Hz, 1H, H-13). 3.51 (m, 1H, H-3), 3.41 
(m, 1 H, H-4), 2.95 (m, 1 H, H-3), 2.68 (m, 2H, H-a), 2.45 ( dd, J=5, 15 Hz, 1 H, H-
4), 1.28 (d, J=5 Hz, 3H, H-13'); APCI-MS(m/z): 558.1 (M++1, 96), 560.1 (M+- 1, 
100). (16 mg, 30%) of 59 and (10 mg, 19%) of 57 were obtained. 
(RJ-1-Benzyi-8-Benzyloxy-6-hydroxy-7 -methoxy-2-(R)-1-phenylethyl)-1 ,2,3,4-
tetrahydroisoquinoline (59). 
1H NMR: o 7.29-.6.0 (m, 16H, Ar-H), 5.65 (s, 1 H, OH), 5.11 (d , JA8=5 Hz, 1 H, H-
a), 4 .16 (d, JaA=5 Hz, 1 H, H-a), 3.98 (s, 3H, OCH3), 3.56 (dd, J=5, 10 Hz, 1 H, H-
1), 3.60 (q, J=5 Hz, 1 H, H-13). 3.51 (m, 1 H, H-3), 3.41 (m, 1 H, H-4), 2.95 (m, 1 H, 
H-3), 2.68 (m, 2H, H-a), 2.45 ( dd, J=5, 15 Hz, 1 H, H-4), 1.28 (d , J=5 Hz, 3H, H-
13'); APCI-MS(m/z): 480.2 (M++1 , 100). 
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(RJ-8-Hydroxy-6, 7 -dimethoxy-1-(4-iodoenzyi)-2-(R)-1-phenylethyl)-1 ,2,3,4-
tetrahydroisoquinoline (65a). 
To a solution of 15b (55 mg, 0.088 mmol ) in dry CH2CI2 was added 
dropwise TiCI4 ( 0.18 ml) at °C. The solution was warmed to rt and stirred for 5 h. 
The reaction solution was poured into cooled aqueous saturated NaHC03. The 
combined mixture was filtered through a Celite pad, and the organic layer was 
isolated. The aqueous layer was extracted with CH2CI2 (1 0 ml x 3). The 
combined organic layers were washed with brain (5 ml x 3), dried over 
anhydrous MgS04, filtered and the solvent was removed on a rotary evaporator. 
The residue obtained was further purified by using PLC (EtOAc/hexane= 30:7) to 
give 65a as a yellow oil (13 mg, 29%); 1H NMR: o 7.50-6.71 (m, 9H, Ar-H), 6.25 
(s, 1 H, H-5), 5.75 (s, 1 H, OH), 3.88 (s, 3H , OCH3) , 3.86 (s, 3H, OCH3), 3.80 (m, 
1 H, H-1), 3.56 (q , 1 H, H- !3), 3.31 (m, 1 H, H-3), 2.86-2.67 (m, 2H, H-4), 2.76 (m, 
1 H, H-3), 2.36 (d , J=16 Hz, 2H, H- a), 1.26 (d , J=5 Hz, 3H, H-13'); 13C NMR: o 
150.35, 146.79, 146.00, 140.21 , 133.51 , 132.61 , 131 .82, 131 .28, 130.82, 128.11 , 
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127.44, 126.42, 119.42, 117.91, 103.72, 61 .21 , 58.91, 56.44, 55.91, 39.63, 
38.91 , 23.11 , 22.11; APCI-MS(m/z) : 530.1 (M+ +1, 1 00). 
(RJ-8-Hydroxy-1-(4-bromobenzyl)-6, 7 -dimethoxy-2-(R)-1-phenylethyl)-
1 ,2,3,4-tetrahydroisoquinoline (65c). 
Br 
To a solution of 15d (74 mg, 0.13 mmol) in dry CH2CI2 was added 
dropwise TiCI4 (0.2 ml) at °C. The solution was warmed to rt and stirred for 5 h. 
The reaction solution was poured into cooled aqueous saturated NaHC03. The 
combined mixture was filtered through a Celite pad, and the organic layer was 
isolated. The aqueous layer was extracted with CH2CI2 (1 0 ml x 3). The 
combined organic layers were washed with brain (5 ml x 3), dried over 
anhydrous MgS04, filtered and the solvent was removed on a rotary evaporator. 
The residue obtained was further purified by using PLC (EtOAc/hexane= 30:7) to 
give 65c as a yellow oil (20 mg, 34%); 1H NMR: o 7.33-6.76 (m, 9H, Ar-H), 6.28 
(s, 1 H, H-5), 5.80 (p, 1 H, OH), 3.91 (s, 3H, OCH3) , 3.88 (s, 3H, OCH3) , 3.85 (m, 
1 H, H-~) , 3.61 (t, 1 H, H-1 ), 3.40 (m, 1 H, H-3), 3.34 (m, 1 H, H-4), 2.91 (m, 1 H, H-
3), 2.73 (m, 2H, H- a), 2.40 (m, 1 H, H-4}, 1.28 (d, 3H, H-W); 13C NMR: o 150.34, 
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146.81, 145.79, 140.11 , 133.51 , 132.61, 130.94, 130.89, 128.11 , 127.82, 
126.18, 119.16, 117.75, 103.46, 61.22, 58.90, 56.44, 55.91 , 39.61 , 38.90, 23.11 , 
22.11; APCI-MS(m/z): 484.1 (M+ +1 , 1 00), 482.2 (M+- 1, 96). 
(RJ-8-Hydroxy-6, 7 -dimethoxy-1-(4-fluoro-3-nitrobenzyi)-2-(R)-1-phenylethyl)-
1 ,2,3,4-tetrahydroisoquinoline (65b). 
4 5 
02N F 
To a solution of 15c (99 mg, 0.18 mmol) in dry CH2CI2 was added 
dropwise TiCI4 (0.2 ml) at °C. The solution was warmed to rt and stirred for 5 h. 
The reaction solution was poured into cooled aqueous saturated NaHC03. The 
combined mixture was filtered through a Celite pad, and the organic layer was 
isolated. The aqueous layer was extracted with CH2CI2 (1 0 ml x 3). The 
combined organic layers were washed with brain (5 ml x 3), dried over 
anhydrous MgS04 , filtered and the solvent was removed on a rotary evaporator. 
The residue obtained was further purified by using PLC (EtOAc/hexane= 30:7) to 
give 65b as a yellow oil (27 mg, 33% ); 1H NMR: o 7.67-6.96 (m, 8H, Ar-H), 6.27 
(s, 1 H, H-5), 5.83 (s, 1 H, OH), 3.91 (s, 3H, OCH3), 3.88 (s, 3H, OCH3), 3.80 (dd, 
J=5, 10 Hz, 1 H, H-1 ), 3.57 (q, 1 H, H- ~) . 3.73 (m, 1 H, H-3), 2.94-2.85 (m, 2H, H-
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4), 2.76 (m, 1 H, H-3), 2.73 (d, J=16 Hz, 2H, H- a), 1.28 (d, J=5 Hz, 3H, H-W); 13C 
NMR: 0 150.54, 146.48, 145.32, 143.21 I 138.31 I 136.77, 136.62, 133.33, 130.92, 
127.67, 127.21, 126.59, 126.51 , 116.96, 116.81 , 103.54, 61 .03, 58.52, 56.02, 
55.69, 38.83, 38.78, 22.80, 21 .31 ; APCI-MS(m/z): 467.3 (M++1 , 100). 
(RJ-6,8-Dihydroxy-7 -methoxy-1-(4-iodobenzyi)-2-(R)-1-phenylethyl)-1,2,3,4-
tetrahydroisoquinoline (68a). 
To a solution of 19a (63 mg, 0.091 mmol) in dry CH2CI2 was added 
dropwise TiCI4 (0.36 ml) at °C. The solution was warmed to rt and stirred for 5 h. 
The reaction solution was poured into cooled aqueous saturated NaHC03 . The 
combined mixture was filtered through a Celite pad, and the organic layer was 
isolated. The aqueous layer was extracted with CH2CI2 (1 0 ml x 3). The 
combined organic layers were washed with brain (5 ml x 3), dried over 
anhydrous MgS04, filtered and the solvent was removed on a rotary evaporator. 
The residue obtained was further purified by using PLC (EtOAc/hexane= 50:50) 
to give 68b as a yellow oil (22 mg, 48%); 1H NMR: o 7.54-6.75 (m, 8H, Ar-H), 
6.33 (s, 1 H, H-5), 5.40 (s, 1 H, OH), 5.21 (s, 1 H, OH), 3.86 (s, 3H, OCH3) , 3.77 
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(m, 1 H, H-1 ), 3.59 (q, J=5 Hz, 1 H, H-13), 3.38 (m, 1 H, H-3), 3.32 (m, 1 H, H-3), 
2.86 (m, 2H, H-a'), 2.75 (m, 1 H, H-4), 2.39 (dd, J=5 , 15 Hz, 1 H, H-4), 1.27 (d, 
J=5 Hz, 1 H, H-13'); 13C NMR: o 146.92, 146.60, 146.21, 141.1 1, 137.00, 132,88, 
132.47, 132.39, 128.29, 127.63, 126.63, 116.91 , 107.72, 99.99, 61 .69, 59.17, 
56.51 , 40.1 0, 39.09, 23.1 0, 22.35; APCI-MS(m/z): 516.0 (M+ +1 , 1 00). 
(RJ-6,8-Dihyd roxy-7 -methoxy-1-( 4-fl uoro-3-n itrobenzyi)-2-(R)-1-phenylethyl)-
1 ,2,3,4-tetrahydroisoquinoline (68b). 
4 5 
02N F 
To a solution of 19b (51 mg, 0.086 mmol) in dry CH2CI2 was added 
dropwise TiCI4 (0.34 ml) at °C. The solution was warmed to rt and stirred for 5 h. 
The reaction solution was poured into cooled aqueous saturated NaHC03. The 
combined mixture was filtered through a Celite pad, and the organic layer was 
isolated. The aqueous layer was extracted with CH2CI2 (10 ml x 3). The 
combined organic layers were washed with brain (5 ml x 3), dried over 
anhydrous MgS04, filtered and the solvent was removed on a rotary evaporator. 
The residue obtained was further purified by using PLC (EtOAc/hexane= 50:50) 
to give 68b as a yellow oil (18 mg, 52%); 1H NMR: o 7.65-6.72 (m, 8H, Ar-H), 
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6.32 (s, 1 H, H-5), 5.63 (s, 1 H, OH), 3.84 (s, 3H, OCH3), 3.79 (m, 1 H, H-1 ), 3.57 
(q, J=5 Hz, 1H, H-~). 3.36 (d, J=10 Hz, H-a'), 2.92-2.74 (m, 3H, H-3, H-4), 2.37 
(d, J=20 Hz, 1 H, H- 4); APCI-MS(m/z) : 454.1 (M+ +1 , 1 00). 
(RJ-6,8-Dihydroxy-7 -methoxy-1-(4-bromobenzyi)-2-(R)-1-phenylethyl)-
1 ,2,3,4-tetrahydroisoquinoline (68b). 
Br 
To a solution of 19c (54 mg, 0.083 mmol) in dry CH2CI2 was added 
dropwise TiCI4 (0.33 ml) at °C. The solution was warmed to rt and stirred for 5 h. 
The reaction solution was poured into cooled aqueous saturated NaHC03. The 
combined mixture was filtered through a Celite pad, and the organic layer was 
isolated. The aqueous layer was extracted with CH2CI2 (1 0 ml x 3). The 
combined organic layers were washed with brain (5 ml x 3), dried over 
anhydrous MgS04 , filtered and the solvent was removed on a rotary evaporator. 
The residue obtained was further purified by using PLC (EtOAc/hexane= 50:50) 
to give 68c as a yellow oil (19 mg, 50%); 1H NMR: o 7.53-6.75 (m, 8H, Ar-H), 
6.33 (s, 1 H, H-5), 5.40 (s, 1 H, OH), 3.86 (s, 3H, OCH3), 3.77 (m, 1 H, H-1 ), 3.59 
(q, J=5 Hz, 1 H, H-~) . 3.38 (m, 1 H, H-3) , 3.32 (m, 1 H, H-3), 2.86 (m, 2H, H-a'), 
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2.75 (m, 1 H, H-4), 2.39 (dd, J=5, 15 Hz, 1 H, H-4), 1.27 (d, J=5 Hz, 1 H, H-W); 13C 
NMR: 0 146.92, 146.60, 146.21 I 141 .11 I 137.00, 132,88, 132.47, 132.39, 128.29, 
127.63, 126.63, 116.91, 107.72, 99.99, 61.69, 59.17, 56.51 , 40.10, 39.09, 23.10, 
22.35; APCI-MS(m/z): 468.3 (M++1, 100), 467.2 (M+-1, 94). 
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Chapter 3 
3.1 Introduction. 
Anthrax is an acute infectious disease caused by Bacillus anthracis 
(B.anthracis), a Gram-positive, spore-forming, aerobic, and rod-shaped 
bacterium.1 Humans usually contract the disease either by contact with infected 
livestock, or ingestion of contaminated animal products. Anthrax recently gained 
public attention as a result of a preceded bioterrorism.2 
3.1.1 Classification of Anthrax. 
Anthrax has been divided into three types, depending on the way in which 
the spore enters the bodl: (1) Cutaneous anthrax, in which spores infect the 
host through skin cuts or abrasions. This type of anthrax is not as dangerous 
and it can be treated effectively or the organism's immune system eliminates the 
spore. (2) Gastrointestinal anthrax disease which results from the consumption of 
spore-contaminated meat by the host. Even though it is a very rare form of 
anthrax infection it is extremely violent and has a high mortality rate; and (3) 
lnhalational anthrax which is the most dangerous form. The bacterium enters the 
host by aerosols which carry it into the lungs and ultimately to the alveoli which is 
facilitated by the small :::::: 5 Jlm aerosol size. Once the bacteria crosses the 
membrane and enters the blood stream the mortality rate is:::::: 100%, if untreated. 
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3.1.2 The lethality of B. anthracis. 
The lethality of B. anthracis can be attributed to two factors: (1) The 
capsule, which consists of poly-a-D-glutamic acid, is a necessary virulence factor 
that reduces the natural host defense through its antiphagocytic action. Poly-a-D-
glutamic acid (Figure 3.1) itself is a weak immunogenic, but when covalently 
bound to a carrier protein, it stimulates the production of serum antibodies.4• 5 (2) 
The anthrax toxin, consists of three proteins, namely Lethal Factor (LF), Edema 
Factor (EF) and Protective Antigen (PA). Experiments have shown that each 
protein individually, is nontoxic. However, a mixture of PA and LF can cause 
lethal shock in experimental animals, and a mixture of PA and EF leads to 
edema at the position of injection in test animals. 6 Among these three proteins, 
LF has been shown to act as the key virulence factor for B. anthracis. 
0 
Figure 3.1. Poly-a-D-glutamic acid. 
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(According to Fori no. et. a/. 7 "Anthrax lethal toxin must enter inside the 
cell compartment to exert its lethal effect. PA binds to the ubiquitously expressed 
cellular receptors and, after its proteolytic activation by the furin-like proprotein 
convertases and the release of the N-terminal 20-kDa fragment, generates the 
mature PA protein. PA heptamerizes and binds both of LF and EF. After 
endocytosis of the resulting complexes, the engulfed molecules of LF and EF are 
liberated and exert their toxic action. Inside the cell compartment, LF cleaves 
mitogen-activated protein kinase kinases (MAPKK), disrupts signal transduction, 
and finally leads to macrophage lysis through a mechanism that is not completely 
understood to date. Accordingly, inhibition of LF is the most promising means for 
treating postexposure anthrax". 
3.1.3 Lethal factor (LF). 
Anthrax Lethal Factor is a zinc-dependent protease that cleaves mitogen-
activated protein kinase kinase and causes lysis of macrophages. 8·9 The mature 
spore exhibits high resistance to: harsh chemicals, desiccation, extreme 
temperatures, radiation, and physical damage.10 This allows the spore to survive 
in soil for many years. It is therefore, highly desirable to develop an effective and 
inexpensive vaccine as well as a method to detect this dangerous bacterium. The 
preparation of effective inhibitors against LF and an understanding of its manner 
of action has become the focus of several studies. 11 -17 
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3.1.4 Detection and inhibition of anthrax lethal factor. 
In 2004 Turnbough 11 isolated anthrax tetrasaccharide from the surface of 
the exosporium glycoprotein BC1A of B. anthracis (Figure 3.2). He also 
explained that the anthrax tetrasaccharide consists of three L-rhamnose sugars 
and a 0-anthrose sugar. The structure of anthrax tetrasaccharide is unique to 
B.anthracis and is not found in other spores of the Bacillus species. Thus, 
anthrax tetrasaccharide has become a target for anthrax detection. 
OH 
0 
, __ OHO H~H ~H 0 0 ~
Figure 3.2. Structure of the surface tetrasaccharide of B. anthracis. 
The tetrasaccharide was first chemically synthesized in the form of an n-
pentenyl glycoside by Seeberger12 in 2005 (Scheme 3.1). Starting with 0-fucose 
the desired target was prepared in 35 steps. The reason for using a terminal 
pentenyl group is to enable its conjugation with the protein in vaccine 
development. 
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Scheme 3.1. Synthetic approach for Anthrax tetrasaccharide analogues. 
O'Doherti 3 used the de novo asymmetric approach to synthesize the 
anthrax tetrasaccharide and its analogue, with an anomeric hexyl azide group 
(Figure 3.3). The total synthesis of anthrax tetrasaccharide has been the major 
goal of many recent reports. 14 
Figure 3.3. The anomeric hexyl azide analogue of tetrasaccharide. 
In 2005 Forino et al.7 prepared a series of phenylfuran-2-ylmethylene-
rhodanineacetic acid derivatives of LF inhibitors with low-micromolar and 
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submicromolar activity. For example, derivatives of compound 1 illustrated in 
Figure 3.4 showed good reactivity as LF inhibitors. 
c~ Br-o-
Figure 3.4. Derivatives of compound 1. 
This study revealed that the presence of a phenyl moiety with a small 
electronegative group in the R1 position, and a carboxylic group in the R2 position 
increased the reactivity of these compounds. All positions on the phenyl moiety 
gave similar results, however an acetyl group in position R2 however, gave the 
best results. It was also concluded from this study that, the presence of multiple 
substituents increases the reactivity. The strategy which was applied to prepare 
those compounds is illustrated in Scheme 3.2. 
0 
0 )lN- R R1 
/, + \~ 2 DMF, MW 
s 
0 
Scheme 3.2. Synthetic approach to prepare derivatives of compound 1 
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Cohen et a/. 15 described the preparation of several nitrogen ligands 
(Figure 4.5) which were identified as being useful for the inhibition of Zn2+ 
metallo-proteinases. Their study showed that these compounds exhibited 
selectivity for Zn2+ -metalloproteins over other metalloproteins. 
(~ NHH~ 
v 
Figure 3.5. Some nitrogen ligands as LF inhibitors. 
Two recent reports 16·17 showed that galloyl derivatives (Figure 3.6) which 
were extracted from green tea can be utilized as LF inhibitors. Wong 17 tested 
more than ten commercial compounds, for example, alizarin (5) , purpurin (6) , and 
purpurogallin (7). 1 ,2 , 3,4 ,6-penta-0-galloyi-~-D-glucose (2) is one of four 
compounds which were identified as inhibitors against the anthrax lethal factor. 
It was found that the presence of the gallate architecture is important for the 
inhibition of LF. In order to test other gallate-like derivatives, the commercially-
available 5-hydroxydopamine hydrochloride (3) was reacted with fifty-nine 
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structurally-diverse aldehydes and seven dialdehydes, respectively, using the 
Pictet-Spengler reaction (Scheme 3.3). 
~OH 
0~0H 
Gallic acid 
Purpurin 
Alizarin 
mOHO OH H I H 
Purpurogallin 
Figure 3.6. Examples of galloyl derivatives which are extracted from green 
tea. 
Better lethal factor inhibition was found for compounds derived from 
dialdehyde moieties. Based upon these results, Wong et a/. 17 prepared a group 
of three paired gallate-like tetrahydroisoquinoline polyphenols, compounds 4a-
6b, starting from 5-hydroxydopamine hydrochloride (Figure 3. 7). All of these 
compounds were found to be "noncompetitive" inhibitors of anthrax LF. The 
report is scant on details of the characterization of these compounds, however 
the authors state that "chiral derivatization led to the identification of 4a and 4b". 
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Scheme 3.3. Using 5-hydroxydopamine HCI to prepare some LF inhibitors. 
It should be noted that 4b, for example, was stated to be "(+/-)". It was 
also represented however, in the paper as being the "S,R" isomer, and therefore 
it is clearly a meso structure as written . As reported therefore, 4b could either be 
a racemic mixture of enantiomers which are respectively, R,R and S,S, and thus 
are"(+/-)"; or, that it is a meso compound. The paper is ambiguous as written. 
Similar observations can be made for the other compounds 5a-6b. 
Nevertheless, the data presented show that under physiological salt 
concentration conditions (150 mM) the most potent inhibitor of LF was 4a having 
Ki = 4.3 ± 1.8 f.!M compared to a value of Ki = 51 .8 ± 1.2 f.!M for the "racemic" 
mixture, 4b. The authors did state, however that "the chiral resolution of each 
racemic mixture is one of our future objectives". 
152 
HO 
HO 
H 
H 
(4a) 
(5a) 
OH H 
OH HO 
H H 
OH 
OH H 
HO 
(6b) 
OH 
OH 
OH 
OH 
OH 
Figure 3.7. Structures of bis(tetrahydroisoquinoline) compounds 4a-6b. 
They also concluded from their screening studies of these and other 
compounds, that "derivatives of tetrahydroisoquinolines, such as 
dihydroisoquinolines and isoquinolines, are also interesting targets for the 
identification of new potent LF inhibitors", and that "the actual potencies of the 
enantiomers are still unknown".16· 17 
These studies 16·17 led us to consider the use of some of the intermediates 
obtained in the course of our on-going studies towards the enantioselective 
synthesis of (-)-cycleanine and of other BBIQs of interest, for the enantioselective 
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synthesis of some analogues of those which have been reported . In particular, N-
[2-(3,5-dibenzyloxy-4-methoxyphenyl)-ethyi]-N-[1-phenylethylamine (7) and N-
[(R)-methylbenzyl]-(5-benzyloxy-3,4-diphenylmethylenedioxy)phenylacetamine 
(8) were considered Figure 3.8. 
PhX O'YYJ rl Ph O~ t;"N ..... ~ 
OBn CH3 
(7) (8) 
Figure 3.8. The structure of 7 and 8. 
Thus, 9, the dismethoxy analogue of Sa was targeted, as were 
compounds 10-12 via the Schotten-Baumann and subsequent Bischler-
Napieralski cyclization methodologies employed in our BBIQ synthetic approach. 
The synthesis of 9 is outlined in Scheme 3.4 using 1 ,3-benzenedicarbonyl 
chloride (isophthaloyl chloride). 
CA CA 
"'. cJdc' N•<>M""'"·,.~~~o'" 
CH30 : OCH3 
! 1. POCI3, benzene ?· NaBH4 , MeOH 
' py 
H 
H2. Pd/C \ 
• ··---------
OH 
HO 
(9) 
Scheme 3.4. Synthesis of compound 9 starting from 7. 
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Scheme 3.5. Synthesis of compound 10 starting from 7 
OBn 
Compound 10 was envisioned to be synthesized using oxalylchloride in 
the key bis-coupling step (Scheme 3.5) while, 11 will be obtained by 1 ,3,5-
Benzenetri-carbonylchloride (Scheme 3.6). 
0 0 
(7) •C~CI 
£f~ICA,Or 
NaOH, CH Cl BnOY~Bn Bn'~Yosn 
............. L'2.,. CH30 CA OCH3 
eX 
HO 
H2. Pd/C .,. ___ _____ __ _ 
HO OCH3 
(11) 
BnO 
BnO 0 P "· .. N" CH3o~ 
BnO 
BnO 
! 1. POCI3, benzene i 2. NaSH,., MeOH 
' 
Scheme 3.6. Synthesis of compound 11 starting from 7 
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The syntheses of compounds 9-11 containing methoxy group could help in 
determining whether they would be less reactive in the presence of 02, a factor 
noted by Numa eta/ for their non-methoxy group-containing compounds 4a-6b. 
Finally, the enantioselective synthesis of the bismethoxythiophene 
analogue, 12, was also envisioned (scheme 3.7). 
0 0 
(7)+CI~CI ~-Q~ - f~·f"~ ~C)~\~ BnoV~Bn Bn~Jylosn 
CH30 OCH3 
i 1. POCh, benzene i 2. NaBH4, MeOH 
' 
H2. Pd/C 
-c-----------
OH 
HO 
OBn 
(12) BnO 
Scheme 3.7. Synthesis of compound 10 starting from 7 
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Chapter 4 
4.1 A retrosynthetic analysis for the synthesis of tetrahydroisoquinolines 
1 -4. 
Since the strategies which were applied to prepare 2,5-bis[(R)-6,8-
dihyd roxy-7 -methoxy-1 ,2, 3 ,4-tetrahyd roisoq u inoline ]-thiophene ( 1), 1 , 3-bis[ ( R)-
6,8-dihydroxy-7-methoxy-1 ,2,3,4-tetrahydroisoquinoline]-benzene (2), 1 ,3,5-
tris[(R)-6,8-dihydroxy-7 -methoxy-1 ,2,3,4-tetrahydroisoquinoline]-benzene (3) and 
1,1 '-bi[(R)-6,8,6',8'-tetrahydroxy-7,7'-dimethoxy]-1 ,2,3,4, 1 ',2' ,3' ,4'-octahydroiso-
quinoline (4) were similar, compound 3 can be chosen as an example to 
describe the retrosynthetic analysis for the synthesis of compounds 1 - 4 (Figure 
4.1 ). 
OH OH 
HO HO 
(1) (2) 
HO 
OH 
HO HO 
(4) 
Figure 4.1. Structures of compounds 1 - 4. 
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As shown in Scheme 4.1, compound 3 was formed by hydrogenation of 
1 ,3,5-tris[(R)-6,8-dibenzyloxy-7 -methoxy-2-((R)-1-phenylethyl)-1 ,2,3,4-tetrahydro 
isoquinoline]-benzene (5) . Application of the BNC conditions on 1 ,3,5-
tricarbonyltris[N-((R)-a-methylbenzyi)-N-((3,5-dibenzyloxy-4-methoxy)phenyl-
ethyl]-benzene (6) led to the formation of (5) by triple cyclization. Compound 6 
was prepared by reaction of 1 ,3,5-benzenetricarbonyl trichloride (7) with N-((R)-
a-Methylbenzyl)-2 -(3, 5-d ibenzyloxy-4-methoxy)phenylethanamine (8). 
HO 
Hydrogenation 
HO 
(3) 
Schotten-Baumann reaction 
(7) 
Scheme 4.1. Retrosynthetic analysis of 3. 
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4.2. Synthetic analysis for the synthesis of tetrahydroisoquinolines 1-4. 
Scheme 4.2 shows the reaction of 1 mole equivalent of (8) with 0.5 mole 
equivalent of the commercially-available 2,5-thiophene-dicarbonyl dichloride (9) 
and 0.5 mole equivalent of the commercially-available isophthaloyl chloride (10). 
0 0 
C~CI 
(9) 
71% 
(10) 
Scheme 4.2. Preparation of the chiral am ides 11 and 12. 
Applying of Schotten-Baumann reaction conditions, the two chiral amides 
2, 5-dicarbonyl-bis[N-( (R)-a-methylbenzyi)-N-( (3, 5-d ibenzyloxy-4-
methoxy)phenylethyl)-thiophene (11) and 1 ,3-dicarbonyl-bis[N-((R)-a-
methylbenzyi)-N-( (3 ,5-dibenzyloxy-4-methoxy)phenylethyl)-benzene (12) were 
produced by double amidation in 65% and 61% yields repectively. 
The same conditions were applied using 1 mole equivalent of 8 with 0.33 
mole equivalents of the commercially-available 1 ,3,5-benzene tricarbonyl 
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trichloride (7) and 0.5 mole equivalent of the commercially-available oxalyl 
chloride (13) respectively. 
CV CI 
Cl 0 
(7) 
52% ~OBn 
6
N..._H ~OCH_3 N_a_O_H,_C-'H2=--C--=-JI2 OBn L_ ______ __ 
I 
(8) 
SnOW OBn c?" "-':: 
:::,... I N N I CH,O CA' K W OCH, 
OBn 0 0 OBn 72% 
(13) (15) 
Scheme 4.3. Preparation of the chiral am ides 14 and 15. 
As shown in Scheme 4.3, the chiral intermediate 1 ,3,5-tricarbonyl-tri[N-
( (R)-a-methylbenzyi)-N-( (3, 5-d ibenzyloxy-4-methoxy)phenylethyl)-benzene ( 14) 
was prepared in 52% yield , while 1 ,2-bis[N-((R)-a-methylbenzyi)-N-((3,5-
dibenzyloxy-4-methoxy)phenylethyl]-oxalamide (15) was prepared in 72% yield . 
As mentioned in Chapter 2, rotation about the amide bond of some 
tetrahydroisoquinolines leads to interconversion of two rotamers and as a result, 
the 1H- and 13C-NMR signals are duplicated. The 1H- and 13C-NMR spectra of 11 , 
12, 14 and 15 showed interconversions of more than two rotamers in each 
compound. As a result, most of the 1H-NMR signals were broader than usual. 
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Figure 4.2. The rotation about three amide bonds in 14. 
As example, the rotation about three amide bonds in compound 14 
presumably led to the formation of more than four rotamers. The 1 H-NMR 
spectrum of 14 in CDCb (Figure 4.3) as an example, showed the CH2-CH2 
signals as a broad signal at o 3.39-2.52 ppm, while the methoxy groups 
appeared as a broad signal at o 3.84-3.74 ppm. Furthermore, the breadth of the 
1H-NMR peaks made the calculation of the rotational conformer ratio extremely 
difficult. 
~- ... ~ - ~ . - ---
...... .... ,.. . .. .. .. 
'·" '" ..... .. • .. .. '' 1~:.... .. ... 
Figure 4.3. The 1H-NMR spectrum of 14. 
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Compounds 11 , 12, 14 and 15 were then each subjected to the BNC 
conditions, at reflux in benzene with POCI3 for 12 h, followed by reduction with 
NaBH4. The corresponding products 16 - 19, respectively were obtained as 
mixtures (Schemes 4.4). 
(11) 1. POCI3• benze'l 
2. NaBH4, MeOH 
(12) 1 . POCI3, benze'\. 
2. NaBH4, MeOH 
(1S) 1. POCI3, benze'\. 
2. NaBH4• MeOH 
BnO 
BnO OCH3 
(16) 
(17 ) 
(18) 
(1 9) 
Scheme 4.4. The structures of compounds 16- 19. 
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Since there were two new stereogenic centers generated in compounds 
16, 17 and 19, and there were three stereogenic centers generated in compound 
18, the crude products of these compounds appeared as complex mixtures. For 
example, compound (16) could conceivably afford four different distereoisomers 
(Figure 4.4). 
However, even though the corresponding masses of compounds 16 - 19 
were detected by HPLC-MS, the desired diastereoisomers could not be easily 
separated. No further investigations were conducted on this project by this 
author. 
(16) 
(1 ,1') = (R, S), (1,1') = (R, R), (1 ,1') = {S, S) and (1,1') = (S, R) 
Figure 4.4. The distereoisomers of compound 16. 
4.3. Summary. 
The chiral amine (8) was successfully reacted with the acyl chlorides 7, 9, 
10 and 13 to prepare the secondary amides 11 , 12, 14 and 15, respectively. 
These intermediates were subjected to the BNC conditions to produce after 
reduction the tetrahydroisoquinolines 16- 19, respectively. Due to the formation 
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of many products pure distereoisomers of those intermediates could not be 
isolated due to this author's time constraints. 
4.4. Proposal for future work. 
Reduction of compounds 16 - 19 may lead to the formation of the 
respective final target products 20 - 23 by debenzylation, and the removal of the 
chiral auxiliaries (Schemes 5.5). If obtained, the final products need then to be 
tested to see if they would be effective inhibitors for anthrax lethal factor. 
HO OCH3 
(20) 
HO OCH, CH30 (21 ) 
OH 
HO (22) 
H H 
"" ··· ·"·~~~~~.. ~ 
HO OCH3 CH30 OH 
(23) 
Scheme 4.5. The structures of 20, 21 , 22 and 23. 
164 
References 
1. Smith, H.; Keppie, J. Nature. 1954, 173, 869. 
2. Puhar, A; Montecucco, C. Trends Microbial. 2007, 15, 477. 
3. Collier, R. J.; Young, J. AT. Annu. Rev. Cell Dev. Bioi. 2003, 19, 
45. 
4. Kubler-Kielb, J.; Liu , T.-Y.; Mocca, C.; Majadly, F. ; Robbins, J. B.; Schneerson, 
R. Infect. lmmun. 2006, 74, 4744. 
5. Candela, T. ; Fouet, A Mol. Microbial. 2006, 60, 1091 . 
6. Gujraty, K.; Sadacharan, S.; Frost, M.; Poon, V .; Kane, S. R. ; Mogridge, J. 
Mol. Pharmaceutics. 2005, 2, 367. 
7. Forino, M.; Johnson, S.; Wong, T. Y.; Rozanov, D. V.; Savinov, A Y. ; Li , W .; 
Fattorusso, R. ; Becattini, B. ; Orry A J.; Jung, D.; Abagyan , R. A; Smith, J. 
W .; Alibek, K. ; Liddington, R. C.; Strongin, A Y.; Pellecchia, M. Proc. Nat/. 
Acad. Sci. U.S.A. 2005, 102, 499. 
8. O'Brien, J. Infect. lmmun. 1985, 47, 306. 
9. Duesbery, N. S. Science. 1998, 280, 734. 
10. Nicholson, W . L.; Munakata, N.; Horneck, G. ; Melosh, H. J. ; Setlow, P. 
Microbial. Mol. Bioi. Rev. 2000, 64, 548. 
11. Daubenspeck, J. M.; Zeng, H.; Chen, P.; Dong, S.; Steichen , C. T. ; Krishna, 
N. R. ; Pritchard, D. G.; Turnbough, C. L. , Jr J. Bioi. Chern. 2004, 279, 30945. 
12. Werz, D. B.; Seeberger, P. H. Angew. Chern. Int. Ed. 2005, 44, 6315 - 6318. 
13. Guo, H.; O'Doherty, A G. J. Org. Chern. 2008, 73, 5211 . 
14. (a) Adamo, R. ; Saksena, R.; Kovac., P. Carbohydr. Res. 2005, 340, 2579. 
(b) Saksena, R.; Adamo, R. ; Kovac, P. Bioorg. Med. Chern. Lett. 2006, 
165 
16,615. (c) Adamo, R.; Saksena, R.; Kovac, P. Helv. Chim. Acta 2006, 
89, 1075. (d) Mehta, A. S.; Saile, E. ; Zhong, W. ; Buskas, T. ; Carlson, R. ; 
Kannenberg , E. ; Reed, Y. ; Quinn, C. P.; Boons, G.-J. Chern. Eur. J. 2006, 
12, 9136. (e) Crich, D.; Vinogradova, 0. J. Org. Chern. 2007, 72, 6513. 
(f) Werz, D. B.; Adibekian, A. ; Seeberger, P. H. Eur. J. Org. Chern. 2007, 
1976. 
15. Jacobsen, F. E.; Lewis, J. A.; Cohen, S. M. J. Am. Chern. Soc. 2006, 128, 
3156. 
16. Deii'Aica, I .; Don, M.; Tonello, F.; Piris, A. ; Mock, M.; Montecucco, C.; 
Garbisa, S. EMBO Rep. 2004, 5, 418. 
17. Numa, M. M. D.; Lee, L. V. ; Hsu, C. ; Bower, K. E.; Wong, C. Chern. Bio. 
Chern. 2005, 6,1002. 
166 
Experimental 
2,5-Dicarbonyl bis[N-((R)-a-Methylbenzyi)-N-((3,5-dibenzyloxy-4-methoxy) 
phenylethyl) thiophene (11) 
To a stirred mixture of N-((R)-a-Methylbenzyl)-2-(3,5-dibenzyloxy-4-
methoxy)phenylethanamine (8) (3.1 g, 6.4 mmol) in CH2CI2:aqueous 5% NaOH (1 :1.5, 
8.5 ml) at 0 °C was added dropwise a solution of 2,5-thiophene dicrabonyl dichloride 
(9) ( 694 mg 3.32 mmol) in CH2CI2. After stirring at room temperature for 1 h, the 
reaction mixture was extracted with chloroform (30 ml x 3), washed with water (20 ml x 
3), dried over anhydrous MgS04 , filtered and the solvent was evaporated. The residue 
was purified by PLC (30% EtOAc:hexane) to afford the amide 11 as a green oil (5.4 g, 
75%): 1H NMR: o 7.45-7.23 (m, 32H, Ar-H), 6.30-6.26 (br, 4H, H-2, 2', 6, 6'), 5.58-5.55 
(br, 2H, H-13. 13\ 5.08-5.03 (br, 8H, H-a, a\ 3.86-3.82 (s, 6H, OCH3), 3.40-2.43 (4br, 
8H, CH2CH2, CH'2CH'2), 1.59-1.51 (m, 6H, H-13', 13'1 ); 13C NMR: 163.98, 152.44, 140.31 , 
139.74, 138.10, 137.19, 128.69, 128.50, 128.45, 127.87, 127.82, 127.64, 127.25, 
127.23, 108.49, 106.49, 71 .06, 65.24, 60.88, 46.19, 29.67, 29.22, 17.60, 14.02; APCI-
MS(m/z): 1072.0 (M+ +1, 1 00). 
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1,3-Dicarbonybis[N-((R)-a-Methylbenzyi)-N-((3,5-dibenzyloxy-4-methoxy)phenyl 
ethyl) benzene (12) 
To a stirred mixture of N-((R)-a-Methylbenzyl)-2-(3,5-dibenzyloxy-4-
methoxy)phenylethanamine (8) (3.0 g, 6.4 mmol) in CH2CI2:aqueous 5% NaOH (1 :1.5, 
8.5 ml) at 0 °C was added dropwise a solution of isophthaloyl chloride (10) ( 652 mg 
3.32 mmol) in CH2CI2 . After stirring at room temperature for 1 h, the reaction mixture 
was extracted with chloroform (30 ml x 3), washed with water (20 ml x 3), dried over 
anhydrous MgS04 , filtered and the solvent was evaporated. The residue was purified by 
PLC (30% EtOAc:hexane) to afford the amide 12 as a yellow oil (4.8 g, 71%): 1H NMR: 
o 7.85-7.16 (m, 34H, Ar-H), 6.29-6.25 (br, 4H, H-4, 4', 8, 8'), 5.80-5.77 (br, 2H, H-~. ~1 }, 
5.09-5.04 (br, 8H, H-a, a\ 4.03-3.74 (br, 6H, OCH3}, 3.39-2.20 (4br, 8H, CHzCHz, 
CH'2CH'2), 1.60-1.25 (2br, 6H, H-W, W1 ) ; 13C NMR: 172.11 , 152.60, 138.30, 137.37, 
128.75, 127.92, 127.41 ' 127.13, 124.64, 108.62, 71.19, 60.80, 56.99, 53.74, 44.77, 
34.89, 31.40, 29.49, 17.69; APCI-MS(m/z): 1066.2 (M++1, 100). 
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1 ,3,5-tricarbony tri[N-((R)-a-Methylbenzyi)-N-((3,5-dibenzyloxy-4-methoxy) 
(phenylethyl) benzene (14). 
To a stirred mixture of N-((R)-a-Methylbenzyl)-2-(3,5-dibenzyloxy-4-
methoxy)phenylethanamine (8) (3.0 g, 6.4 mmol) in CH2CI2:aqueous 5% NaOH (1 :1.5, 
8.5 ml) at 0 °C was added dropwise a solution of 1,3,5-benzene tricarbony trichloride 
(7) ( 560 mg 2.12 mmol) in CH2CI2. After stirring at room temperature for 1 h, the 
reaction mixture was extracted with chloroform (30 ml x 3), washed with water (20 ml x 
3) , dried over anhydrous MgS04, filtered and the solvent was evaporated. The residue 
was purified by PLC (30% EtOAc:hexane) to afford the amide 14 as a yellow oil (5.2 g, 
52%): 1H NMR: o 7.65-7.19 (m, 48H, Ar-H), 6.40-6.36 (br, 6H, H-4, 4', 8, 8', 4", 8"), 
6.13-5.82 (2br, 3H, H-~. ~\ ~\ 5.17-5.04 (brs, 12H, H-a, a1, a2), 4.01-3.88 (br, 9H, 
OCH3), 3.46-2.55 (4br, 12H, CH2CH2, CH'2CH'2, CH"2CH"2), 1.60-1.47 (2br s, 9H, H-W. 
W1. W2); 13C NMR: 172.11 , 152.60, 138.30, 137.37, 128.75, 127.92, 127.41 , 127.13, 
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124.64, 108.62, 71.19, 60.80, 56.99, 53.74, 44.77, 34.89, 31.40, 29.49, 17.69i APCI-
MS(m/z): 1559.4 (M+ +1, 1 00). 
1 ,2-bis[N-((R)-a-Methylbenzyi)-N-((3,5-dibenzyloxy-4-ethoxy)phenylethyl] 
oxalamide (15). 
n ~0 
a 
2' 2 
y 
0 a 
To a stirred mixture of N-((R)-a-Methylbenzyl)-2-(3,5-dibenzyloxy-4-
methoxy)phenylethanamine (8) (3.0 g, 6.4 mmol) in CH2CI2:aqueous 5% NaOH (1 :1.5, 
8.5 ml) at 0 °C was added dropwise a solution of oxalyl chloride (13) ( 0.28 ml 3.2 
mmol) in CH2CI2. After stirring at room temperature for 1 h, the reaction mixture was 
extracted with chloroform (30 ml x 3), washed with water (20 ml x 3), dried over 
anhydrous MgS04, filtered and the solvent was evaporated. The residue was purified by 
PLC (30% EtOAc:hexane) to afford the amide 15 as a yellow oil (4.5 g, 72%): 1H NMR: 
o 7.60-7.26 (m, 30H, Ar-H), 6.25-6.21 (4s, 4H, H-4, 4', 8, 8'), 5.94 and 5.16 (2m, 2H, H-
~. ~\ 4.95-4.91 (4s, 8H, H-a, a\ 3.83-3.74 (br, 6H, OCH3) , 3.30-2.28 (4br, 8H, 
CH2CH2, CH'2CH'2), 1.72-1.25 (5 d, 6H, H-W, W1 ); 13C NMR: 167.11, 152.60, 152.33, 
170 
138.30, 137.37, 128.75, 127.92, 127.41 , 127.13, 124.64, 108.62, 71 .19, 60.80, 56.99, 
53.74, 44.77, 34.89, 31.40, 29.49, 17.69; APCI-MS(m/z): 1066.2 (M++1 , 100). 
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Appendix A: 
Selected 1 H NMR and 13C NMR spectra of compounds 
of Chapter 2 
Index of NMR spectra : page numbers and compound numbers 
Compound* Page# Page# Compound* Page# Page# 
1H-NMR 13C-NMR 1H-NMR 13C-NMR 
12 206 207 55 259 
13 216 217 56 257 258 
18 189 190 59 266 
25 214 215 64 . 260 261 
26 173 174 14b 242 243 
27 175 176 14c 238 239 
28 177 178 15b 244 245 
29 179 180 15d 248 249 
30 181 182 16b 246 247 
31 183 184 16d 250 
32 185 186 19a 253 254 
33 187 188 19b 251 252 
34 191 192 19c 255 256 
35 193 194 22a 226 227 
36 195 196 22b 228 
37 197 198 22c 229 
38 199 200 23a 220 221 
39 201 202 23b 222 223 
40 203 204 23c 224 225 
41 205 58 a 262 
42 208 209 58b 263 264 
43 210 211 58c 265 
44 212 213 65a 267 268 
45 218 219 65b 269 270 
47 230 231 66c 271 272 
48 232 233 68a 273 274 
49 234 235 68b 275 
50 236 237 68c 276 
53 240 241 
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Appendix B: 
Selected 1 H NMR and 13C NMR spectra of compounds 
~ ... ,of Chapter 4 
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